

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 5
MAY 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 5
May 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2017**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

JAI PHARMA LTD
(JAI PHARMA LTD)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

MYLAN LABORATORIES LTD
(MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)			
MULTISOURCE	15484 (85.4%)	15703 (85.4%)			
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)			
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)			
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	7	14			
NUMBER OF APPLICANTS	1051	1053			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE; 300MG	A206151	001	Mar 28, 2017	Mar	NEWA
AB	CIPLA LTD	EQ 600MG BASE; 300MG	A091144	001	Mar 28, 2017	Mar	NEWA
AB	LUPIN LTD	EQ 600MG BASE; 300MG	A204990	001	Mar 28, 2017	Mar	NEWA

ABALOPARATIDE

SOLUTION; SUBCUTANEOUS
TYMLOS

+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr	NEWA
----	-------------------	------------------------	---------	-----	--------------	-----	------

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

>A>	+	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017	May	NEWA
-----	---	-----------------	-------	---------	-----	--------------	-----	------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

>A>	AB	ZYDUS PHARMS USA INC	333MG	A205995	001	May 26, 2017	May	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan	CAHN
----	----------------	---------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

>A>	AA	TEDOR PHARMA INC	300MG; 50MG	A207635	001	Jun 05, 2017	May	NEWA
-----	----	------------------	-------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	Apr	CTNA
AA	MALLINCKRODT INC	325MG; 50MG; 40MG	A087804	001	Jan 24, 1985	Mar	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT INC	300MG; 5MG	A206718	001	Mar 31, 2017	Mar	NEWA	
AA		300MG; 7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA	
AA		300MG; 10MG	A206718	003	Mar 31, 2017	Mar	NEWA	
>D>	AA	MIKART	300MG; 7.5MG	A040658	002	Mar 24, 2006	May	CHRS
>A>	AA	!	300MG; 7.5MG	A040658	002	Mar 24, 2006	May	CHRS
AA		300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1	
>D>	AA		300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS
>A>	AA	!	300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS
AA		300MG; 10MG	A040658	003	Jun 23, 2004	Apr	CMS1	
AA	UPSHER-SMITH LABS	325MG; 5MG	A206484	001	Mar 24, 2017	Mar	NEWA	
AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA	
AA		325MG; 10MG	A206484	003	Mar 24, 2017	Mar	NEWA	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	AA	AMNEAL PHARMS	325MG; 5MG	A040777	001	Nov 27, 2007	May	CAHN
>D>	AA	AMNEAL PHARMS NY	325MG; 5MG	A040777	001	Nov 27, 2007	May	CAHN
AA	ASCENT PHARMS INC	325MG; 2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA	
AA		325MG; 5MG	A207419	002	Mar 22, 2017	Mar	NEWA	
AA		325MG; 7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA	
AA		325MG; 10MG	A207419	004	Mar 22, 2017	Mar	NEWA	
AA	NOVEL LABS INC	325MG; 2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA	
AA		325MG; 5MG	A204407	002	Feb 24, 2017	Feb	NEWA	
AA		325MG; 7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA	
AA		325MG; 10MG	A204407	004	Feb 24, 2017	Feb	NEWA	
		PERCOCET						
AA	!	VINTAGE PHARMS LLC	325MG; 7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
AA	!		325MG; 10MG	A040330	004	Nov 23, 2001	Jan	CMS1

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	AUROBINDO PHARMA LTD	325MG; 37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
AB	MACLEODS PHARMS LTD	325MG; 37.5MG	A206885	001	May 02, 2017	Apr	NEWA

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	250MG/100ML	N017656	001		Feb	CAHN
----	-----------------	-------------	---------	-----	--	-----	------

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

>D>	@ WATSON LABS	250MG	A071893	001	Nov 25, 1987	May	CAHN
>D>	@	500MG	A071894	001	Nov 25, 1987	May	CAHN
>A>	@ WATSON LABS TEVA	250MG	A071893	001	Nov 25, 1987	May	CAHN
>A>	@	500MG	A071894	001	Nov 25, 1987	May	CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

>D>	+! AUXILIUM PHARMS INC	8MG; 60MG	N019806	001	Mar 25, 1994	May	CAHN
>A>	+! AUXILIUM PHARMS LLC	8MG; 60MG	N019806	001	Mar 25, 1994	May	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>A>	AB	BOSCOGEN	200MG	A075090	001	Jan 26, 1999	May	CAHN
		@ CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997	Jan	CAHN
>D>	AB	STASON	200MG	A075090	001	Jan 26, 1999	May	CAHN

ZOVIRAX

AB	+! MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Jan	CAHN
----	---------------------	-------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

ZOVIRAX

AB	+! MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan	CAHN
----	---------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

		@ CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997	Jan	CAHN
		@	800MG	A074834	002	Apr 24, 1997	Jan	CAHN
AB		HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	Apr	CMFD
AB			800MG	A074891	002	Oct 31, 1997	Apr	CMFD
AB		MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar	CAHN
AB			800MG	A075211	002	Sep 28, 1998	Mar	CAHN

ZOVIRAX

AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan	CAHN
AB	+!		800MG	N020089	002	Apr 30, 1991	Jan	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

		@ ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN
		@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN
AP	!	HIKMA PHARMS LLC	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar	CTEC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar	NEWA
AP			EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar	NEWA
>A>	AP	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May	NEWA

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan	CAHN
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan	CAHN
		@	3MG/ML	A076501	001	Jun 16, 2004	Jan	CAHN

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
PROVENTIL-HFA

>D>	BX	+!	3M	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN
>A>	BX	+!	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN			WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb CAHN
----	--	--	------------------	------------------------	---------	-----	--------------	----------

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>D>	AB		AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May CAHN
>A>	AB			EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May CAHN
>D>	AB			EQ 1MG BASE	A206647	002	Dec 22, 2016	May CAHN
>A>	AB			EQ 1MG BASE	A206647	002	Dec 22, 2016	May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

>D>		+!	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May CAHN
>A>		+!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

>D>		+!	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May CAHN
>A>		+!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May CAHN

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB			ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
AB				0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
AB				1MG	A074342	003	Oct 31, 1993	Apr CAHN
AB				2MG	A074342	004	Oct 31, 1993	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB			AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
AB				1MG	A090871	002	Jun 07, 2011	Jan CAHN
AB				2MG	A090871	003	Jun 07, 2011	Jan CAHN
AB				3MG	A090871	004	Jun 07, 2011	Jan CAHN
		@	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007	Feb CAHN
		@		1MG	A077996	002	Jan 31, 2007	Feb CAHN
		@		2MG	A077996	003	Jan 31, 2007	Feb CAHN
		@		3MG	A077996	004	Jan 31, 2007	Feb CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

>D>		@	AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
>D>	AP	+		0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN
>D>		+!		0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
>D>	AP	+		0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
>D>		+!		0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
>D>	AP	+!		0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
>D>		+!		0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN
>A>		@	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
>A>	AP	+		0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN

INJECTABLE; INJECTION
EDEX

>A>	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
>A> AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
>A>	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
>A> AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
>A>	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN

SUPPOSITORY; URETHRAL
MUSE

+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
+		0.25MG	N020700	002	Nov 19, 1996	Mar CAHN
+		0.5MG	N020700	003	Nov 19, 1996	Mar CAHN
+		1MG	N020700	004	Nov 19, 1996	Mar CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

>A> AB	HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May NEWA
>A> AB	LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May NEWA
>A> AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May NEWA

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr CAHN
>D> AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May CAHN
>A> AA	!		50MG/5ML	A074509	001	Jul 17, 1995	May CAHN

SYMMETREL

+	@ ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD
---	---------------	----------	---------	-----	--	----------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA
>A> AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May NEWA

AMIFOSTINE

INJECTABLE; INJECTION
AMIFOSTINE

AP		SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr CAHN
----	--	-------------------	------------	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb CAHN
--	-----------------	------------------	---------	-----	--	----------

AMINOSYN 10% (PH6)

	ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb CAHN
--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN 3.5%

	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb CAHN
--	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 5%

	ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb CAHN
--	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7%

	ICU MEDICAL INC	7% (7GM/100ML)	N017673	002		Feb CAHN
--	-----------------	----------------	---------	-----	--	----------

AMINOSYN 7% (PH6)

	ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
--	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN 8.5%

	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
--	-----------------	--------------------	---------	-----	--	----------

AMINOSYN 8.5% (PH6)

	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
--	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 10%

	ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 10% IN PLASTIC CONTAINER

	ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 15% IN PLASTIC CONTAINER

	ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
--	-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 3.5%

@	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
---	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 5%

@	ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
---	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN II 7%

	ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
--	-----------------	----------------	---------	-----	--------------	----------

AMINOSYN II 8.5%

	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
--	-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN-HBC 7%

	ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
--	-----------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

AMINOSYN-PF 10%

ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
-----------------	------------------	---------	-----	--------------	----------

AMINOSYN-PF 7%

ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-RF 5.2%

ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001		Apr CAHN
-----------------	--------------------	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N017789	003		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789	005		Feb CAHN
-------------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	004	Apr 03, 1986	Apr CAHN
-----------------	--	---------	-----	--------------	----------

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	006	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	005	Apr 03, 1986	Apr CAHN
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML	N019437	007	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017789	002		Feb CAHN
-----------------	---	---------	-----	--	----------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017673	005		Feb CAHN
-----------------	---	---------	-----	--	----------

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar DISC
AB	! SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
		300MG	A076362	002	Dec 02, 2003	Mar CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN
	CORDARONE					
	+ @ WYETH PHARMS INC	200MG	N018972	001	Dec 24, 1985	Jan DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

+ @	ASTRAZENECA	10MG	N012703	001		Mar CRLD
+ @		25MG	N012703	003		Mar CRLD
+ @		50MG	N012703	004		Mar CRLD
+ @		75MG	N012703	005		Mar CRLD
+ @		100MG	N012703	006		Mar CRLD
+ @		150MG	N012703	007		Mar CRLD

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	@ WATSON LABS	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN
>A>	@ WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar CAHN
>D> AB		EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
>A>	@	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar CAHN
>D> AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
>A>	@	EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar CAHN
>D> AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC
>A>	@	EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>A> AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May NEWA
>A> AB		EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May NEWA
>A> AB		EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May NEWA
>A> AB		EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May NEWA
>A> AB	JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May NEWA
>A> AB		EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May NEWA
>A> AB		EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May NEWA
>A> AB		EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr CAHN
AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>A> AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
>D> AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

+ @ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
-------------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb CAHN
@	50MG	A072419	001	May 11, 1989	Feb CAHN
@	100MG	A072420	001	May 11, 1989	Feb CAHN
@	150MG	A072421	001	May 11, 1989	Feb CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

@ DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Feb DISC
@	400MG/5ML	N050760	002	Apr 15, 1999	Feb DISC

TABLET; ORAL

AMOXIL

+ @ DR REDDYS LABS INC	500MG	N050754	002	Jul 10, 1998	Mar DISC
+ @	875MG	N050754	001	Jul 10, 1998	Mar DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

TEVA	125MG	A064013	002	Sep 11, 1995	Feb CTEC
!	250MG	A064013	001	Dec 22, 1992	Feb CTEC
AMOXIL					
+ @ DR REDDYS LABS INC	125MG	N050542	002		Feb DISC
+ @	250MG	N050542	001		Feb DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

+ @ DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb DISC
------------------------	------------------------------	---------	-----	--------------	----------

AUGMENTIN '400'

+ @ DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb DISC
------------------------	----------------------------	---------	-----	--------------	----------

AUGMENTIN ES-600

+ @ DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb DISC
------------------------	------------------------------	---------	-----	--------------	----------

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB ! SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb CHRS
-------------	---------------------	---------	-----	--------------	----------

AB ! SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb CHRS
-----------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '250'

+ @ DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb DISC
------------------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '500'

+ @ DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb DISC
------------------------	---------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb CTEC
----------------------	---------	-----	--------------	----------

!

400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb CTEC
--------------------	---------	-----	--------------	----------

AUGMENTIN '200'

+ @ DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb DISC
------------------------	----------------------	---------	-----	--------------	----------

AUGMENTIN '400'

+ @ DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb DISC
------------------------	--------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D> AB	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May CAHN
>D> AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May CAHN
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May CAHN
>D> AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May CAHN
>D> AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May CAHN
>D> AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN
>A> AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May CAHN
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May CAHN
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May CAHN
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May CAHN
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May CAHN
>A> AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@ WEST-WARD PHARMS INT EQ 125MG BASE/VIAL

A062692	001	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

@ EQ 250MG BASE/VIAL

A062692	002	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

@ EQ 500MG BASE/VIAL

A062692	003	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

@ EQ 1GM BASE/VIAL

A062692	004	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

@ EQ 2GM BASE/VIAL

A062692	005	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

@ EQ 10GM BASE/VIAL

A062692	006	Jun 24, 1986	Jan CAHN
---------	-----	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
----	----------------------	-------------------------------------	---------	-----	--------------	----------

AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
----	--	-----------------------------------	---------	-----	--------------	----------

AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan CAHN
----	--	------------------------------------	---------	-----	--------------	----------

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>D> AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
>A>	@	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
AB		EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar CAHN
>D> AB		EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
>A>	@	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
>D> AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC
>A>	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC

CAPSULE; ORAL
ANAGRELIDE HYDROCHLORIDE

AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar CAHN
>D>	AB	EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC
>A>	@	EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC

ANASTROZOLETABLET; ORAL
ANASTROZOLE

>D>	@ WATSON LABS	1MG	A078984	001	Jun 28, 2010	May CAHN
>A>	@ WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May CAHN
ARIMIDEX						
>D>	AB +!	ASTRAZENECA 1MG	N020541	001	Dec 27, 1995	May CAHN
>A>	AB +!	ASTRAZENECA PHARMS 1MG	N020541	001	Dec 27, 1995	May CAHN

ARGATROBANINJECTABLE; INJECTION
ARGATROBAN

	+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb NEWA
INJECTABLE; IV (INFUSION)							
ARGATROBAN IN SODIUM CHLORIDE							
>A>	AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	May NEWA
>D>	+!	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May CFTG
>A>	AP	+!	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May CFTG

ARIPIPIRAZOLETABLET; ORAL
ARIPIPIRAZOLE

>A>	AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May NEWA
>A>	AB		5MG	A202683	002	May 23, 2017	May NEWA
>A>	AB		10MG	A202683	003	May 23, 2017	May NEWA
>A>	AB		15MG	A202683	004	May 23, 2017	May NEWA
>A>	AB		20MG	A202683	005	May 23, 2017	May NEWA
>A>	AB		30MG	A202683	006	May 23, 2017	May NEWA
>A>	AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May CAHN
>A>	AB		5MG	A091279	002	Jan 09, 2017	May CAHN
>A>	AB		10MG	A091279	003	Jan 09, 2017	May CAHN
>A>	AB		15MG	A091279	004	Jan 09, 2017	May CAHN
>A>	AB		20MG	A091279	005	Jan 09, 2017	May CAHN
>A>	AB		30MG	A091279	006	Jan 09, 2017	May CAHN
>D>	AB	STASON PHARMS	2MG	A091279	001	Jan 09, 2017	May CAHN
>D>	AB		5MG	A091279	002	Jan 09, 2017	May CAHN
>D>	AB		10MG	A091279	003	Jan 09, 2017	May CAHN
>D>	AB		15MG	A091279	004	Jan 09, 2017	May CAHN
>D>	AB		20MG	A091279	005	Jan 09, 2017	May CAHN
>D>	AB		30MG	A091279	006	Jan 09, 2017	May CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN KINJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC

>D>	+!	SANDOZ	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	001	Feb 21, 2001	May CAHN
>A>	+!	SANDOZ INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	001	Feb 21, 2001	May CAHN
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)							
>D>	+!	SANDOZ	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021646	001	Jan 29, 2004	May CAHN
>A>	+!	SANDOZ INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021646	001	Jan 29, 2004	May CAHN

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
FIORINAL

+ @ ALLERGAN SALES LLC 325MG; 50MG; 40MG N017534 003 Apr 16, 1986 Jan CRLD

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

>D>	AB	AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	May CAHN
>A>	AB		25MG; 200MG	A206392	001	Mar 08, 2016	May CAHN
	AB	IMPAX LABS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Jan NEWA
	AB	PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Jan NEWA
	AB	SANDOZ INC	25MG; 200MG	A206739	001	Jan 18, 2017	Jan NEWA

ATENOLOLTABLET; ORAL
ATENOLOL

>D>	@	WATSON LABS	100MG	A073353	001	Dec 27, 1991	May CAHN
>A>	@	WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May CAHN

ATOMOXETINE HYDROCHLORIDECAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

>A>	AB	APOTEX INC	10MG	A078983	001	May 30, 2017	May NEWA
>A>	AB		18MG	A078983	002	May 30, 2017	May NEWA
>A>	AB		25MG	A078983	003	May 30, 2017	May NEWA
>A>	AB		40MG	A078983	004	May 30, 2017	May NEWA
>A>	AB		60MG	A078983	005	May 30, 2017	May NEWA
>A>	AB		80MG	A078983	006	May 30, 2017	May NEWA
>A>	AB		100MG	A078983	007	May 30, 2017	May NEWA
>A>	AB	AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May NEWA
>A>	AB		18MG	A079016	002	May 30, 2017	May NEWA
>A>	AB		25MG	A079016	003	May 30, 2017	May NEWA
>A>	AB		40MG	A079016	004	May 30, 2017	May NEWA
>A>	AB		60MG	A079016	005	May 30, 2017	May NEWA
>A>	AB		80MG	A079016	006	May 30, 2017	May NEWA
>A>	AB		100MG	A079016	007	May 30, 2017	May NEWA
>A>	AB	GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	May NEWA
>A>	AB		18MG	A079019	002	May 30, 2017	May NEWA
>A>	AB		25MG	A079019	003	May 30, 2017	May NEWA
>A>	AB		40MG	A079019	004	May 30, 2017	May NEWA
>A>	AB		60MG	A079019	005	May 30, 2017	May NEWA
>A>	AB		80MG	A079019	006	May 30, 2017	May NEWA
>A>	AB		100MG	A079019	007	May 30, 2017	May NEWA
>A>	AB	TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	May NEWA
>A>	AB		18MG	A079022	002	May 30, 2017	May NEWA
>A>	AB		25MG	A079022	003	May 30, 2017	May NEWA
>A>	AB		40MG	A079022	004	May 30, 2017	May NEWA
>A>	AB		60MG	A079022	005	May 30, 2017	May NEWA
>A>	AB		80MG	A079022	006	May 30, 2017	May NEWA
>A>	AB		100MG	A079022	007	May 30, 2017	May NEWA
STRATTERA							
>D>	+	LILLY	10MG	N021411	002	Nov 26, 2002	May CFTG
>A>	AB	+	10MG	N021411	002	Nov 26, 2002	May CFTG
>D>	+		18MG	N021411	003	Nov 26, 2002	May CFTG
>A>	AB	+	18MG	N021411	003	Nov 26, 2002	May CFTG
>D>	+		25MG	N021411	004	Nov 26, 2002	May CFTG
>A>	AB	+	25MG	N021411	004	Nov 26, 2002	May CFTG
>D>	+		40MG	N021411	005	Nov 26, 2002	May CFTG
>A>	AB	+	40MG	N021411	005	Nov 26, 2002	May CFTG
>D>	+		60MG	N021411	006	Nov 26, 2002	May CFTG
>A>	AB	+	60MG	N021411	006	Nov 26, 2002	May CFTG
>D>	+		80MG	N021411	007	Feb 14, 2005	May CFTG
>A>	AB	+	80MG	N021411	007	Feb 14, 2005	May CFTG
>D>	+		100MG	N021411	008	Feb 14, 2005	May CFTG
>A>	AB	+	100MG	N021411	008	Feb 14, 2005	May CFTG

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE	A205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE	A205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE	A205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr NEWA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr NEWA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr NEWA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	PADDOCK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr NEWA
----	-------------	-----------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

	@ WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar NEWA
	TRACRIUM					
+	@ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr CMS1
	TRACRIUM PRESERVATIVE FREE					
+	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

>A>	+	!	CEREZA	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May CAHN
>D>	+	!	CEREZA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May CAHN

AZACITIDINE

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar CTEC		
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar CDJR		
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar CDJR		
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar CDJR		
	VIDAZA							
AP	+	!	CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar CDJR

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb CAHN		
	OPTIVAR							
AT	+	!	MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar CAHN
	SPRAY, METERED;NASAL							
	ASTELIN							
AB	+	!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar CAHN
	ASTEPRO							
	@	!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar CAHN
AB	+	!		EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar CAHN
	AZELASTINE HYDROCHLORIDE							
AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb CAHN		
AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar NEWA		

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA		
	DYMISTA							
AB	+	!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG

SPRAY, METERED;NASAL
DYMISTA

+! EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Mar CAHN

AZITHROMYCIN

INJECTABLE;INJECTION
AZITHROMYCIN

AP MYLAN LABS LTD EQ 500MG BASE/VIAL A204732 001 Jan 26, 2017 Jan NEWA

TABLET;ORAL
AZITHROMYCIN

>D> AB MYLAN EQ 500MG BASE A065366 001 May 30, 2007 May DISC

>A> @ EQ 500MG BASE A065366 001 May 30, 2007 May DISC

ZITHROMAX

AB + PFIZER EQ 250MG BASE N050711 001 Jul 18, 1996 Apr CRLD

AB + EQ 500MG BASE N050784 001 May 24, 2002 Apr CRLD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL
CORTISPORIN

+! MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG N050168 002 May 04, 1984 Feb CAHN
BASE/GM;5,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOSPORIN

AT + CASPER PHARMA LLC 400 UNITS/GM;EQ 3.5MG N050417 001 Apr CMFD
BASE/GM;10,000 UNITS/GM

BACLOFEN

INJECTABLE;INTRATHECAL
BACLOFEN

AP EMERALD INTL LTD 0.05MG/ML A091193 001 May 03, 2016 Mar CAHN

AP 0.5MG/ML A091193 002 May 03, 2016 Mar CAHN

AP 2MG/ML A091193 003 May 03, 2016 Mar CAHN

GABLOFEN

+! MALLINCKRODT INC 1MG/ML N022462 004 Jun 22, 2012 Mar CRLD

AP PIRAMAL CRITICAL 0.05MG/ML N022462 001 Nov 19, 2010 Apr CAHN

AP 0.5MG/ML N022462 002 Nov 19, 2010 Apr CAHN

+! 1MG/ML N022462 004 Jun 22, 2012 Apr CAHN

AP 2MG/ML N022462 003 Nov 19, 2010 Apr CAHN

TABLET;ORAL

BACLOFEN

>D> AB MYLAN 10MG A077181 001 Jul 29, 2005 May DISC

>A> @ 10MG A077181 001 Jul 29, 2005 May DISC

AB OXFORD PHARMS 10MG A077088 002 Oct 31, 2007 Apr CMS1

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

BX WEST-WARD PHARMS INT 750MG A077806 001 Dec 28, 2007 Apr CTEC

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+! BRACCO 98% (334GM/BOTTLE) N208036 001 Jan 11, 2016 Apr CPOT

E-Z-PAQUE

+! BRACCO 96% (169GM/BOTTLE) N208036 002 Apr 07, 2017 Apr NEWA

SUSPENSION;ORAL

LIQUID E-Z-PAQUE

+! BRACCO 60% (213GM/355ML) N208143 003 Mar 01, 2017 Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS 5MG A076820 001 Feb 03, 2006 Apr CAHN

AB 10MG A076820 002 Feb 03, 2006 Apr CAHN

AB 20MG A076820 003 Feb 03, 2006 Apr CAHN

AB 40MG A076820 004 Feb 03, 2006 Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
LOTENSIN HCT

>D>	AB	+	US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May	DISC
>A>		+	@	5MG;6.25MG	N020033	001	May 19, 1992	May	DISC

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL
CORZIDE

AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+	!	5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN

BENZONATATE

CAPSULE;ORAL
TESSALON

AA	+	PFIZER	100MG	N011210	001		Apr	CRLD
----	---	--------	-------	---------	-----	--	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

>D>		@	COREPHARMA	50MG	A040714	001	Oct 29, 2007	May	CAHN
>A>		@	EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May	CAHN
AA			TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL
BENZTROPINE MESYLATE

>D>	AA		COREPHARMA	0.5MG	A072264	001	Feb 27, 1989	May	CAHN
>D>	AA			1MG	A072265	001	Feb 27, 1989	May	CAHN
>D>	AA			2MG	A072266	001	Feb 27, 1989	May	CAHN
>A>	AA		EPIC PHARMA LLC	0.5MG	A072264	001	Feb 27, 1989	May	CAHN
>A>	AA			1MG	A072265	001	Feb 27, 1989	May	CAHN
>A>	AA			2MG	A072266	001	Feb 27, 1989	May	CAHN
>A>			OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	May	CMS1
>A>				1MG	A040706	003	Feb 14, 2008	May	CMS1
	AA	!	UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb	CAHN
	AA	!		1MG	A040103	002	Dec 12, 1996	Feb	CAHN
	AA	!		2MG	A040103	003	Dec 12, 1996	Feb	CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan	CAHN
		@ TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr	CAHN
		DIPROSONE						
		+ @ SCHERING	EQ 0.05% BASE	N017781	001		Jan	CRLD

OINTMENT;TOPICAL
BETAMETHASONE DIPROPIONATE

AB		TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr	CAHN
----	--	------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL
BETAMETHASONE VALERATE

AB		PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr	CAHN
>A>	AB	RICONPHARMA LLC	0.12%	A207144	001	May 24, 2017	May	NEWA
>A>	AB	TARO PHARM	0.12%	A208204	001	May 24, 2017	May	NEWA
		LUXIQ						
AB	+	! MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT		TELIGENT	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr	CAHN
----	--	----------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL
BETHANECHOL CHLORIDE

		@ IMPAX LABS	5MG	A040721	001	Nov 01, 2006	Jan	CMS1	
		@	10MG	A040721	002	Nov 01, 2006	Jan	CMS1	
		@	25MG	A040721	003	Nov 01, 2016	Jan	CMS1	
>A>	AA		LANNETT HOLDINGS INC	5MG	A040677	002	Mar 27, 2008	May	CMS1

TABLET;ORAL

BETHANECHOL CHLORIDE

>A>	AA		10MG	A040677	003	Mar 27, 2008	May CMS1
>A>	AA		25MG	A040677	004	Mar 27, 2008	May CMS1

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

>D>	AB	ACTAVIS TOTOWA	50MG	A078634	001	Aug 28, 2009	May CAHN
>A>	AB	SANTOS BIOTECH	50MG	A091011	001	Jun 10, 2015	May CAHN
>D>	AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May CAHN
>A>	AB	WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009	May CAHN

CASODEX

>D>	AB	+! ASTRAZENECA	50MG	N020498	001	Oct 04, 1995	May CAHN
>A>	AB	+! ASTRAZENECA PHARMS	50MG	N020498	001	Oct 04, 1995	May CAHN

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT		SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar CAHN
----	--	------------	-------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan NEWA
AB			10MG	A204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>D>		@ WATSON LABS	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May CAHN
>D>		@	5MG;6.25MG	A075469	002	Sep 25, 2000	May CAHN
>D>		@	10MG;6.25MG	A075469	003	Sep 25, 2000	May CAHN
>A>		@ WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May CAHN
>A>		@	5MG;6.25MG	A075469	002	Sep 25, 2000	May CAHN
>A>		@	10MG;6.25MG	A075469	003	Sep 25, 2000	May CAHN

ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Jan CAHN
AB	+!		10MG;6.25MG	N020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

>A>	AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May NEWA
-----	----	--------------------	------------	---------	-----	--------------	----------

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan CAHN
---	----------------------	---------	---------	-----	--------------	----------

BRIGATINIB

TABLET;ORAL

ALUNBRIG

+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr NEWA
+	!	90MG	N208772	002	Apr 28, 2017	Apr NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT		SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb CAHN
AT			0.2%	A078075	001	Jan 30, 2008	Mar CAHN

QOLIANA

AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar CAHN
----	--	------------	-------	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT1		AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar CAHN
AT1	!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb CHRS
		@ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb DISC
AT2	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar CHRS

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA	TARO PHARM	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Feb NEWA

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar NEWA
AB	ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr NEWA

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	! ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CAHN

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN
>A>	AB		EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN

ZUBSOLV

+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA
	FORFIVO XL					
+	! ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA
>A>	AB		7.5MG	A208829	002	May 24, 2017	May NEWA
>A>	AB		10MG	A208829	003	May 24, 2017	May NEWA
>A>	AB		15MG	A208829	004	May 24, 2017	May NEWA
>A>	AB		30MG	A208829	005	May 24, 2017	May NEWA
	AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN
	AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN
	AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN
	AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN

BUSULFAN

INJECTABLE;INJECTION						
BUSULFAN						
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA

BUTABARBITAL SODIUM

TABLET;ORAL

BUTISOL SODIUM

	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
+	!	30MG	N000793	004		Mar CAHN
	@	50MG	N000793	003		Mar CAHN
	@	100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

+	!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan CAHN
---	---	--------------	--------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CALCIPOTRIENE

>D>	!	GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010	May CAHN
>A>	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May CAHN

CALCITONIN SALMON

SPRAY, METERED;NASAL

CALCITONIN-SALMON

AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
		MIACALCIN					
	+	@ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

>A>	AB	AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May NEWA
>A>	AB		0.5MCG	A203289	001	Jun 14, 2017	May NEWA

INJECTABLE;INJECTION

CALCIJEX

>D>	@	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May CRLD
>A>	+	@	0.001MG/ML	N018874	001	Sep 25, 1986	May CRLD
>D>	@		0.002MG/ML	N018874	002	Sep 25, 1986	May CRLD
>A>	+	@	0.002MG/ML	N018874	002	Sep 25, 1986	May CRLD

CALCITRIOL

>D>		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	May CHRS
>A>	!		0.001MG/ML	A078066	001	Jan 29, 2008	May CHRS

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar CAHN
----	--	--------------	-------	---------	-----	--------------	----------

TABLET;ORAL

CALCIUM ACETATE

AB	!	PADDock LLC	667MG	A091561	001	Apr 13, 2011	Apr CHRS
		ELIPHOS					

AB		CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr CHRS
----	--	---------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;30MG/100ML;60	N017608	001		Feb CAHN
		0MG/100ML;310MG/100ML				

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	005	Oct 17, 1988	Feb CAHN
		00MG/100ML;310MG/100ML				

@		20MG/100ML;5GM/100ML;179MG/100ML;6	N019685	006	Oct 17, 1988	Feb CAHN
		00MG/100ML;310MG/100ML				

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	007	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;6	N019685	002	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN
AP		20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	008	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	003	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	004	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	001	Oct 17, 1988
		00MG/100ML;310MG/100ML			Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N018251	001	Feb CAHN
SOLUTION;IRRIGATION					
RINGER'S IN PLASTIC CONTAINER					
AT	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N017635	001	Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;	N017641	001	Feb CAHN
		310MG/100ML			
SOLUTION;IRRIGATION					
LACTATED RINGER'S IN PLASTIC CONTAINER					
AT	+! ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;	N019416	001	Jan 17, 1986
		310MG/100ML			Feb CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN LABS	16MG;12.5MG	A090704	001	Dec 04, 2012	May CAHN
>D>	AB		32MG;12.5MG	A090704	002	Dec 04, 2012	May CAHN
>D>	AB		32MG;25MG	A090704	003	Dec 04, 2012	May CAHN
>A>	AB	MYLAN PHARMS INC	16MG;12.5MG	A090704	001	Dec 04, 2012	May CAHN
>A>	AB		32MG;12.5MG	A090704	002	Dec 04, 2012	May CAHN
>A>	AB		32MG;25MG	A090704	003	Dec 04, 2012	May CAHN

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb NEWA
AB		500MG	A204741	002	Feb 28, 2017	Feb NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>A>	@	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	May CAHN
>A>	@		25MG	A074677	002	May 30, 1997	May CAHN
>A>	@		50MG	A074677	001	May 30, 1997	May CAHN
>A>	@		100MG	A074677	003	May 30, 1997	May CAHN
AB		MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar CAHN
AB			25MG	A074434	002	Feb 13, 1996	Mar CAHN
AB			50MG	A074434	003	Feb 13, 1996	Mar CAHN
AB	!		100MG	A074434	004	Feb 13, 1996	Mar CAHN
>D>	@	STASON	12.5MG	A074677	004	May 30, 1997	May CAHN
>D>	@		25MG	A074677	002	May 30, 1997	May CAHN
>D>	@		50MG	A074677	001	May 30, 1997	May CAHN
>D>	@		100MG	A074677	003	May 30, 1997	May CAHN

CARBAMAZEPINESOLUTION; IV (INFUSION)
CARNEXIV

	+!	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan CAHN
		SUSPENSION; ORAL					
		TERIL					
AB		TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar CAHN

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

>D>	@	WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May CAHN
>D>	@		150MG/VIAL	A076162	002	Oct 14, 2004	May CAHN
>D>	@		450MG/VIAL	A076162	003	Oct 14, 2004	May CAHN
>A>	@	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May CAHN
>A>	@		150MG/VIAL	A076162	002	Oct 14, 2004	May CAHN
>A>	@		450MG/VIAL	A076162	003	Oct 14, 2004	May CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan NEWA
AP			150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan NEWA
AP			450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan NEWA
AP			600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan NEWA
AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan NEWA
AP			150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan NEWA
AP			450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan NEWA
AP			600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan NEWA
AP		INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr NEWA
AP			150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr NEWA
AP			450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr NEWA
AP			600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr NEWA

CARISOPRODOLCAPSULE; ORAL
SOMA

	@	MYLAN SPECIALITY LP	250MG	N011792	003		Mar CAHN
--	---	---------------------	-------	---------	-----	--	----------

TABLET; ORAL
CARISOPRODOL

>D>	@	COREPHARMA	350MG	A040397	001	Sep 21, 2000	May CAHN
>A>	@	EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May CAHN
AA		HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr CMFD
AB		NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr NEWA
>D>	@	WATSON LABS	350MG	A086179	001		May CAHN
>A>	@	WATSON LABS TEVA	350MG	A086179	001		May CAHN
		SOMA					
AB	+!	MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar CAHN
AA	+		350MG	N011792	001		Mar CAHN

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

>D>	AT	SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CHRS
>A>	AT	!	1%	A075476	001	Jan 03, 2000	May CHRS
	AT		1%	A075476	001	Jan 03, 2000	Mar CAHN
>D>		OCUPRESS					
>D>	AT	+! NOVARTIS	1%	N019972	001	May 23, 1990	May DISC
>A>	+	@	1%	N019972	001	May 23, 1990	May DISC

CASPOFUNGIN ACETATEPOWDER; IV (INFUSION)
CANCIDAS

AP	+!	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar CDFR
AP	+!		70MG/VIAL	N021227	002	Jan 26, 2001	Mar CDFR

CEFDINIRCAPSULE; ORAL
OMNICEF

	+	@	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan CRLD
--	---	---	--------	-------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL
OMNICEF

+ @ ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
+ @	250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan NEWA
SUPRAX						
AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG

CEFOTETAN DISODIUMINJECTABLE;INJECTION
CEFOTAN

AP	+ TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr CAHN
AP	+	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr CAHN
CEFOTAN IN PLASTIC CONTAINER						
	@ TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN

CEFOXITIN SODIUMINJECTABLE;INJECTION
CEFOXITIN

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN

CEFPROZILFOR SUSPENSION;ORAL
CEFZIL

>D>	@ CORDEN PHARMA	125MG/5ML	N050665	001	Dec 23, 1991	May CRLD
>A>	+ @	125MG/5ML	N050665	001	Dec 23, 1991	May CRLD
>D>	@	250MG/5ML	N050665	002	Dec 23, 1991	May CRLD
>A>	+ @	250MG/5ML	N050665	002	Dec 23, 1991	May CRLD

TABLET;ORAL

CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB		500MG	A065340	002	May 24, 2007	Jan CAHN

CEFZIL

>D>	@ CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	May CRLD
>A>	+ @	250MG	N050664	001	Dec 23, 1991	May CRLD
>D>	@	500MG	N050664	002	Dec 23, 1991	May CRLD
>A>	+ @	500MG	N050664	002	Dec 23, 1991	May CRLD

CEFTAZIDIMEINJECTABLE;INJECTION
FORTAZ

AP	+! TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+!	1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+!	2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+!	6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN

CEFTAZIDIME SODIUMINJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

>D>	@ IGI LABS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
>D>	+!	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
>D>	+!	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN
>A>	@ TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
>A>	+!	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
>A>	+!	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN

CEFTRIAXONE SODIUMINJECTABLE;INJECTION
CEFTRIAXONE SODIUM

AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
----	---------------	-------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+ @	HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
+ @		EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
+ @		EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

>D>	AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
>D>	AP	+	!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN
>A>	AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
>A>	AP	+	!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN

ZINACEF IN PLASTIC CONTAINER

>D>		@	IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
>D>		+	!	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN
>A>		@	TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
>A>		+	!	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

>D>	AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN
>A>	AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION

CEPHAPIRIN SODIUM

@ WEST-WARD PHARMS INT EQ 500MG BASE/VIAL

@ EQ 1GM BASE/VIAL

@ EQ 2GM BASE/VIAL

@ EQ 20GM BASE/VIAL

A062720	001	Jul 02, 1987	Jan CAHN
A062720	002	Jul 02, 1987	Jan CAHN
A062720	003	Jul 02, 1987	Jan CAHN
A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDE

>A> SOLUTION/DROPS;OPHTHALMIC

>A> ZERVIAE

>A>	+	NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May NEWA
-----	---	-------------------	---------------	---------	-----	--------------	----------

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN
----	-------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

>D>	AB	PACK PHARMS LLC	30MG	A203775	001	Jun 04, 2014	May CAHN
>A>	AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May CAHN

CHENODIOLTABLET; ORAL
CHENIX

+ @ LEADIANT BIOSCI INC 250MG

N018513 002 Jul 28, 1983 Feb CAHN

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE; INJECTION
CHLOROMYCETIN

+ @ PARKEDALE EQ 1GM BASE/VIAL

N050155 001 Mar CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE; ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE
@ USL PHARMA 10MG

A084623 001 Apr DISC

CHLORHEXIDINE GLUCONATESOLUTION; DENTAL
PERIOGARD>D> AT COLGATE 0.12%
>A> AT COLGATE PALMOLIVE CO 0.12%A073695 001 Jan 14, 1994 May CAHN
A073695 001 Jan 14, 1994 May CAHNCHLORPHENESIN CARBAMATETABLET; ORAL
MAOLATE

@ PAMLAB LLC 400MG

N014217 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATESOLUTION; ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

>A> AA ACELLA PHARMS LLC 4MG/5ML; 5MG/5ML

A206891 001 Jun 09, 2017 May NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA BIO-PHARM INC 4MG/5ML; 5MG/5ML; 60MG/5ML

A206660 001 May 15, 2017 May NEWA

CHLORPROMAZINE HYDROCHLORIDETABLET; ORAL
CHLORPROMAZINE HYDROCHLORIDE>D> BP USL PHARMA 10MG
>A> 10MG
>D> BP 25MG
>A> ! 25MG
>D> BP 50MG
>A> 50MG
>D> BP 100MG
>A> ! 100MG
>D> BP 200MG
>A> 200MGA083386 001 May CTEC
A083386 001 May CTEC
A084112 001 May CHRS
A084112 001 May CHRS
A084113 001 May CTEC
A084113 001 May CTEC
A084114 001 May CHRS
A084114 001 May CHRS
A084115 001 May CTEC
A084115 001 May CTEC

THORAZINE

>D> + @ GLAXOSMITHKLINE 10MG
>A> @ 10MG
>D> + @ 25MG
>A> @ 25MG
>D> + @ 50MG
>A> @ 50MG
>D> + @ 100MG
>A> @ 100MG
>D> + @ 200MG
>A> @ 200MGN009149 002 May CRLD
N009149 002 May CRLD
N009149 007 May CRLD
N009149 007 May CRLD
N009149 013 May CRLD
N009149 013 May CRLD
N009149 018 May CRLD
N009149 018 May CRLD
N009149 020 May CRLD
N009149 020 May CRLDCHLORPROPAMIDETABLET; ORAL
CHLORPROPAMIDE>D> @ ANI PHARMS INC 250MG
>D> @ WATSON LABS INC 100MG
>D> @ 250MG
>A> @ WATSON LABS TEVA 100MG
>A> @ 250MGA087353 001 Jan CAHN
A088852 001 Sep 26, 1984 May CAHN
A088826 001 Sep 26, 1984 May CAHN
A088852 001 Sep 26, 1984 May CAHN
A088826 001 Sep 26, 1984 May CAHN

INJECTABLE; INJECTION

CIPROFLOXACIN

AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb CHRS
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT		AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN
AT		TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
AB			EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB			EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB			EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA
----	--	---------------------	----------------	---------	-----	--------------	----------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP		GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar NEWA
AP	+	HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
PLATINOL							
	+	@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar CRLD
	+	@	50MG/VIAL	N018057	002		Mar CRLD
PLATINOL-AQ							
	+	@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

@ MYLAN PHARMS INC

@

@

			EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar DISC
			EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar DISC
			EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar DISC

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN
----	--	----------------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>		@ COREPHARMA	EQ 10MG BASE	A077036	001	Oct 28, 2004	May CAHN
>D>		@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May CAHN
>D>		@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May CAHN
>A>		@ EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May CAHN
>A>		@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May CAHN
>A>		@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May CAHN
>D>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May DISC
>A>		@	EQ 10MG BASE	A077037	001	Nov 05, 2004	May DISC
>D>	AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	May DISC
>A>		@	EQ 20MG BASE	A077037	002	Nov 05, 2004	May DISC
>D>	AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	May DISC
>A>		@	EQ 40MG BASE	A077037	003	Nov 05, 2004	May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

	+	!	FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Mar CAHN
--	---	---	--------------------	---	---------	-----	--------------	----------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>D>	AB	MYLAN	250MG	A065195	001	Mar 11, 2005	May DISC
>A>		@	250MG	A065195	001	Mar 11, 2005	May DISC
>D>	AB		500MG	A065195	002	Mar 11, 2005	May DISC

TABLET;ORAL							
CLARITHROMYCIN							
>A>	@	500MG		A065195	002	Mar 11, 2005	May DISC
<u>CLEMASTINE FUMARATE</u>							
TABLET;ORAL							
CLEMASTINE FUMARATE							
	@ SANDOZ	2.68MG		A073459	001	Oct 31, 1993	Feb DISC
!	TEVA	2.68MG		A073283	001	Jan 31, 1992	Feb CTEC
<u>CLINDAMYCIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
CLINDAMYCIN HYDROCHLORIDE							
>D> AB	COREPHARMA	EQ 150MG BASE		A065194	001	Mar 22, 2004	May CAHN
>D> AB		EQ 300MG BASE		A065194	002	Mar 22, 2004	May CAHN
>A> AB	EPIC PHARMA LLC	EQ 150MG BASE		A065194	001	Mar 22, 2004	May CAHN
>A> AB		EQ 300MG BASE		A065194	002	Mar 22, 2004	May CAHN
>D> AB	MYLAN PHARMS INC	EQ 75MG BASE		A091225	001	May 31, 2011	May DISC
>A>	@	EQ 75MG BASE		A091225	001	May 31, 2011	May DISC
>D> AB		EQ 150MG BASE		A091225	002	May 31, 2011	May DISC
>A>	@	EQ 150MG BASE		A091225	002	May 31, 2011	May DISC
>D> AB		EQ 300MG BASE		A091225	003	May 31, 2011	May DISC
>A>	@	EQ 300MG BASE		A091225	003	May 31, 2011	May DISC
<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>							
FOR SOLUTION;ORAL							
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
AA	INVAGEN PHARMS	EQ 75MG BASE/5ML		A206958	001	May 05, 2017	Apr NEWA
AA	PADDOCK LLC	EQ 75MG BASE/5ML		A090902	001	Jul 07, 2010	Apr CAHN
<u>CLINDAMYCIN PHOSPHATE</u>							
AEROSOL, FOAM;TOPICAL							
EVOCLIN							
AT	+! MYLAN PHARMS INC	1%		N050801	001	Oct 22, 2004	Jan CAHN
INJECTABLE;INJECTION							
CLINDAMYCIN PHOSPHATE							
AP	SAGENT PHARMS	EQ 150MG BASE/ML		A090109	001	Sep 30, 2011	Apr CAHN
AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML		A065206	001	Sep 24, 2004	Jan CAHN
SOLUTION;IV (INFUSION)							
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE							
>A>	+! BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)		N208083	001	Apr 20, 2017	May CAHN
>A>	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)		N208083	002	Apr 20, 2017	May CAHN
>A>	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)		N208083	003	Apr 20, 2017	May CAHN
>D>	+! CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)		N208083	001	Apr 20, 2017	May CAHN
	+!	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)		N208083	001	Apr 20, 2017	Apr NEWA
>D>	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)		N208083	002	Apr 20, 2017	May CAHN
	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)		N208083	002	Apr 20, 2017	Apr NEWA
>D>	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)		N208083	003	Apr 20, 2017	May CAHN
	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)		N208083	003	Apr 20, 2017	Apr NEWA
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT	FOUGERA PHARMS INC	EQ 1% BASE		A064159	001	Jun 05, 1997	Jan CAHN
SWAB;TOPICAL							
CLINDETS							
AT	PERRIGO CO	EQ 1% BASE		A064136	001	Sep 30, 1996	Apr CAHN
<u>CLOBAZAM</u>							
SUSPENSION;ORAL							
ONFI							
+	+! LUNDBECK PHARMS LLC	2.5MG/ML		N203993	001	Dec 14, 2012	Jan CAHN
TABLET;ORAL							
ONFI							
	@ LUNDBECK PHARMS LLC	5MG		N202067	001	Oct 21, 2011	Jan CAHN
+		10MG		N202067	002	Oct 21, 2011	Jan CAHN
+		20MG		N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATEAEROSOL, FOAM;TOPICAL
OLUX

AB1	+!	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN
		OLUX E					

AB2	+!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
-----	----	------------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
>D>	@	MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
>A>			0.05%	A075338	001	Feb 09, 2001	May CMFD
	@		0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN
AB		TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb NEWA

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar NEWA
>D>	@	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	May CMFD
>A>			0.05%	A075057	001	Aug 12, 1998	May CMFD
	@		0.05%	A075057	001	Aug 12, 1998	Jan CAHN
AB		TARO	0.05%	A074248	001	Jul 12, 1996	Apr CAHN
		TEMOVATE					
	+	@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CRLD

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT		TARO	0.05%	A075224	001	Nov 16, 1998	Apr CAHN
----	--	------	-------	---------	-----	--------------	----------

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT		AKORN	0.05%	A207218	001	Apr 28, 2017	Apr NEWA
AT		ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb NEWA

CLOFARABINE

INJECTABLE;IV (INFUSION)

CLOFARABINE

AP		ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr NEWA
		CLOLAR					
AP	+!	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr CFTG

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB		SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB			50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB			75MG	A074953	003	Jun 25, 1997	Feb CMFD

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

	@	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@		1MG	A074940	002	Oct 30, 1997	Mar DISC
	@		2MG	A074940	003	Oct 30, 1997	Mar DISC
AB		PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB			1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB			2MG	A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@	CHARTWELL MOLECULES	0.1MG	A071783	001	Apr 05, 1988	Feb CAHN
	@		0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB		PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
AB			0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
AB			0.3MG	A077901	003	Mar 09, 2007	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN
AB1			0.1MG	A203320	001	May 15, 2015	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

@ 0.2MG
@ 0.2MG

A202792 002 May 15, 2015 Apr CAHN
A203320 002 May 15, 2015 Apr CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB ALLIED PHARMA INC EQ 75MG BASE
AB CSPC OUYI PHARM CO EQ 75MG BASE

A078004 001 May 17, 2012 Mar CAHN
A204359 001 Feb 02, 2017 Jan NEWA

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB TARO PHARM 3.75MG
AB 7.5MG
AB 15MG

A075731 003 Apr 27, 2000 Mar CAHN
A075731 002 Apr 27, 2000 Mar CAHN
A075731 001 Apr 27, 2000 Mar CAHN

CLOTRIMAZOLE

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT ! TARO 1%

A074580 001 Jul 29, 1996 Apr CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>D> @ PHARM ASSOC 10MG/5ML; 6.25MG/5ML
>A> @ 10MG/5ML; 6.25MG/5ML

A089647 001 Dec 22, 1988 May CAHN
A089647 001 Dec 22, 1988 May CAHN

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ WEST-WARD PHARMS INT 30MG/5ML

N202245 001 Jun 30, 2011 Jan CAHN

TABLET;ORAL

CODEINE SULFATE

AB + WEST-WARD PHARMS INT 15MG
AB + 30MG
AB +! 60MG

N022402 001 Jul 16, 2009 Jan CAHN
N022402 002 Jul 16, 2009 Jan CAHN
N022402 003 Jul 16, 2009 Jan CAHN

CORTICOTROPIN

INJECTABLE;INJECTION

PURIFIED CORTROPHIN GEL

>D> @ ANI PHARMS 40 UNITS/ML
>D> @ 80 UNITS/ML
>A> @ ANI PHARMS INC 40 UNITS/ML
>A> @ 80 UNITS/ML

N008975 001 May CAHN
N008975 002 May CAHN
N008975 001 May CAHN
N008975 002 May CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION

CORTROPHIN-ZINC

>D> @ ANI PHARMS 40 UNITS/ML
>A> @ ANI PHARMS INC 40 UNITS/ML

N009854 001 May CAHN
N009854 001 May CAHN

CORTISONE ACETATE

TABLET;ORAL

CORTONE

+ @ MERCK 25MG

N007750 003 Mar CRLD

COSYNTROPIN

SOLUTION;INTRAVENOUS

COSYNTROPIN

>D> @ SANDOZ 0.25MG/ML (0.25MG/ML)
>A> @ SANDOZ INC 0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008 May CAHN
N022028 001 Feb 21, 2008 May CAHN

CROMOLYN SODIUM

AEROSOL, METERED;INHALATION

INTAL

>D> @ KING PFIZER 0.8MG/INH
>A> @ KING PHARMS LLC 0.8MG/INH

N018887 001 Dec 05, 1985 May CAHN
N018887 001 Dec 05, 1985 May CAHN

CONCENTRATE;ORAL
GASTROCROM

AA	+! MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar CAHN
----	------------------------	-----------	---------	-----	--------------	----------

SOLUTION;INHALATION
CROMOLYN SODIUM

AN	BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN
----	-----------------	---------	---------	-----	--------------	----------

INTAL

>D>	@ KING PHARMS	10MG/ML	N018596	001	May 28, 1982	May CAHN
>A>	@ KING PHARMS LLC	10MG/ML	N018596	001	May 28, 1982	May CAHN

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

>A> AP	MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May NEWA
--------	----------------	--------	---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A> AB	OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May CMS1
AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb CAHN
AB		10MG	A077797	002	Feb 28, 2007	Feb CAHN
>A> AB	RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May NEWA
>A> AB		7.5MG	A208170	002	May 31, 2017	May NEWA
>A> AB		10MG	A208170	003	May 31, 2017	May NEWA

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan CAHN
+!		50MG	N203856	002	Sep 16, 2013	Jan CAHN

INJECTABLE;INJECTION

CYTOXAN (LYOPHILIZED)

+	@ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb CRLD
+	@	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
+	@	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

PERIACTIN

+	@ MERCK	2MG/5ML	N013220	002		Jan CRLD
---	---------	---------	---------	-----	--	----------

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan NEWA
AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN
>A> AA	SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May CAHN
>D> AA	STASON PHARMS	4MG	A040644	001	May 30, 2006	May CAHN
>A> AA	ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
+!		EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN
---	---------------------	---------------	---------	-----	--------------	----------

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS

CYTOSAR-U

@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

DACARBAZINE

INJECTABLE;INJECTION
DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
		DTIC-DOME					
	+	@ BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
	+	@	200MG/VIAL	N017575	002		Apr DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
AMPYRA

AB	+	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
		DALFAMPRIDINE					
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
QTERN

	+	ASTRAZENECA AB	EQ 10MG BASE;EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb NEWA
--	---	----------------	--------------------------	---------	-----	--------------	----------

DAPSONE

TABLET;ORAL
DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar NEWA
AB			100MG	A204380	002	Mar 23, 2017	Mar NEWA

DECITABINE

INJECTABLE;INTRAVENOUS
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb NEWA
>A> AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May NEWA

DEFERASIROX

>A>		GRANULE;ORAL					
>A>		JADENU SPRINKLE					
>A>	+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May NEWA
>A>	+		180MG	N207968	002	May 18, 2017	May NEWA
>A>	+	!	360MG	N207968	003	May 18, 2017	May NEWA

DEFLAZACORT

SUSPENSION;ORAL
EMFLAZA

	+	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb NEWA
	+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CAHN

TABLET;ORAL
EMFLAZA

	+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb NEWA
	+		18MG	N208684	002	Feb 09, 2017	Feb NEWA
	+		30MG	N208684	003	Feb 09, 2017	Feb NEWA
	+	!	36MG	N208684	004	Feb 09, 2017	Feb NEWA
	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr CAHN
	+		18MG	N208684	002	Feb 09, 2017	Apr CAHN
	+		30MG	N208684	003	Feb 09, 2017	Apr CAHN
	+	!	36MG	N208684	004	Feb 09, 2017	Apr CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB		IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb CAHN
AB			25MG	A205153	002	Oct 28, 2016	Feb CAHN
AB			50MG	A205153	003	Oct 28, 2016	Feb CAHN
AB			75MG	A205153	004	Oct 28, 2016	Feb CAHN
AB			100MG	A205153	005	Oct 28, 2016	Feb CAHN
AB			150MG	A205153	006	Oct 28, 2016	Feb CAHN

DESMETHYL PIROXICAMCAPSULE;ORAL
PIROXICAM

SUN PHARM INDS

10MG

A073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATESPRAY, METERED;NASAL
NOCTIVA

+ SERENITY PHARMS LLC

0.00083MG/SPRAY

N201656 001 Mar 03, 2017 Mar NEWA

+!

0.00166MG/SPRAY

N201656 002 Mar 03, 2017 Mar NEWA

TABLET;ORAL

DESMOPRESSIN ACETATE

>A> AB

HERITAGE PHARMA

0.1MG

A207880 001 May 26, 2017 May NEWA

>A> AB

0.1MG

A207880 001 May 26, 2017 May CAHN

>A> AB

0.2MG

A207880 002 May 26, 2017 May NEWA

>A> AB

0.2MG

A207880 002 May 26, 2017 May CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

>A> AB

ACCORD HLTHCARE

0.15MG,N/A;0.02MG,0.01MG

A209170 001 Jun 05, 2017 May NEWA

AB

AUROBINDO PHARMA LTD

0.15MG,N/A;0.02MG,0.01MG

A206853 001 Mar 22, 2017 Mar NEWA

KALLIGA

>A> AB

AUROBINDO PHARMA LTD

0.15MG;0.03MG

A207081 001 May 17, 2017 May NEWA

DESONIDE

OINTMENT;TOPICAL

DESONIDE

AB

HI-TECH PHARMACAL

0.05%

A208836 001 Mar 27, 2017 Mar NEWA

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

AB

! TARO

0.05%

A073210 001 Nov 30, 1990 Apr CAHN

AB

!

0.25%

A073193 001 Nov 30, 1990 Apr CAHN

>A>

+ @

0.25%

N017856 001 May CAHN

>D>

+ @ TARO PHARMS NORTH

0.25%

N017856 001 May CAHN

TOPICORT LP

>A>

+ @ TARO

0.05%

N018309 001 May CAHN

>D>

+ @ TARO PHARMS NORTH

0.05%

N018309 001 May CAHN

GEL;TOPICAL

DESOXIMETASONE

>D> AB

GROUPE PARIMA INC

0.05%

A204675 001 Aug 12, 2016 May CAHN

>A> AB

RISING PHARMS INC

0.05%

A204675 001 Aug 12, 2016 May CAHN

TOPICORT

AB

! TARO

0.05%

A074904 001 Jul 14, 1998 Apr CAHN

>A>

+ @

0.05%

N018586 001 Mar 29, 1982 May CAHN

>D>

+ @ TARO PHARMS NORTH

0.05%

N018586 001 Mar 29, 1982 May CAHN

+ @

0.05%

N018586 001 Mar 29, 1982 Jan CRLD

OINTMENT;TOPICAL

DESOXIMETASONE

>D> AB

GROUPE PARIMA INC

0.25%

A204272 001 Nov 30, 2016 May CAHN

>A> AB

RISING PHARMS INC

0.25%

A204272 001 Nov 30, 2016 May CAHN

TOPICORT

>A> AB

+! TARO

0.05%

N018594 001 Jan 17, 1985 May CAHN

AB

!

0.25%

A074286 001 Jun 07, 1996 Apr CAHN

>A>

+ @

0.25%

N018763 001 Sep 30, 1983 May CAHN

>D> AB

+! TARO PHARMS NORTH

0.05%

N018594 001 Jan 17, 1985 May CAHN

>D>

+ @

0.25%

N018763 001 Sep 30, 1983 May CAHN

SPRAY;TOPICAL

DESOXIMETASONE

AT

PERRIGO ISRAEL

0.25%

A206441 001 Jan 20, 2017 Jan NEWA

TOPICORT

AT

+! TARO

0.25%

N204141 001 Apr 11, 2013 Jan CFTG

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

>A>	AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May CAHN
>A>	AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May CAHN
>A>	AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May CAHN
>D>	AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	May CAHN
>D>	AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May CAHN
>D>	AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May CAHN

DEUTETRABENAZINE

TABLET;ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr NEWA
+		9MG	N208082	002	Apr 03, 2017	Apr NEWA
+	!	12MG	N208082	003	Apr 03, 2017	Apr NEWA

DEXAMETHASONE

TABLET;ORAL
DEXAMETHASONE

>D>	BP	!	PAR PHARM	6MG	A088481	001	Nov 28, 1983	May CHRS
>A>	BP			6MG	A088481	001	Nov 28, 1983	May CHRS

DEXAMETHASONE ACETATE

INJECTABLE;INJECTION
DEXAMETHASONE ACETATE

>D>		@	WATSON LABS	EQ 16MG BASE/ML	A087711	001	May 24, 1982	May CAHN
>A>		@	WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001	May 24, 1982	May CAHN

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb CAHN
----	---	------------	-------------------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC
MAXITROL

AT		SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341	001	May 22, 1984	Feb CAHN
----	--	------------	---------------------------------------	---------	-----	--------------	----------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL
DEXILANT

AB	+	TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr CFTG
AB		PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar CAHN
>A>	AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May CAHN
>A>	AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May NEWA
AP		WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr NEWA

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMPHETAMINE SULFATE

>D>		@	COREPHARMA	5MG	A090652	001	Mar 07, 2014	May CAHN
>D>		@		10MG	A090652	002	Mar 07, 2014	May CAHN
>A>		@	EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014	May CAHN
>A>		@		10MG	A090652	002	Mar 07, 2014	May CAHN

DEXTROSE

INJECTABLE;INJECTION									
DEXTROSE 10% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	10GM/100ML	N018080	001			Feb	CAHN
DEXTROSE 20% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982		Feb	CAHN
DEXTROSE 30% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985		Feb	CAHN
DEXTROSE 40% IN PLASTIC CONTAINER									
>D> AP	+	HOSPIRA	40GM/100ML	N018562	001	Mar 23, 1982		May	CAHN
>A> AP	+	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982		May	CAHN
DEXTROSE 5% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	50MG/ML	N016367	002			Feb	CAHN
DEXTROSE 50% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982		Feb	CAHN
DEXTROSE 70% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982		Apr	CAHN
AP	+		70GM/100ML	N019893	001	Dec 26, 1989		Feb	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION									
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;2	N017610	001			Feb	CAHN
34MG/100ML									

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION									
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;1	N019513	001	May 08, 1986		Feb	CAHN
5MG/100ML;260MG/100ML;25MG/100ML									

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION									
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;22	N017609	001			Feb	CAHN
2MG/100ML;526MG/100ML;502MG/100ML									

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION									
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001			Apr	CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003			Apr	CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002			Apr	CAHN

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION									
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983		Feb	CAHN
			5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988		Feb	CAHN
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988		Feb	CAHN
AP			5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983		Feb	CAHN
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988		Apr	CAHN
AP			5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988		Apr	CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988		Feb	CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988		Feb	CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988		Apr	CAHN
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
		ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001			Feb	CAHN
			5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988		Feb	CAHN
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP		ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983		Feb	CAHN
AP			5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988		Feb	CAHN

INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Apr CAHN
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Apr CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Apr CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Apr CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb CAHN
		5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb CAHN
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr CAHN
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

		DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001		Feb CAHN

DIAZEPAM

TABLET;ORAL

DIAZEPAM

@	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb CAHN
@		5MG	A070463	001	Feb 25, 1986	Feb CAHN
@		10MG	A070464	001	Feb 25, 1986	Feb CAHN

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

>D>	@	WATSON LABS	50MG	A075152	001	Nov 27, 1998	May CAHN
>A>	@	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

>A>	AT	ACTAVIS LABS UT INC	2%	A207238	001	May 15, 2017	May NEWA
	AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar CAHN
		PENNSAID					
>D>	+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	May CFTG
>A>	AT	+	2%	N204623	001	Jan 16, 2014	May CFTG
		+ @ NUVO PHARMS INC	1.5%	N020947	001	Nov 04, 2009	Apr CAHN
		+ @ NUVO RES INC	1.5%	N020947	001	Nov 04, 2009	Feb DISC

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb CAHN
	TABLET, DELAYED RELEASE;ORAL					
	DICLOFENAC SODIUM					
	@ ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr CAHN
	@	75MG	A074986	002	Feb 26, 1999	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

	@	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr DISC
AB	!	DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
AB	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP	LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb NEWA
----	---------------------	---------	---------	-----	--------------	----------

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

>D>	AB	MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010	May DISC
>A>		@	125MG	A090788	001	Apr 08, 2010	May DISC
>D>	AB		200MG	A090788	002	Apr 08, 2010	May DISC
>A>		@	200MG	A090788	002	Apr 08, 2010	May DISC
>D>	AB		250MG	A090788	003	Apr 08, 2010	May DISC
>A>		@	250MG	A090788	003	Apr 08, 2010	May DISC
>D>	AB		400MG	A090788	004	Apr 08, 2010	May DISC
>A>		@	400MG	A090788	004	Apr 08, 2010	May DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

+	!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr CTEC
---	---	----------------	--	---------	-----	--------------	----------

G, N/A

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

>D>		@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	May CAHN
>A>		@ EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008	May CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb NEWA
AB	!	TARO	0.05%	A075331	001	May 14, 1999	Apr CAHN
		PSORCON					
	+	@ PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985	Mar CRLD

DIGOXIN

ELIXIR;ORAL

DIGOXIN

+	!	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004	Jan CAHN
---	---	----------------------	-----------	---------	-----	--------------	----------

INJECTABLE;INJECTION

DIGOXIN

AP		SANDOZ INC	0.25MG/ML	A040481	001	Aug 21, 2003	Mar CAHN
		LANOXIN					

>A>	AP	+	!	COVIS PHARMA BV	0.25MG/ML	N009330	002		May CAHN
>D>	AP	+	!	COVIS PHARMA SARL	0.25MG/ML	N009330	002		May CAHN
				LANOXIN PEDIATRIC					
>A>		+	!	COVIS PHARMA BV	0.1MG/ML	N009330	004		May CAHN
>D>		+	!	COVIS PHARMA SARL	0.1MG/ML	N009330	004		May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan CAHN
----	--	----------------------	--------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB3		SUN PHARM INDS LTD	120MG	A203023	001	Jun 08, 2017	May NEWA
>A>	AB3			180MG	A203023	002	Jun 08, 2017	May NEWA
>A>	AB3			240MG	A203023	003	Jun 08, 2017	May NEWA
>A>	AB3			300MG	A203023	004	Jun 08, 2017	May NEWA

CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
>A>	AB3	360MG	A203023	005	Jun 08, 2017	May	NEWA
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP	! ATHENEX INC	5MG/ML	A074617	001	Feb 28, 1996	Mar	CAHN
AP	WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan	CAHN
TABLET;ORAL							
DILTIAZEM HYDROCHLORIDE							
	@ CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992	Feb	CAHN
	@	60MG	A074093	002	Nov 05, 1992	Feb	CAHN
	@	90MG	A074093	003	Nov 05, 1992	Feb	CAHN
	@	120MG	A074093	004	Nov 05, 1992	Feb	CAHN
<u>DIMENHYDRINATE</u>							
INJECTABLE;INJECTION							
DIMENHYDRINATE							
>D>	@ WATSON LABS	50MG/ML	A080615	001		May	CAHN
>A>	@ WATSON LABS TEVA	50MG/ML	A080615	001		May	CAHN
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
ELIXIR;ORAL							
DIPHENHYDRAMINE HYDROCHLORIDE							
>D>	! PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	May	CAHN
>A>	!	12.5MG/5ML	A087513	001	Feb 10, 1982	May	CAHN
INJECTABLE;INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
>D>	@ WATSON LABS INC	10MG/ML	A080873	001		May	CAHN
>D>	@	50MG/ML	A080873	002		May	CAHN
>A>	@ WATSON LABS TEVA	10MG/ML	A080873	001		May	CAHN
>A>	@	50MG/ML	A080873	002		May	CAHN
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE							
>D>	@ WATSON LABS INC	50MG/ML	A080873	003		May	CAHN
>A>	@ WATSON LABS TEVA	50MG/ML	A080873	003		May	CAHN
<u>DIPYRIDAMOLE</u>							
INJECTABLE;INJECTION							
DIPYRIDAMOLE							
AP	! ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar	CAHN
<u>DISULFIRAM</u>							
TABLET;ORAL							
DISULFIRAM							
AB	CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan	CAHN
AB		500MG	A091563	002	Dec 31, 2012	Jan	CAHN
>D>	@ WATSON LABS	500MG	A086890	001		May	CAHN
>A>	@ WATSON LABS TEVA	500MG	A086890	001		May	CAHN
<u>DIVALPROEX SODIUM</u>							
TABLET, DELAYED RELEASE;ORAL							
DIVALPROEX SODIUM							
AB	PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb	CAHN
AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb	CAHN
AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb	CAHN
<u>DOCETAXEL</u>							
INJECTABLE;INJECTION							
DOCETAXEL							
AP	ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb	CAHN
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb	CAHN
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb	CAHN
AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan	NEWA
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan	NEWA
+	HOSPIRA INC	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan	NEWA
!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017	Jan	NEWA
	@ PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan	DISC
	@	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan	DISC
	@	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan	DISC
	@	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan	DISC

DOFETILIDECAPSULE;ORAL
DOFETILIDE

AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
AB		0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
AB		0.5MG	A207058	003	Jun 06, 2016	Feb CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar CAHN
AB		10MG	A078662	002	May 31, 2011	Mar CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB		10MG;28MG	A208328	002	Jan 27, 2017	Jan NEWA
	NAMZARIC					
AB	+ FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+!	10MG;28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

>D>	@ IGI LABS INC	40MG/ML	N018656	001	Jun 28, 1983	May CAHN
>A>	@ TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar CAHN
----	------------	-------------------------	---------	-----	--------------	----------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
----	-------------	---------	---------	-----	--------------	----------

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>D>	@ WATSON LABS	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN
>A>	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN
	CREAM;TOPICAL					
	ZONALON					
	+! MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>A>	AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May NEWA
>A>	AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May NEWA
>A>	AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

>A>	AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May NEWA
>A>	AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May NEWA

DOXYCYCLINE HYCLATEINJECTABLE; INJECTION
VIBRAMYCIN

+ @ PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD
+ @	EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

CARIBE HOLDINGS

EQ 50MG BASE

A062269 003

Mar CMFD

@

EQ 50MG BASE

A062269 003

Jan CAHN

AB

EQ 100MG BASE

A062269 002 Nov 08, 1982 Jan CAHN

>D>

@ COREPHARMA

EQ 20MG BASE

A065182 001 May 13, 2005 May CAHN

>A>

@ EPIC PHARMA LLC

EQ 20MG BASE

A065182 001 May 13, 2005 May CAHN

>A> AB

MAYNE PHARMA INC

EQ 75MG BASE

A208765 001 Jun 14, 2017 May NEWA

>A> AB

EQ 150MG BASE

A208765 002 Jun 14, 2017 May NEWA

DRONABINOLSOLUTION; ORAL
SYNDROS

+! INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA
---------------------	--------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB MACLEODS PHARMS LTD

EQ 20MG BASE

A204815 001 Mar 23, 2017 Mar NEWA

AB

EQ 30MG BASE

A204815 002 Mar 23, 2017 Mar NEWA

AB

EQ 60MG BASE

A204815 003 Mar 23, 2017 Mar NEWA

>A> AB

PRINSTON INC

EQ 20MG BASE

A206653 001 May 18, 2017 May NEWA

>A> AB

EQ 30MG BASE

A206653 002 May 18, 2017 May NEWA

>A> AB

EQ 60MG BASE

A206653 003 May 18, 2017 May NEWA

AB

ZYDUS HLTHCARE

EQ 20MG BASE

A090739 001 Jan 08, 2014 Apr CAHN

AB

EQ 30MG BASE

A090739 002 Jan 08, 2014 Apr CAHN

AB

EQ 60MG BASE

A090739 003 Jan 08, 2014 Apr CAHN

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

>D> AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May	CAHN
>A> AB		0.5MG	A203118	001	Nov 20, 2015	May	CAHN
AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA

DYPHYLLINETABLET; ORAL
LUFYLLIN

@ MYLAN SPECIALITY LP

200MG

A084566 001

Mar CAHN

@

400MG

A084566 002

Mar CAHN

ECONAZOLE NITRATEAEROSOL, FOAM; TOPICAL
ECOZA

>A>	+! CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	May	CAHN
>D>	+! EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	May	CAHN

CREAM; TOPICAL
SPECTAZOLE

+ @ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Mar	CMS1
-------------------	----	---------	-----	--------------	-----	------

>A> EDARAVONESOLUTION; IV (INFUSION)
RADICAVA

>A>	+! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	May	NEWA
-----	----------------------	-----------------------	---------	-----	--------------	-----	------

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON

+ @ TELIGENT	10MG/ML	N007959	001		Apr	CAHN
--------------	---------	---------	-----	--	-----	------

TENSILON PRESERVATIVE FREE

+ @ TELIGENT	10MG/ML	N007959	002		Apr	CAHN
--------------	---------	---------	-----	--	-----	------

>D>	<u>ELVITEGRAVIR</u>										
>D>	TABLET;ORAL										
>D>	VITEKTA										
>D>	+	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	May	DISC			
>A>	+	@	85MG	N203093	001	Sep 24, 2014	May	DISC			
>D>	+	!	150MG	N203093	002	Sep 24, 2014	May	DISC			
>A>	+	@	150MG	N203093	002	Sep 24, 2014	May	DISC			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>											
TABLET;ORAL											
>A>	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE										
>A>	AB	TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May	NEWA			
TRUVADA											
>D>	+	!	GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May	CFTG		
>A>	AB	+	!	200MG;300MG	N021752	001	Aug 02, 2004	May	CFTG		
<u>ENALAPRILAT</u>											
INJECTABLE;INJECTION											
ENALAPRILAT											
AP	!	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN			
VASOTEC											
	+	@	BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar	CRLD		
<u>ENTACAPONE</u>											
TABLET;ORAL											
ENTACAPONE											
>A>	AB	MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May	NEWA			
>D>	AB	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May	DISC			
>A>		@	200MG	A202394	001	May 13, 2013	May	DISC			
<u>ENTECAVIR</u>											
TABLET;ORAL											
ENTECAVIR											
>A>	AB	SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May	NEWA			
>A>	AB		1MG	A206672	002	May 11, 2017	May	NEWA			
<u>EPHEDRINE SULFATE</u>											
SOLUTION;INTRAVENOUS											
AKOVAZ											
AP	+	!	FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar	CTEC		
EPHEDRINE SULFATE											
AP			AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar	NEWA		
SOLUTION;IV (INFUSION)											
CORPHEDRA											
			PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan	NEWA		
<u>EPINASTINE HYDROCHLORIDE</u>											
SOLUTION/DROPS;OPHTHALMIC											
EPINASTINE HYDROCHLORIDE											
AT			AKORN	0.05%	A204055	001	May 05, 2017	Apr	NEWA		
AT			SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN		
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>											
INJECTABLE;INJECTION											
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE											
	@		BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb	CAHN		
	@			0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb	CAHN		
	@		WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar	CAHN		
	@			0.01MG/ML;2%	A080406	002		Mar	CAHN		
<u>EPLERENONE</u>											
TABLET;ORAL											
EPLERENONE											
AB			MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan	NEWA		
AB				50MG	A203896	002	Feb 02, 2017	Jan	NEWA		

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
>D> AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
>A> AP		2MG/ML	A205581	001	Dec 08, 2016	May CAHN
>D> AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN
>A> AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

>D> AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	May CHRS
>A>	!	1MG	A081113	001	Oct 31, 1991	May CHRS
	HYDERGINE					
>D> AB	+! NOVARTIS	1MG	N017993	001		May DISC
>A>	+ @	1MG	N017993	001		May DISC

ERYTHROMYCIN

GEL; TOPICAL

E-GLADES

@ MYLAN PHARMS INC

2%

A065009 001 Mar 18, 2002 Jan CAHN

ERYGEL

AT +! MYLAN PHARMS INC

2%

N050617 001 Oct 21, 1987 Jan CAHN

ERYTHROMYCIN

AT PERRIGO CO

2%

A063211 001 Jan 29, 1993 Apr CAHN

SOLUTION; TOPICAL

A/T/S

@ TARO

2%

A062405 001 Nov 18, 1982 Apr CAHN

SWAB; TOPICAL

ERYTHROMYCIN

@ MYLAN PHARMS INC

2%

A064128 001 Jul 03, 1996 Jan CAHN

AT ! PERRIGO CO

2%

A064126 001 Jul 03, 1996 Apr CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

>A> AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May NEWA
>A> AB		EQ 10MG BASE	A205619	002	May 17, 2017	May NEWA
>A> AB		EQ 20MG BASE	A205619	003	May 17, 2017	May NEWA

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

>D>	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May CRLD
>A>	+	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

>D> AP	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May CHRS
>A> AP	!	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May CHRS
>D> AP		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May CHRS
>A> AP	!	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May CHRS
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb NEWA
>A> AP	MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May NEWA
>A> AP		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May NEWA
>D>	NEXIUM IV					
>D> AP	+! ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May DISC
>A>	+ @	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May DISC
>D> AP	+!	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May DISC
>A>	+ @	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May DISC

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADERM

>D> BX	+ NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May DISC
>A>	+ @	0.05MG/24HR	N019081	002	Sep 10, 1986	May DISC
>D> BX	+!	0.1MG/24HR	N019081	003	Sep 10, 1986	May DISC
>A>	+ @	0.1MG/24HR	N019081	003	Sep 10, 1986	May DISC

FILM, EXTENDED RELEASE;TRANSDERMAL
VIVELLE

>D>	AB1	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May DISC
>A>		@	0.05MG/24HR	N020323	002	Oct 28, 1994	May DISC
>D>	AB1		0.1MG/24HR	N020323	004	Oct 28, 1994	May DISC
>A>		@	0.1MG/24HR	N020323	004	Oct 28, 1994	May DISC

GEL, METERED;TRANSDERMAL
ELESTRIN

	+	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar CAHN
SPRAY;TRANSDERMAL							
EVAMIST							
>D>	+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN
>A>	+	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

	@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr CAHN
	@		20MG/ML	A040628	002	Oct 04, 2007	Apr CAHN
	@		40MG/ML	A040628	003	Oct 04, 2007	Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

AB		MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB			1MG;0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVIA							
		TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
			0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
	@		0.625MG	N021443	003	May 10, 2004	Apr CAHN
			0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
	@		1.25MG	N021443	004	May 10, 2004	Apr CAHN

ESTRONE

INJECTABLE;INJECTION
ESTRONE

>D>	@	WATSON LABS	5MG/ML	A085239	001		May CAHN
>A>	@	WATSON LABS TEVA	5MG/ML	A085239	001		May CAHN

ESTROPIPATE

TABLET;ORAL
ESTROPIPATE

>D>	AB	BARR	0.75MG	A040135	001	Nov 27, 1996	May DISC
>A>		@	0.75MG	A040135	001	Nov 27, 1996	May DISC
>D>	AB		1.5MG	A040135	002	Nov 27, 1996	May DISC
>A>		@	1.5MG	A040135	002	Nov 27, 1996	May DISC
>D>	AB		3MG	A040135	003	Nov 27, 1996	May DISC
>A>		@	3MG	A040135	003	Nov 27, 1996	May DISC
>D>	AB	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	May CHRS
>A>	!		3MG	A081215	001	Sep 23, 1993	May CHRS
	AB		3MG	A081215	001	Sep 23, 1993	Feb CAHN
>D>		OGEN .625					
>D>	AB	PHARMACIA AND UPJOHN	0.75MG	A083220	001		May DISC
>A>		@	0.75MG	A083220	001		May DISC
>D>		OGEN 1.25					
>D>	AB	PHARMACIA AND UPJOHN	1.5MG	A083220	002		May DISC
>A>		@	1.5MG	A083220	002		May DISC
>D>		OGEN 2.5					
>D>	AB	! PHARMACIA AND UPJOHN	3MG	A083220	003		May DISC
>A>		@	3MG	A083220	003		May DISC

ETELCALCETIDE

SOLUTION;INTRAVENOUS
PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb NEWA
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb NEWA
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb NEWA

ETHACRYNIC ACID

TABLET;ORAL
ETHACRYNIC ACID

AB WEST-WARD PHARMS INT 25MG A207262 001 Feb 23, 2017 Feb NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21
ZOVIA 1/35E-21

@ WATSON PHARMS TEVA 0.035MG;1MG A072720 001 Dec 30, 1991 Mar CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
LO SIMPESSE

AB AUROBINDO PHARMA LTD 0.02MG,0.01MG;0.01MG,N/A A206852 001 Apr 28, 2017 Apr NEWA
SIMPESSE

AB AUROBINDO PHARMA LTD 0.03MG,0.01MG;0.15MG,N/A A206851 001 Apr 07, 2017 Mar NEWA

TABLET;ORAL-28
ELIFEMME

AB LABS LEON FARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A202507 001 Dec 04, 2015 Feb CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
XULANE

AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Mar CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21
NORETHIN 1/35E-21

@ WATSON PHARMS TEVA 0.035MG;1MG A071480 001 Apr 12, 1988 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL
@ WATSON PHARMS TEVA 0.035MG;1MG A070685 001 Jan 29, 1987 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

>D> @ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991 May CAHN

>A> @ WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991 May CAHN

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB ACCORD HLTHCARE 0.035MG;1MG A206864 001 Apr 28, 2017 Apr NEWA

>D> AB WATSON LABS 0.035MG;1MG A070687 001 Jan 29, 1987 May CAHN

>A> AB WATSON LABS TEVA 0.035MG;1MG A070687 001 Jan 29, 1987 May CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

>D> WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071044 001 Apr 01, 1988 May CAHN

>A> WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A071044 001 Apr 01, 1988 May CAHN

TABLET, CHEWABLE;ORAL

NEXESTA FE

AB AUROBINDO PHARMA LTD 0.035MG;0.4MG A207535 001 Feb 02, 2017 Jan NEWA

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB ACCORD HLTHCARE 0.035MG;0.4MG A207066 001 Mar 29, 2017 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.0025MG;0.5MG A207260 001 Feb 02, 2017 Jan NEWA

TABLET;ORAL-28

AUROVELA FE 1.5/30

>A> AB AUROBINDO PHARMA LTD 0.03MG;1.5MG A207580 001 Jun 15, 2017 May NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

NORGESTREL AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.05MG;0.5MG A202875 001 May 08, 2017 Apr NEWA

OGESTREL 0.5/50-28

>D> ! WATSON LABS 0.05MG;0.5MG A075406 002 Dec 15, 1999 May CTEC

>A> AB ! 0.05MG;0.5MG A075406 002 Dec 15, 1999 May CTEC

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

>D>	AA	PHARM ASSOC	250MG/5ML	A 040253	001	Nov 22, 2000	May CAHN
>A>	AA		250MG/5ML	A 040253	001	Nov 22, 2000	May CAHN
		ZARONTIN					
	AA	! PARKE-DAVIS	250MG/5ML	A 080258	001		Mar CAHN

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ CHARTWELL MOLECULES

200MG

A 074842 001 Jul 17, 1997 Mar CAHN

@

300MG

A 074842 002 Jul 17, 1997 Mar CAHN

@ CHARTWELL PHARMS LLC

200MG

A 074842 001 Jul 17, 1997 Jan CAHN

@

300MG

A 074842 002 Jul 17, 1997 Jan CAHN

@ ECI PHARMS LLC

300MG

A 074929 001 Jan 30, 1998 Apr CAHN

TABLET; ORAL

ETODOLAC

@ CHARTWELL MOLECULES

400MG

A 074841 001 Jun 27, 1997 Jan CAHN

@ ECI PHARMS LLC

400MG

A 074927 001 Oct 30, 1997 Apr CAHN

>D> AB MYLAN PHARMS INC

400MG

A 075104 001 Feb 06, 1998 May DISC

>A> @

400MG

A 075104 001 Feb 06, 1998 May DISC

AB

400MG

A 075104 001 Feb 06, 1998 Mar CAHN

>D> AB

500MG

A 075104 002 Nov 20, 1998 May DISC

>A> @

500MG

A 075104 002 Nov 20, 1998 May DISC

AB

500MG

A 075104 002 Nov 20, 1998 Mar CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP AUROBINDO PHARMA LTD

2MG/ML

A 206126 001 Feb 24, 2017 Feb NEWA

AP GLAND PHARMA LTD

2MG/ML

A 209058 001 Apr 18, 2017 Apr NEWA

AP MYLAN LABS LTD

2MG/ML

A 201044 001 Feb 07, 2017 Jan NEWA

AP WEST-WARD PHARMS INT

2MG/ML

A 074593 001 Nov 04, 1996 Jan CAHN

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB MYLAN PHARMS INC

25MG

A 203315 001 Mar 10, 2017 Feb NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

>A> AB AMNEAL PHARMS CO

10MG

A 208803 001 Jun 12, 2017 May NEWA

>A> AB APOTEX INC

10MG

A 208332 001 Jun 12, 2017 May NEWA

>A> AB OHM LABS INC

10MG

A 207311 001 Jun 12, 2017 May NEWA

>A> AB SANDOZ INC

10MG

A 203931 001 Jun 12, 2017 May NEWA

>A> AB TEVA PHARMS USA

10MG

A 078724 001 Jun 12, 2017 May NEWA

>A> AB WATSON LABS INC

10MG

A 200831 001 Jun 12, 2017 May NEWA

>A> AB ZYDUS PHARMS USA INC

10MG

A 204331 001 Jun 12, 2017 May NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

>D> AB DR REDDYS LABS INTL

10MG; 10MG

A 200909 001 Apr 26, 2017 May CAHN

AB

10MG; 10MG

A 200909 001 Apr 26, 2017 Apr NEWA

>D> AB 10MG; 20MG

10MG; 20MG

A 200909 002 Apr 26, 2017 May CAHN

AB

10MG; 20MG

A 200909 002 Apr 26, 2017 Apr NEWA

>D> AB 10MG; 40MG

10MG; 40MG

A 200909 003 Apr 26, 2017 May CAHN

AB

10MG; 40MG

A 200909 003 Apr 26, 2017 Apr NEWA

>D> AB 10MG; 80MG

10MG; 80MG

A 200909 004 Apr 26, 2017 May CAHN

AB

10MG; 80MG

A 200909 004 Apr 26, 2017 Apr NEWA

>A> AB DR REDDYS LABS SA

10MG; 10MG

A 200909 001 Apr 26, 2017 May CAHN

>A> AB 10MG; 20MG

10MG; 20MG

A 200909 002 Apr 26, 2017 May CAHN

>A> AB 10MG; 40MG

10MG; 40MG

A 200909 003 Apr 26, 2017 May CAHN

>A> AB 10MG; 80MG

10MG; 80MG

A 200909 004 Apr 26, 2017 May CAHN

AB

IMPAX LABS INC

10MG; 10MG

A 201890 001 Apr 26, 2017 Apr NEWA

AB

10MG; 20MG

A 201890 002 Apr 26, 2017 Apr NEWA

AB

10MG; 40MG

A 201890 003 Apr 26, 2017 Apr NEWA

AB

10MG; 80MG

A 201890 004 Apr 26, 2017 Apr NEWA

AB

WATSON LABS INC

10MG; 10MG

A 202968 001 Apr 26, 2017 Apr NEWA

AB

10MG; 20MG

A 202968 002 Apr 26, 2017 Apr NEWA

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		10MG;40MG	A202968	003	Apr 26, 2017	Apr NEWA	
AB		10MG;80MG	A202968	004	Apr 26, 2017	Apr NEWA	
VYTORIN							
AB	+	MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Apr CFTG
AB	+		10MG;20MG	N021687	002	Jul 23, 2004	Apr CFTG
AB	+		10MG;40MG	N021687	003	Jul 23, 2004	Apr CFTG
AB	+	!	10MG;80MG	N021687	004	Jul 23, 2004	Apr CFTG

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan CHRS
FAMVIR							
	+	@ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan DISC
	+	@	250MG	N020363	001	Apr 26, 1996	Jan DISC
	+	@	500MG	N020363	002	Jun 29, 1994	Jan DISC

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

AP		ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar CAHN
AP			10MG/ML	A075684	001	Apr 16, 2001	Mar CAHN
FAMOTIDINE PRESERVATIVE FREE							
AP		ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar CAHN
AP			10MG/ML	A075825	001	Apr 17, 2001	Mar CAHN

TABLET;ORAL

FAMOTIDINE

AB		PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr CAHN
AB			40MG	A077352	001	Jul 27, 2005	Apr CAHN

FELBAMATE

SUSPENSION;ORAL

FELBATOL

AB	+	!	MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar CAHN
----	---	---	---------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

FELBAMATE

AB		IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb CAHN
AB			600MG	A202284	002	Nov 04, 2015	Feb CAHN
AB		TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr NEWA
AB			600MG	A207093	002	Apr 20, 2017	Apr NEWA
>A>	AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May NEWA
>A>	AB		600MG	A208970	002	May 30, 2017	May NEWA
FELBATOL							
AB	+	MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar CAHN
AB	+	!	600MG	N020189	002	Jul 29, 1993	Mar CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar NEWA
AB			134MG	A205566	002	Apr 07, 2017	Mar NEWA
AB			200MG	A205566	003	Apr 07, 2017	Mar NEWA
AB		INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar NEWA
AB			134MG	A207378	002	Mar 28, 2017	Mar NEWA
AB			200MG	A207378	003	Mar 28, 2017	Mar NEWA

TABLET;ORAL

FENOFIBRATE

AB	!	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar CHRS
AB		RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar CHRS

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

AP		SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar CAHN
----	--	------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

>D>	@ WATSON LABS	EQ 600MG BASE	A072407	001	Aug 17, 1988	May CAHN
>A>	@ WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988	May CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar CAHN

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar CAHN
----	------------------	------------	---------	-----	--------------	----------

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar CAHN

FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar CAHN

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar CAHN

SPRAY;SUBLINGUAL

SUBSYS

>A>	+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May CAHN
>A>	+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
>A>	+		0.4MG	N202788	003	Jan 04, 2012	May CAHN
>A>	+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
>A>	+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
>A>	+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
>A>	+		1.6MG	N202788	007	Aug 30, 2012	May CAHN
>D>	+	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012	May CAHN
>D>	+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
>D>	+		0.4MG	N202788	003	Jan 04, 2012	May CAHN
>D>	+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
>D>	+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
>D>	+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
>D>	+		1.6MG	N202788	007	Aug 30, 2012	May CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar CAHN
>D> AB	ACTAVIS TOTOWA	5MG	A077914	001	Mar 28, 2007	May CAHN
>A> AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar CHRS

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CHRS
AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

TABLET;ORAL

FLUCONAZOLE

AB		UNIQUE PHARM LABS	150MG	A076957	004	Feb 27, 2017	Feb NEWA
AB		ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
AB			100MG	A208963	002	Feb 16, 2017	Feb NEWA
AB			150MG	A208963	003	Feb 16, 2017	Feb NEWA
AB			200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
----	--	-------------	--------------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr CAHN
AP			1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr CAHN
AP		WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

+	!	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar CAHN
---	---	---------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
AT			0.025%	A088169	001	Dec 16, 1982	Jan CAHN
		@ TARO	0.01%	A040035	001	Oct 31, 1994	Apr CAHN
		@	0.025%	A040042	001	Oct 31, 1994	Apr CAHN

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
AT		TARO	0.025%	A040041	001	Sep 15, 1994	Apr CAHN

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1		FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan CAHN
AB		PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr CAHN
AB1		TARO	0.05%	A071500	001	Jun 10, 1987	Mar CMFD

FLUOCINONIDE EMULSIFIED BASE

>D>		@ G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May CMFD
>A>	AB2		0.05%	A074204	001	Jun 13, 1995	May CMFD

GEL;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan CAHN
AB	!	TARO	0.05%	A074935	001	Jul 29, 1997	Apr CAHN

OINTMENT;TOPICAL
FLUOCINONIDE

AB	!	TARO	0.05%	A075008	001	Jun 30, 1999	Apr CAHN
SOLUTION;TOPICAL							
FLUOCINONIDE							
AT	!	TARO	0.05%	A074799	001	Dec 31, 1996	Apr CAHN
LIDEX							
AT	+	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar CRLD

FLUOROURACIL

INJECTABLE;INJECTION
FLUOROURACIL

>A>	AP	SAGENT PHARMS	500MG/10ML (50MG/ML)	A203608	001	May 11, 2017	May NEWA
>A>	AP		1GM/20ML (50MG/ML)	A203608	002	May 11, 2017	May NEWA
		+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CRLD
SOLUTION;TOPICAL							
FLUOROURACIL							
AT		TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar CAHN
AT			5%	A076526	002	Nov 05, 2003	Mar CAHN

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN
>D>	AA	!	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002
>A>	AA	!		EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar NEWA
AB			EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar NEWA
		+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
FLUPHENAZINE HYDROCHLORIDE

		@ ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN
>D>		!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996
>A>		!		5MG/ML	A074725	001	Sep 16, 1996

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

>D>		!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996
>A>		!		2.5MG/5ML	A040146	001	Aug 21, 1996

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE
@ AUROLIFE PHARMA LLC 15MG

A071717	002	Jul 31, 1991	Jan CMS1
---------	-----	--------------	----------

FLUTICASONE PROPIONATE

POWDER;INHALATION
ARMONAIR RESPICLICK

+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
+	!	0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION
AIRDUO RESPICLICK

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
+	!	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FLUVASTATIN SODIUM

CAPSULE;ORAL
FLUVASTATIN SODIUM

>D>	AB	MYLAN PHARMS INC	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
>A>	AB	!	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
>D>		LESCOL					
>D>	AB	+	NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993
>A>		+	@	EQ 20MG BASE	N020261	001	Dec 31, 1993
>D>	AB	+	!	EQ 40MG BASE	N020261	002	Dec 31, 1993

		CAPSULE;ORAL							
		LESCOL							
>A>	+	@	EQ 40MG BASE	N020261	002	Dec 31, 1993	May	DISC	
		<u>FLUVOXAMINE MALEATE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL							
		FLUVOXAMINE MALEATE							
AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr	CHRS	
		LUVOX CR							
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr	DISC	
	+	@	150MG	N022033	002	Feb 28, 2008	Apr	DISC	
		TABLET;ORAL							
		FLUVOXAMINE MALEATE							
>A>	@	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May	CAHN	
>A>	@		50MG	A075900	002	Feb 23, 2006	May	CAHN	
>A>	@		100MG	A075900	003	Feb 23, 2006	May	CAHN	
>D>	@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	May	CAHN	
>D>	@		50MG	A075900	002	Feb 23, 2006	May	CAHN	
>D>	@		100MG	A075900	003	Feb 23, 2006	May	CAHN	
		<u>FOLIC ACID</u>							
		TABLET;ORAL							
		FOLIC ACID							
	@	CONTRACT PHARMACAL	1MG	A085061	001		Mar	DISC	
		<u>FORMOTEROL FUMARATE</u>							
		POWDER;INHALATION							
		FORADIL							
	+	@ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb	DISC	
		<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE</u>							
		AEROSOL, METERED;INHALATION							
		BEVESPI AEROSPHERE							
	+	! ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar	CAHN	
		<u>FOSINOPRIL SODIUM</u>							
		TABLET;ORAL							
		MONOPRIL							
	+	@ BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan	CRLD	
	+	@	20MG	N019915	003	May 16, 1991	Jan	CRLD	
	+	@	40MG	N019915	004	Mar 28, 1995	Jan	CRLD	
		<u>FOSPHENYTOIN SODIUM</u>							
		INJECTABLE;INJECTION							
		FOSPHENYTOIN SODIUM							
	@	HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar	DISC	
AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan	CAHN	
AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan	CAHN	
		<u>FUROSEMIDE</u>							
		TABLET;ORAL							
		FUROSEMIDE							
BX		IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Apr	CTEC	
BX			40MG	A078010	002	Sep 18, 2006	Apr	CTEC	
BX			80MG	A078010	003	Sep 18, 2006	Apr	CTEC	
AB		PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb	CAHN	
AB			40MG	A076796	002	Mar 26, 2004	Feb	CAHN	
AB			80MG	A076796	003	Mar 26, 2004	Feb	CAHN	
>D> AB		SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May	DISC	
>A>	@		20MG	A091258	001	Apr 01, 2014	May	DISC	
>D> AB			40MG	A091258	002	Apr 01, 2014	May	DISC	
>A>	@		40MG	A091258	002	Apr 01, 2014	May	DISC	
>D> AB			80MG	A091258	003	Apr 01, 2014	May	DISC	
>A>	@		80MG	A091258	003	Apr 01, 2014	May	DISC	
>D>	@	WATSON LABS	20MG	A070449	001	Nov 22, 1985	May	CAHN	
>D>	@		80MG	A070528	001	Jan 07, 1986	May	CAHN	
>A>	@	WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985	May	CAHN	
>A>	@		80MG	A070528	001	Jan 07, 1986	May	CAHN	
AB		WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan	CAHN	
AB			40MG	N018823	002	Nov 10, 1983	Jan	CAHN	

GABAPENTINCAPSULE;ORAL
GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA

TABLET;ORAL
GABAPENTIN

>D>	AB	GLENMARK GENERICS	600MG	A077662	001	Aug 18, 2006	May CAHN
>D>	AB		800MG	A077662	002	Aug 18, 2006	May CAHN
>A>	AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
>A>	AB		800MG	A077662	002	Aug 18, 2006	May CAHN
	AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
	AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA

GANCICLOVIRSOLUTION;IV (INFUSION)
GANCICLOVIR

+	!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
---	---	----------------------	----------------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT		SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

>A>	AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
>A>	AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
>A>	AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

AB		CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN
----	--	-----------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATETABLET;ORAL
FACTIVE

AB	+	!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar CAHN
----	---	---	-------------	---------------	---------	-----	--------------	----------

GENTAMICIN SULFATECREAM;TOPICAL
GENTAMICIN SULFATE

	AT	@	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan DISC
		!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
		@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

OINTMENT;TOPICAL

GENTAMICIN SULFATE

	AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
--	----	--	--------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC
GENTAMICIN SULFATE

	AT		SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar CAHN
--	----	--	------------	--------------	---------	-----	--	----------

GLIMEPIRIDETABLET;ORAL
GLIMEPIRIDE

>D>		@	COREPHARMA	1MG	A077274	001	Oct 06, 2005	May CAHN
>D>		@		2MG	A077274	002	Oct 06, 2005	May CAHN
>D>		@		4MG	A077274	003	Oct 06, 2005	May CAHN
>A>		@	EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005	May CAHN
>A>		@		2MG	A077274	002	Oct 06, 2005	May CAHN
>A>		@		4MG	A077274	003	Oct 06, 2005	May CAHN
	AB		PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb CAHN
	AB			2MG	A077370	002	Dec 23, 2005	Feb CAHN
	AB			4MG	A077370	003	Dec 23, 2005	Feb CAHN
	AB			8MG	A077370	004	Dec 23, 2005	Feb CAHN

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

>D>	AB	WATSON LABS	5MG	A074223	001	Feb 27, 1995	May CAHN
>D>	AB		10MG	A074223	002	Feb 27, 1995	May CAHN
>A>	AB	WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May CAHN
>A>	AB		10MG	A074223	002	Feb 27, 1995	May CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May NEWA
>A>	AB		5MG	A206928	002	May 12, 2017	May NEWA
>A>	AB		10MG	A206928	003	May 12, 2017	May NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	COREPHARMA	2.5MG;250MG	A077507	001	Oct 27, 2005	May CAHN
>D>	AB		2.5MG;500MG	A077507	002	Oct 27, 2005	May CAHN
>D>	AB		5MG;500MG	A077507	003	Oct 27, 2005	May CAHN
>A>	AB	EPIC PHARMA LLC	2.5MG;250MG	A077507	001	Oct 27, 2005	May CAHN
>A>	AB		2.5MG;500MG	A077507	002	Oct 27, 2005	May CAHN
>A>	AB		5MG;500MG	A077507	003	Oct 27, 2005	May CAHN

METAGLIP

+	@	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
+	@		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
+	@		5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD

GLYBURIDE

TABLET;ORAL

GLYBURIDE

>D>	AB1	COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	May CAHN
>D>	AB1		2.5MG	A076257	002	Jun 27, 2002	May CAHN
>D>	AB1		5MG	A076257	003	Jun 27, 2002	May CAHN
>A>	AB1	EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May CAHN
>A>	AB1		2.5MG	A076257	002	Jun 27, 2002	May CAHN
>A>	AB1		5MG	A076257	003	Jun 27, 2002	May CAHN
	AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb CAHN
	AB2		2.5MG	A206079	002	Sep 30, 2015	Feb CAHN
	AB2		5MG	A206079	003	Sep 30, 2015	Feb CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb CAHN
@		2.5MG;500MG	A076731	002	Nov 19, 2004	Feb CAHN
@		5MG;500MG	A076731	003	Nov 19, 2004	Feb CAHN

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	1.5GM/100ML	N018315	001		Feb CAHN
----	-----------------	-------------	---------	-----	--	----------

GLYCOPYRROLATE

POWDER;INHALATION

SEEBRI

+	!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan CAHN
---	---	---------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

GLYCOPYRROLATE

>D>	@	COREPHARMA	1MG	A040568	001	Dec 22, 2004	May CAHN
>D>	@		2MG	A040568	002	Dec 22, 2004	May CAHN
>A>	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May CAHN
>A>	@		2MG	A040568	002	Dec 22, 2004	May CAHN
>A>	AA	SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May CAHN
>A>	AA		2MG	A091182	002	Feb 03, 2014	May CAHN
>D>	AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	May CAHN
>D>	AA		2MG	A091182	002	Feb 03, 2014	May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATEPOWDER; INHALATION
UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH;27.5MCG/INH N207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDEINJECTABLE; INJECTION
FACTREL

@ WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar CAHN
@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar CAHN
@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar CAHN

GONADOTROPIN, CHORIONICINJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL N017016 006 Jan CMFD

GOSERELIN ACETATEIMPLANT; IMPLANTATION
ZOLADEX

>D>	+! ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May CAHN
>D>	+!	EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May CAHN
>A>	+! TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May CAHN
>A>	+!	EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar CAHN
----	---------------	---	---------	-----	--------------	----------

NEOSPORIN

AT	! MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr CAHN
----	------------------	---	---------	-----	--	----------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Mar NEWA
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Mar NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan NEWA
AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078534	001	Apr 30, 2009	Mar CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

>D>	@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	May CAHN
>A>	@ EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May CAHN
AB	TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr CHRS
	ULTRAVATE					
AB	+ SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr CHRS
AB	+!	0.05%	N019967	001	Dec 27, 1990	Mar CAHN

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr CAHN
----	----------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ FRONTIDA BIOPHARM

20MG

A071177 001 Jan 07, 1988 Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

>A> AO

GLAND PHARMA LTD

EQ 50MG BASE/ML

A205241 001 May 12, 2017 May NEWA

>A> AO

EQ 100MG BASE/ML

A205241 002 May 12, 2017 May NEWA

@ SANDOZ INC

EQ 50MG BASE/ML

A076463 001 Jun 24, 2005 Mar CAHN

@

EQ 100MG BASE/ML

A076463 002 Jun 24, 2005 Mar CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

>D> AA

PHARM ASSOC

EQ 2MG BASE/ML

A073037 001 Feb 26, 1993 May CAHN

>A> AA

EQ 2MG BASE/ML

A073037 001 Feb 26, 1993 May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

@ SANDOZ INC

EQ 5MG BASE/ML

A076464 001 Sep 29, 2004 Mar CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP

GLAND PHARMA LTD

5,000 UNITS/ML

A205323 001 Feb 06, 2017 Jan NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA

ABHAI LLC

1.5MG/5ML; 5MG/5ML

A207487 001 Feb 21, 2017 Feb NEWA

AA

BIO-PHARM INC

1.5MG/5ML; 5MG/5ML

A204765 001 Mar 06, 2017 Feb NEWA

AA

NOVEL LABS INC

1.5MG/5ML; 5MG/5ML

A203535 001 Feb 13, 2017 Jan NEWA

AA

PADDOCK LLC

1.5MG/5ML; 5MG/5ML

A205731 001 Feb 15, 2017 Jan NEWA

TABLET; ORAL

TUSSIGON

AA

!

KING PHARMS

1.5MG; 5MG

A088508 001 Jul 30, 1985 Feb CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A> AA

SCIEGEN PHARMS INC

10MG

A205236 001 May 26, 2017 May NEWA

>A> AA

25MG

A205236 002 May 26, 2017 May NEWA

>A> AA

50MG

A205236 003 May 26, 2017 May NEWA

>A> AA

100MG

A205236 004 May 26, 2017 May NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB

PRINSTON INC

12.5MG

A075907 001 Sep 17, 2002 Feb CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB

PRINSTON INC

25MG

A040412 001 Mar 29, 2002 Feb CAHN

AB

50MG

A040412 002 Mar 29, 2002 Feb CAHN

>D>

@ WATSON LABS

50MG

A083232 001 May CAHN

>A>

@ WATSON LABS TEVA

50MG

A083232 001 May CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB

ATLAS PHARMS LLC

12.5MG; 150MG

A203036 001 Jan 15, 2016 Mar CAHN

AB

12.5MG; 300MG

A203036 002 Jan 15, 2016 Mar CAHN

AB

25MG; 300MG

A203036 003 Jan 15, 2016 Mar CAHN

>A> AB

WEST-WARD PHARMS INT

25MG; 300MG

A090351 003 Jun 08, 2017 May NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May NEWA
>A>	AB		12.5MG;20MG	A204058	002	May 23, 2017	May NEWA
>A>	AB		25MG;20MG	A204058	003	May 23, 2017	May NEWA
		PRINZIDE					
	+	@ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan CRLD
	+	@	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@		12.5MG;15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@		25MG;15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB		HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB			25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A204233	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A204233	003	Apr 24, 2017	Apr NEWA
AB		AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A205391	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A205391	003	Apr 24, 2017	Apr NEWA
AB		PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A207804	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A207804	003	Apr 24, 2017	Apr NEWA
AB		TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr NEWA
AB			12.5MG;40MG	A200532	002	Apr 24, 2017	Apr NEWA
AB			25MG;40MG	A200532	003	Apr 24, 2017	Apr NEWA
AB		TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr NEWA
AB			12.5MG;40MG	A206515	002	May 03, 2017	Apr NEWA
AB			25MG;40MG	A206515	003	May 03, 2017	Apr NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May CAHN
>D>	AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May CAHN
>D>	AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May CAHN
>D>	AB		25MG;160MG	A201662	004	Mar 21, 2013	May CAHN
>D>	AB		25MG;320MG	A201662	005	Mar 21, 2013	May CAHN
>A>	AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May CAHN
>A>	AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May CAHN
>A>	AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May CAHN
>A>	AB		25MG;160MG	A201662	004	Mar 21, 2013	May CAHN
>A>	AB		25MG;320MG	A201662	005	Mar 21, 2013	May CAHN
>D>	AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	May CAHN
>D>	AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May CAHN
>D>	AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May CAHN
>D>	AB		25MG;160MG	A091519	004	Mar 21, 2013	May CAHN
>D>	AB		25MG;320MG	A091519	005	Mar 21, 2013	May CAHN
>A>	AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May CAHN
>A>	AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May CAHN
>A>	AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May CAHN
>A>	AB		25MG;160MG	A091519	004	Mar 21, 2013	May CAHN
>A>	AB		25MG;320MG	A091519	005	Mar 21, 2013	May CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan NEWA

HYDROCORTISONE

CREAM;TOPICAL							
HYDROCORTISONE							
AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN
LOTION;TOPICAL							
STIE-CORT							
	@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr CAHN
OINTMENT;TOPICAL							
HYDROCORTISONE							
AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan CAHN
HYDROCORTISONE IN ABSORBASE							
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr CAHN
TABLET;ORAL							
HYDROCORTISONE							
AB		PII	5MG	A207029	001	Apr 27, 2017	Apr NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL							
CORTIFOAM							
	+	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar CAHN

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL							
CORTISPORIN							
	+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL							
EPIFOAM							
BX		MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar CAHN
PROCTOFOAM HC							
BX		MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar CAHN

HYDROCORTISONE VALERATE

CREAM;TOPICAL							
HYDROCORTISONE VALERATE							
AB	!	TARO	0.2%	A075042	001	Aug 25, 1998	Apr CAHN
OINTMENT;TOPICAL							
HYDROCORTISONE VALERATE							
	!	TARO	0.2%	A075043	001	Aug 25, 1998	Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC							
CORTISPORIN							
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr CAHN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar CAHN
AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb CAHN
SUSPENSION/DROPS;OPHTHALMIC							
CORTISPORIN							
	@	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr CAHN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
	!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb CAHN
SUSPENSION/DROPS;OTIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Mar CAHN
AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb CAHN
PEDIOTIC							
	@	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Apr CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

AP	+	!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
AP	+			2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
AP	+			4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN

DILAUDID-HP

AP	+	!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
			@	250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN

TABLET;ORAL

DILAUDID

>D>	AB	+	KNOLL PHARM	8MG	N019892	001	Dec 07, 1992	May CAHN
>A>	AB	+	PURDUE PHARM PRODS	4MG	N019892	002	Nov 09, 2007	May CAHN
>A>	AB	+	!	8MG	N019892	001	Dec 07, 1992	May CAHN

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998	001			Feb CAHN
---	-------------	--------	---------	-----	--	--	----------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VISTARIL

+	@	PFIZER	25MG/ML	N011111	001		Jan CRLD
+	@		50MG/ML	N011111	002		Jan CRLD

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan CMS1
	@		25MG	A087871	003	Dec 20, 1982	Jan CMS1
AB		NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar NEWA
AB			25MG	A207121	001	Mar 29, 2017	Mar NEWA
AB			50MG	A207122	001	Mar 29, 2017	Mar NEWA
AB		PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb CAHN
AB			25MG	A040574	001	May 27, 2005	Feb CAHN
AB			50MG	A040580	001	May 27, 2005	Feb CAHN
	@	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Apr DISC
	@		25MG	A040899	002	Jun 10, 2008	Apr DISC
	@		50MG	A040899	003	Jun 10, 2008	Apr DISC

IBANDRONATE SODIUM

TABLET;ORAL

IBANDRONATE SODIUM

>D>	AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	May DISC
>A>		@		EQ 150MG BASE	A078995	001	Mar 19, 2012	May DISC
>D>	AB		WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012	May CAHN
>A>	AB		WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May CAHN

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>D>	AB	!	ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May CAHN
>A>	AB	!		100MG/5ML	A074978	001	Mar 25, 1998	May CAHN

MOTRIN

+	@	MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan CRLD
---	---	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

	@	MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar CAHN
>A>		STRIDES PHARMA	200MG	A207052	001	May 30, 2017	May NEWA

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

BX			WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007	Apr CTEC
----	--	--	-------------	-----------	---------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE;ORAL

VASCEPA

+		AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar NEWA
---	--	---------------	-------	---------	-----	--------------	----------

IFOSFAMIDE; MESNAINJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT

@ TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002	Mar DISC
@	3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002	Mar DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>A>	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	May CMS1
>A>		25MG	A040751	002	Feb 28, 2008	May CMS1

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jan CAHN
----	---------------------	---------------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb CAHN
@		50MG	A070651	001	Mar 05, 1986	Apr CAHN
@		50MG	N018829	001	Aug 06, 1984	Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr NEWA
	@ WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb DISC

IOPAMIDOL

INJECTABLE; INJECTION

SCANLUX-300

AP	MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010	Jan CAHN
AP	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Feb CAHN

SCANLUX-370

AP	MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010	Jan CAHN
AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP	INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May NEWA
>A>	AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May NEWA
	AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan CAHN
	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan CAHN

INJECTABLE, LIPOSOMAL; IV (INFUSION)

ONIVYDE

+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Apr CAHN
----	-----------	---	---------	-----	--------------	----------

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar CAHN
---	------------	----------	---------	-----	--------------	----------

SYRUP; ORAL

ISONIAZID

!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Apr CAHN
---	----------------	----------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

>D>	@	WATSON LABS	5MG	A086031	001	Sep 29, 1987	May CAHN
>A>	@	WATSON LABS TEVA	5MG	A086031	001	Sep 29, 1987	May CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb CAHN
---	----------------	------	---------	-----	--------------	----------

ISRADIPINECAPSULE;ORAL
ISRADIPINE

>D>	AB	WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	May CAHN
>D>	AB	!	5MG	A077317	002	Jan 05, 2006	May CAHN
>A>	AB	WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May CAHN
>A>	AB	!	5MG	A077317	002	Jan 05, 2006	May CAHN

ITRACONAZOLECAPSULE;ORAL
ITRACONAZOLE

>A>	AB	ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May NEWA
	AB	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb NEWA

KANAMYCIN SULFATEINJECTABLE;INJECTION
KANAMYCIN

@	WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan CAHN
@		EQ 500MG BASE/2ML	A062324	002		Jan CAHN
@		EQ 1GM BASE/3ML	A062324	003		Jan CAHN

KETOCONAZOLEAEROSOL, FOAM;TOPICAL
EXTINA

AT	+!	MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan CAHN
----	----	------------------	----	---------	-----	--------------	----------

CREAM;TOPICAL
NIZORAL

>D>		@ JANSSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May CRLD
>A>		+ @	2%	N019084	001	Dec 31, 1985	May CRLD

KETOPROFENCAPSULE;ORAL
KETOPROFEN

		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb CAHN
AB			50MG	A074014	002	Jan 29, 1993	Feb CAHN
AB			75MG	A074014	003	Jan 29, 1993	Feb CAHN

KETOROLAC TROMETHAMINEINJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

		@ SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar CAHN
AP			30MG/ML	A076271	002	Oct 06, 2004	Mar CAHN

SOLUTION/DROPS;OPHTHALMIC
KETOROLAC TROMETHAMINE

AT		SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

AP		SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb CAHN
----	--	------------------	--------	---------	-----	--------------	----------

LACOSAMIDETABLET;ORAL
LACOSAMIDE

>D>	AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	May CAHN
>A>	AB		50MG	A204857	001	Sep 09, 2016	May CAHN
>D>	AB		100MG	A204857	002	Sep 09, 2016	May CAHN
>A>	AB		100MG	A204857	002	Sep 09, 2016	May CAHN
>D>	AB		150MG	A204857	003	Sep 09, 2016	May CAHN
>A>	AB		150MG	A204857	003	Sep 09, 2016	May CAHN
>D>	AB		200MG	A204857	004	Sep 09, 2016	May CAHN
>A>	AB		200MG	A204857	004	Sep 09, 2016	May CAHN

LACTULOSESOLUTION;ORAL
LACTULOSE

>D>	AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May CAHN
>A>	AA		10GM/15ML	A074623	001	Jul 30, 1996	May CAHN

LAMIVUDINETABLET; ORAL
LAMIVUDINE

AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG; 300MG	A077558	001	May 05, 2017	Apr NEWA
BX	PHARMACARE	150MG; 300MG	N022018	001	Mar 17, 2017	Mar NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ MYLAN LABS LTD

25MG

A078443 001 Feb 11, 2009 Mar CAHN

@

100MG

A078443 002 Feb 11, 2009 Mar CAHN

@

150MG

A078443 003 Feb 11, 2009 Mar CAHN

@

200MG

A078443 004 Feb 11, 2009 Mar CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

>D>	AB	GLENMARK GENERICS	5MG	A079099	001	Feb 19, 2009	May CAHN
>D>	AB		25MG	A079099	002	Feb 19, 2009	May CAHN
>A>	AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May CAHN
>A>	AB		25MG	A079099	002	Feb 19, 2009	May CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

>A> LETROZOLE; RIBOCICLIB SUCCINATE

>A> TABLET, TABLET; ORAL

>A> KISQALI FEMARA CO-PACK (COPACKAGED)

>A>	+	NOVARTIS PHARMS CORP	2.5MG, N/A; N/A, EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
-----	---	----------------------	--------------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>A>	AP	MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
>A>	AP		EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
>A>	AP		EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA

TABLET; ORAL

LEUCOVORIN CALCIUM

>D>	@	COREPHARMA	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
>D>	@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN
>A>	@	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
>A>	@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar CAHN
AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN

TABLET; ORAL

LEVETIRACETAM

AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar CAHN
AB		500MG	A078042	002	Jan 15, 2009	Mar CAHN

TABLET;ORAL

LEVETIRACETAM						
AB		750MG	A078042	003	Jan 15, 2009	Mar CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar CAHN
ROWEEPRA						
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM						
AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr DISC
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC						
LEVOBUNOLOL HYDROCHLORIDE						
	@ ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Feb DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN

LEVOCARNITINE

INJECTABLE;INJECTION						
CARNITOR						
AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
SOLUTION;ORAL						
CARNITOR						
	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN
CARNITOR SF						
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN
TABLET;ORAL						
CARNITOR						
AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
LEVOCARNITINE						
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
>A> AA	SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	May NEWA
TABLET;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
AB	ALLIED PHARMA INC	5MG	A204323	001	Dec 20, 2016	Apr CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION						
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+ @ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
	+ @	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
	+ @	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD
LEVOFLOXACIN						
>A> AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May NEWA
>A> AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May NEWA
SOLUTION/DROPS;OPHTHALMIC						
LEVOFLOXACIN						
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)						
LEVOLEUCOVORIN CALCIUM						
AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
>D>		EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
>A>	+!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

>D>	@ NOVOCOL	0.05MG/ML;2%	A084697	001		May	CAHN
>A>	@ SEPTODONT INC	0.05MG/ML;2%	A084697	001		May	CAHN
	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN						
	@ BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb	CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOXYL

>A>	AB1, +	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.05MG	N021301	002	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.075MG	N021301	003	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.088MG	N021301	004	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.1MG	N021301	005	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.112MG	N021301	006	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.125MG	N021301	007	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.137MG	N021301	008	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.15MG	N021301	009	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +		0.175MG	N021301	010	May 25, 2001	May	CAHN
	AB3							
>A>	AB1, +!		0.2MG	N021301	011	May 25, 2001	May	CAHN
	AB3							
>A>	+ @		0.3MG	N021301	012	May 25, 2001	May	CAHN
>D>	AB1, +	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.05MG	N021301	002	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.075MG	N021301	003	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.088MG	N021301	004	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.1MG	N021301	005	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.112MG	N021301	006	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.125MG	N021301	007	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.137MG	N021301	008	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.15MG	N021301	009	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +		0.175MG	N021301	010	May 25, 2001	May	CAHN
	AB3							
>D>	AB1, +!		0.2MG	N021301	011	May 25, 2001	May	CAHN
	AB3							
>D>	+ @		0.3MG	N021301	012	May 25, 2001	May	CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
	XYLOCAINE						
	+ @ ASTRAZENECA	5%	N008048	001		Jan	CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

@ BELMORA LLC	2%	A080504	001		Feb	CAHN
---------------	----	---------	-----	--	-----	------

LIDOCAINE; TETRACAINECREAM; TOPICAL
PLIAGLIS

>D>	+	GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006	May CAHN
>A>	+	TARO PHARMS	7%;7%	N021717	001	Jun 29, 2006	May CAHN

LINACLOTIDECAPSULE; ORAL
LINZESS

+	FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan NEWA
---	-----------------	-------	---------	-----	--------------	----------

LINEZOLIDSOLUTION; IV (INFUSION)
LINEZOLID

AP		SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb NEWA
AP			600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb NEWA

TABLET; ORAL
LINEZOLID

AB		ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

LIOTHYRONINE SODIUMTABLET; ORAL
CYTOMEL

AB	+	KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar CAHN
AB	+		EQ 0.025MG BASE	N010379	002		Mar CAHN
AB	+		EQ 0.05MG BASE	N010379	003		Mar CAHN

LISDEXAMFETAMINE DIMESYLATETABLET, CHEWABLE; ORAL
VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan NEWA
+		20MG	N208510	002	Jan 28, 2017	Jan NEWA
+		30MG	N208510	003	Jan 28, 2017	Jan NEWA
+		40MG	N208510	004	Jan 28, 2017	Jan NEWA
+		50MG	N208510	005	Jan 28, 2017	Jan NEWA
+		60MG	N208510	006	Jan 28, 2017	Apr CHRS
+		60MG	N208510	006	Jan 28, 2017	Jan NEWA

LISINAPRILTABLET; ORAL
LISINAPRIL

AB		PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
AB			5MG	A075743	002	Jul 01, 2002	Feb CAHN
AB			10MG	A075743	003	Jul 01, 2002	Feb CAHN
AB			20MG	A075743	004	Jul 01, 2002	Feb CAHN
AB			30MG	A075743	005	Jul 01, 2002	Feb CAHN
AB			40MG	A075743	006	Jul 01, 2002	Feb CAHN

LITHIUM CARBONATECAPSULE; ORAL
LITHIUM CARBONATE

AB		MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
AB			300MG	A076243	001	Jun 27, 2002	Jan CAHN
AB			600MG	A078763	001	Apr 15, 2008	Jan CAHN
AB	+	WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+		300MG	N017812	001		Jan CAHN
AB	+		600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET; ORAL
LITHIUM CARBONATE

AB	+	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
----	---	----------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

>A>	AB	UNIQUE PHARM LABS	450MG	A205663	001	Jun 05, 2017	May NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

LITHIUM CITRATESYRUP; ORAL
LITHIUM CITRATE

AA	+	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
----	---	----------------------	------------------------	---------	-----	--	----------

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP	SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Mar NEWA
AP		2MG/ML	A200542	001	Apr 28, 2017	Apr NEWA
AP		4MG/ML	A200217	002	Apr 04, 2017	Mar NEWA
AP		4MG/ML	A200542	002	Apr 28, 2017	Apr NEWA
	@ WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar CAHN
	@	4MG/ML	A074496	002	Sep 28, 1998	Mar CAHN

TABLET; ORAL
LORAZEPAM

AB	SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr CMS1
AB		1MG	A071141	003	Apr 21, 1987	Apr CMS1

LOVASTATIN

TABLET; ORAL
LOVASTATIN

@ MYLAN	10MG	A075935	001	Dec 17, 2001	Mar DISC
@	20MG	A075935	002	Dec 17, 2001	Mar DISC
@	40MG	A075935	003	Dec 17, 2001	Mar DISC

TABLET, EXTENDED RELEASE; ORAL
ALTOPREV

@ COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002	Apr CAHN
+	20MG	N021316	002	Jun 26, 2002	Apr CAHN
+	40MG	N021316	003	Jun 26, 2002	Apr CAHN
+	60MG	N021316	004	Jun 26, 2002	Apr CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017586	001		Feb CAHN
-----------------	---	---------	-----	--	----------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017637	002	Jul 08, 1982	Feb CAHN
-----------------	---	---------	-----	--------------	----------

>D> MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

>D> SOLUTION; ORAL

>D> SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

>D> AA	NOVEL LABS INC	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
AA		1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA

>D> SUPREP BOWEL PREP KIT

>D> AA	+! BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN
AA	+!	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG

>A> MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

>A> SOLUTION; ORAL

>A> SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

>A> AA	NOVEL LABS INC	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
--------	----------------	-----------------------------------	---------	-----	--------------	----------

>A> SUPREP BOWEL PREP KIT

>A> AA	+! BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN
--------	-------------------	-----------------------------------	---------	-----	--------------	----------

MALATHION

LOTION; TOPICAL

OVIDE

>A> AT	+! TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
>D> AT	+! TARO PHARMS NORTH	0.5%	N018613	001	Aug 02, 1982	May CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 15% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 20% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 5% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN
----	-----------------	-----------	---------	-----	--------------	----------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC

540MG/100ML; 2.7GM/100ML

N018316 001

Feb CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

>D> @ WATSON LABS 25MG
 >D> @ 50MG
 >A> @ WATSON LABS TEVA 25MG
 >A> @ 50MG

A072162 001 Jun 01, 1988 May CAHN
 A072163 001 Jun 01, 1988 May CAHN
 A072162 001 Jun 01, 1988 May CAHN
 A072163 001 Jun 01, 1988 May CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

>D> NEXGEN PHARMA 2.5MG
 >A> ! 2.5MG

A204054 001 Mar 19, 2013 May CHRS
 A204054 001 Mar 19, 2013 May CHRS

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>D> AA AMNEAL PHARMS 12.5MG
 >A> AA 12.5MG
 >D> AA 25MG
 >A> AA 25MG
 >D> @ 50MG
 >A> @ 50MG

A201451 001 Feb 23, 2011 May CAHN
 A201451 001 Feb 23, 2011 May CAHN
 A201451 002 Feb 23, 2011 May CAHN
 A201451 002 Feb 23, 2011 May CAHN
 A201451 003 Feb 23, 2011 May CAHN
 A201451 003 Feb 23, 2011 May CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

>D> @ WATSON LABS EQ 100MG BASE
 >A> @ WATSON LABS TEVA EQ 100MG BASE

A071469 001 Apr 15, 1987 May CAHN
 A071469 001 Apr 15, 1987 May CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB SANDOZ INC 150MG/ML
 AB TEVA PHARMS USA 150MG/ML

A078711 001 May 20, 2009 Mar CAHN
 A076553 001 Jul 28, 2004 Jan CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

AB ! BARR 250MG
 @ SANDOZ 250MG

A076392 001 Dec 29, 2003 Apr CHRS
 A076175 001 Feb 20, 2002 Apr DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ @ BRISTOL MYERS SQUIBB 40MG/ML
 MEGESTROL ACETATE

N020264 001 Sep 10, 1993 Feb DISC

>A> AB HI-TECH PHARMACAL 40MG/ML
 AB ! WEST-WARD PHARMS INT 40MG/ML

A203960 001 Jun 09, 2017 May NEWA
 A075997 001 Feb 15, 2002 Feb CHRS

MELOXICAM

TABLET; ORAL

MELOXICAM

@ SUN PHARM INDS INC 7.5MG
 @ 15MG

A077937 001 Jul 19, 2006 Apr DISC
 A077937 002 Jul 19, 2006 Apr DISC

MELPHALAN

TABLET; ORAL

ALKERAN

AB +! APOTEX INC 2MG
 MELPHALAN

N014691 002 Mar CFTG

AB ALVOGEN MALTA 2MG

A207809 001 Mar 22, 2017 Mar NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

>D> ALKERAN

>D> AP	+!	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	May DISC
>A>	+	@	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	May DISC

MELPHALAN HYDROCHLORIDE

>D> AP		MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	May CHRS
>A> AP	!		EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	May CHRS
AP		SAGENT PHARMS	EQ 50MG BASE/VIAL	A201379	001	Feb 28, 2017	Feb NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

>D> AB		AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	May CAHN
>A> AB			7MG	A205825	001	Oct 12, 2016	May CAHN
>D> AB			14MG	A205825	002	Oct 12, 2016	May CAHN
>A> AB			14MG	A205825	002	Oct 12, 2016	May CAHN
>D> AB			21MG	A205825	003	Oct 12, 2016	May CAHN
>A> AB			21MG	A205825	003	Oct 12, 2016	May CAHN
>D> AB			28MG	A205825	004	Oct 12, 2016	May CAHN
>A> AB			28MG	A205825	004	Oct 12, 2016	May CAHN
>A> AB		ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017	May NEWA
>A> AB			14MG	A205784	002	Jun 09, 2017	May NEWA
>A> AB			21MG	A205784	003	Jun 09, 2017	May NEWA
>A> AB			28MG	A205784	004	Jun 09, 2017	May NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>D> AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	May CAHN
>A> AB			5MG	A090041	001	Apr 10, 2015	May CAHN
>D> AB			10MG	A090041	002	Apr 10, 2015	May CAHN
>A> AB			10MG	A090041	002	Apr 10, 2015	May CAHN
>A> AB		STRIDES PHARMA	5MG	A202350	001	May 23, 2017	May NEWA
>A> AB			10MG	A202350	002	May 23, 2017	May NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
AP			25MG/ML	A080455	007		Jan CAHN
AP			50MG/ML	A080445	002		Jan CAHN
AP			50MG/ML	A080455	008		Jan CAHN
AP			75MG/ML	A080445	003		Jan CAHN
AP			75MG/ML	A080455	009		Jan CAHN
AP			100MG/ML	A080445	004		Jan CAHN
AP			100MG/ML	A080455	010		Jan CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	!	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr CAHN
	@	MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar CAHN
AP		WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE

>D> AP	!	NOVOCOL	3%	A080925	001		May CAHN
>A> AP	!	SEPTODONT INC	3%	A080925	001		May CAHN

MEPIVACAINE HYDROCHLORIDE

@	BELMORA LLC	3%	A083559	001		Feb CAHN
---	-------------	----	---------	-----	--	----------

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA

MESALAMINE

ENEMA;RECTAL

ROWASA

AB	+!	MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar CAHN
		SFROWASA					
AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar CAHN

TABLET, DELAYED RELEASE;ORAL
LIALDA

>D>	+	SHIRE	1.2GM	N022000	001	Jan 16, 2007	May CFTG
>A>	AB	+	1.2GM	N022000	001	Jan 16, 2007	May CFTG
>A>		MESALAMINE					
>A>	AB	ZYDUS PHARMS USA INC	1.2GM	A091640	001	Jun 05, 2017	May NEWA

METAXALONE

TABLET;ORAL

METAXALONE

>D>	@	COREPHARMA	640MG	N022503	001	Jun 01, 2015	May CAHN
>A>	@	EPIC PHARMA LLC	640MG	N022503	001	Jun 01, 2015	May CAHN
		IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb CAHN
		SKELAXIN					
>D>	+	@ KING PHARMS	400MG	N013217	001		May CAHN
>A>	+	@	400MG	N013217	001		May CAHN
>D>	AB	+	800MG	N013217	003	Aug 30, 2002	May CAHN
>A>	AB	+	800MG	N013217	003	Aug 30, 2002	May CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002	May DISC
>A>	@		500MG	A075969	001	Jan 29, 2002	May DISC
>D>	AB		850MG	A075969	002	Jan 29, 2002	May DISC
>A>	@		850MG	A075969	002	Jan 29, 2002	May DISC
>D>	AB		1GM	A075969	003	Jan 29, 2002	May DISC
>A>	@		1GM	A075969	003	Jan 29, 2002	May DISC
	@	WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002	Mar DISC
	@		850MG	A075961	002	Jan 25, 2002	Mar DISC
	@		1GM	A075961	003	Jan 25, 2002	Mar DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1		INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb NEWA
AB			750MG	A202306	002	Feb 23, 2017	Feb NEWA
AB1		TORRENT PHARMS LTD	500MG	A090014	001	Dec 30, 2009	Apr CAHN

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>A>		TEVA	500MG;EQ 1MG BASE	A077337	005	May 19, 2017	May NEWA
-----	--	------	-------------------	---------	-----	--------------	----------

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADOSE

AA	+	MALLINCKRODT INC	10MG/ML	N017116	002		Apr CAHN
		POWDER;FOR RX COMPOUNDING					
		METHADONE HYDROCHLORIDE					
		MALLINCKRODT INC	50GM/BOT	N006383	002		Apr CAHN
			100GM/BOT	N006383	003		Apr CAHN
			500GM/BOT	N006383	004		Apr CAHN

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

@	WEST-WARD PHARMS INT	10MG/30ML	N006134	004		Jan CAHN
---	----------------------	-----------	---------	-----	--	----------

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	5MG	N006134	002		Jan CAHN
AA	+		10MG	N006134	010		Jan CAHN

METHADONE HYDROCHLORIDE

>D>	AA	COREPHARMA	5MG	A090065	001	Aug 18, 2015	May CAHN
>D>	AA		10MG	A090065	002	Aug 18, 2015	May CAHN
>A>	AA	EPIC PHARMA LLC	5MG	A090065	001	Aug 18, 2015	May CAHN
>A>	AA		10MG	A090065	002	Aug 18, 2015	May CAHN

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	40MG	N017058	001		Jan CAHN
----	---	----------------------	------	---------	-----	--	----------

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB	IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb CAHN
----	----------------	-----	---------	-----	--------------	----------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

>D>	@ CEDAR PHARMS	15MG	A040619	003	Jul 12, 2005	May CAHN
>A>	@ ECI PHARMS LLC	15MG	A040619	003	Jul 12, 2005	May CAHN

TAPAZOLE

AB	KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb CAHN
AB		10MG	A040320	002	Mar 31, 2000	Feb CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan NEWA
AP	RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar CAHN

TABLET;ORAL

METHOCARBAMOL

AA	ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan NEWA
AA		750MG	A203550	002	Feb 08, 2017	Jan NEWA

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr CMS1

SOLUTION;ORAL

XATMEP

+	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr NEWA
---	-------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

METHOTREXATE SODIUM

AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
---	----------	---------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb CAHN
!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS

RITALIN LA

+	@ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Feb DISC
---	------------	------	---------	-----	--------------	----------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr NEWA
AB		10MG	A206932	002	May 11, 2017	Apr NEWA
AB		20MG	A206932	003	May 11, 2017	Apr NEWA
AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb CAHN
AB		10MG	A091159	002	Mar 12, 2014	Feb CAHN
AB		20MG	A091159	003	Mar 12, 2014	Feb CAHN
AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb NEWA
AB		10MG	A207587	002	Mar 03, 2017	Feb NEWA
AB		20MG	A207587	003	Mar 03, 2017	Feb NEWA

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
AB		5MG	A204954	002	Jan 26, 2017	Jan NEWA

TABLET, CHEWABLE;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AB	10MG	A204954	003	Jan 26, 2017	Jan NEWA
TABLET, EXTENDED RELEASE;ORAL					
RITALIN-SR					
AB	+ NOVARTIS 20MG	N018029	001	Mar 30, 1982	Feb CRLD
<u>METHYLPREDNISOLONE ACETATE</u>					
INJECTABLE;INJECTION					
METHYLPREDNISOLONE ACETATE					
AB	SANDOZ INC 40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
AB	80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>					
INJECTABLE;INJECTION					
A-METHAPRED					
@ HOSPIRA INC EQ 40MG BASE/VIAL		A040793	001	Nov 25, 2008	Jan DISC
@ EQ 125MG BASE/VIAL		A040827	001	Nov 25, 2008	Jan DISC
<u>METHYLTESTOSTERONE</u>					
TABLET;ORAL					
ANDROID 10					
>D>	@ VALEANT PHARM INTL 10MG	A086450	001		May CAHN
>A>	@ VALEANT PHARMS NORTH 10MG	A086450	001		May CAHN
<u>METIPRANOLOL HYDROCHLORIDE</u>					
SOLUTION/DROPS;OPHTHALMIC					
METIPRANOLOL					
AT	SANDOZ INC 0.3%	A075720	001	Aug 06, 2001	Feb CAHN
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>					
SOLUTION;ORAL					
METOCLOPRAMIDE HYDROCHLORIDE					
>D> AA	PHARM ASSOC EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN
>A> AA	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN
TABLET;ORAL					
METOCLOPRAMIDE HYDROCHLORIDE					
@ NORTHSTAR HLTHCARE EQ 5MG BASE		A078374	001	Nov 30, 2007	Feb DISC
@ EQ 10MG BASE		A078374	002	Nov 30, 2007	Feb DISC
>D> AB	SUN PHARM INDS EQ 5MG BASE	A071536	002	Jan 16, 1997	May DISC
>A>	@ EQ 5MG BASE	A071536	002	Jan 16, 1997	May DISC
<u>METOPROLOL SUCCINATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
TOPROL-XL					
AB	+ ARALEZ PHARMS EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
AB	+! EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
AB	+ EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
AB	+! EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN
<u>METOPROLOL TARTRATE</u>					
INJECTABLE;INJECTION					
METOPROLOL TARTRATE					
AP	SANDOZ INC 1MG/ML	A077360	001	Oct 02, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT 1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN
<u>METRONIDAZOLE</u>					
CAPSULE;ORAL					
METRONIDAZOLE					
>D> AB	ALEMBIC LTD 375MG	A079065	001	Jun 23, 2009	May CAHN
>A> AB	ALEMBIC PHARMS LTD 375MG	A079065	001	Jun 23, 2009	May CAHN
GEL;TOPICAL					
METRONIDAZOLE					
AB	TARO PHARM 1%	A204651	001	Mar 14, 2017	Feb NEWA
INJECTABLE;INJECTION					
METRONIDAZOLE					
>D>	@ EUROHLTH INTL SARL 500MG/100ML	N018907	001	Mar 30, 1984	May CAHN
>A>	@ WEST-WARD PHARMS INT 500MG/100ML	N018907	001	Mar 30, 1984	May CAHN
METRONIDAZOLE IN PLASTIC CONTAINER					
AP	MYLAN LABS LTD 500MG/100ML	A205531	001	May 09, 2017	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL
METRONIDAZOLE

>D>	AB	ALEMBIC LTD	750MG	A090222	001	May 05, 2010	May CAHN
>A>	AB	ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May CAHN

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL
MICONAZOLE NITRATE

>D>	AB	ACTAVIS MID ATLANTIC	200MG	A073508	001	Nov 19, 1993	May CAHN
>A>	AB	ACTAVIS PHARMA	200MG	A073508	001	Nov 19, 1993	May CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL
VUSION

+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
---	---	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar NEWA
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar CAHN
AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN
		MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
>A>	AP	SAGENT AGILA LLC	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May CAHN
>A>	AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May CAHN
>D>	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May CAHN
>D>	AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May CAHN

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

>D>	AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	May DISC
>A>		@	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	May DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL
PROAMATINE

+	@	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
+	@		5MG	N019815	002	Sep 06, 1996	Feb CRLD
+	@		10MG	N019815	003	Mar 20, 2002	Feb CRLD

MIDOSTAURIN

CAPSULE;ORAL
RYDAPT

+	!	NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017	Apr NEWA
---	---	----------------------	------	---------	-----	--------------	----------

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL
SAVELLA

AB	+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
AB	+		25MG	N022256	002	Jan 14, 2009	Feb CAHN
AB	+		50MG	N022256	003	Jan 14, 2009	Feb CAHN
AB	+		100MG	N022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN
		@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
		@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar CAHN
AP			EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN

INJECTABLE;INJECTION

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
+ @		EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
+ @		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
+ @		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D> AB	WATSON LABS	EQ 50MG BASE	A063181	001	Dec 30, 1991	May CAHN
>A> AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr NEWA
	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr NEWA
>D> AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May DISC
>A>	@	EQ 45MG BASE	A090911	001	Jul 20, 2010	May DISC
>D> AB		EQ 80MG BASE	A203443	002	Aug 22, 2014	May DISC
>A>	@	EQ 80MG BASE	A203443	002	Aug 22, 2014	May DISC
>D> AB		EQ 90MG BASE	A090911	002	Jul 20, 2010	May DISC
>A>	@	EQ 90MG BASE	A090911	002	Jul 20, 2010	May DISC
>D> AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	May DISC
>A>	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	May DISC
>D> AB		EQ 135MG BASE	A090911	003	Jul 20, 2010	May DISC
>A>	@	EQ 135MG BASE	A090911	003	Jul 20, 2010	May DISC
>A>	MINOLIRA					
>A>	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May NEWA
>A>		EQ 135MG BASE	N209269	002	May 08, 2017	May NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb CHRS
----	-------	------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN
>A> AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May NEWA
>A> AB		30MG	A205798	002	Jun 01, 2017	May NEWA
>A> AB		45MG	A205798	003	Jun 01, 2017	May NEWA

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MUTAMYCIN

+ @	BRISTOL	5MG/VIAL	N050450	001		Jan CRLD
+ @		20MG/VIAL	N050450	002		Jan CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

>D> AB	ALEMBIC LTD	100MG	A202700	001	Oct 18, 2012	May CAHN
>D> AB		200MG	A202700	002	Oct 18, 2012	May CAHN
>A> AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May CAHN
>A> AB		200MG	A202700	002	Oct 18, 2012	May CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

>D>	COREPHARMA	5MG	A090453	001	Mar 20, 2015	May CAHN
>D>		10MG	A090453	002	Mar 20, 2015	May CAHN
>D>	!	25MG	A090453	003	Mar 20, 2015	May CAHN
>A>	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May CAHN
>A>		10MG	A090453	002	Mar 20, 2015	May CAHN
>A>	!	25MG	A090453	003	Mar 20, 2015	May CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr CAHN
	SPRAY, METERED;NASAL					
	MOMETASONE FUROATE					
AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar NEWA

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr NEWA
	TABLET, CHEWABLE;ORAL					
	MONTELUKAST SODIUM					
AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr CAHN
		45MG	A079040	002	Jan 16, 2013	Apr CAHN
		60MG	A079040	003	Jan 16, 2013	Apr CAHN
		75MG	A079040	004	Jan 16, 2013	Apr CAHN
		90MG	A079040	005	Jan 16, 2013	Apr CAHN
	!	120MG	A079040	006	Jan 16, 2013	Apr CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

AP	+! ICU MEDICAL INC	1MG/ML	N019916	001	Oct 30, 1992	Apr CAHN
	+!	5MG/ML	N019916	002	Oct 27, 2006	Apr CAHN
	@ MALLINCKRODT INC	1MG/ML	N020631	001	Jul 03, 1996	Apr CAHN
	@	2MG/ML	N020631	002	Jul 03, 1996	Apr CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan CAHN
AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN
AA	+!	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN

TABLET;ORAL

MORPHINE SULFATE

	+ WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan CAHN
	+!	30MG	N022207	002	Mar 17, 2008	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

	+ EGALET	15MG	N208603	001	Jan 09, 2017	Jan NEWA
	+	30MG	N208603	002	Jan 09, 2017	Jan NEWA
	+	60MG	N208603	003	Jan 09, 2017	Jan NEWA

MORPHABOND ER

	+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan CTNA
	+	30MG	N206544	002	Oct 02, 2015	Jan CTNA
	+	60MG	N206544	003	Oct 02, 2015	Jan CTNA
	+!	100MG	N206544	004	Oct 02, 2015	Jan CTNA

MORPHINE SULFATE

AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr CAHN
AB		30MG	A203849	002	Apr 06, 2015	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		60MG	A203849	003	Apr 06, 2015	Apr CAHN	
AB		100MG	A203849	004	Apr 06, 2015	Apr CAHN	
AB		200MG	A203849	005	Apr 06, 2015	Apr CAHN	
>D>	AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	May CAHN
>D>	AB		30MG	A091357	002	Jun 23, 2016	May CAHN
>D>	AB		60MG	A091357	003	Jun 23, 2016	May CAHN
>D>	AB		100MG	A091357	004	Jun 23, 2016	May CAHN
>D>	AB		200MG	A091357	005	Jun 23, 2016	May CAHN
>A>	AB	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	May CAHN
>A>	AB		30MG	A091357	002	Jun 23, 2016	May CAHN
>A>	AB		60MG	A091357	003	Jun 23, 2016	May CAHN
>A>	AB		100MG	A091357	004	Jun 23, 2016	May CAHN
>A>	AB		200MG	A091357	005	Jun 23, 2016	May CAHN
AB		SUN PHARM INDS	15MG	A205634	001	Aug 25, 2016	Mar CAHN
AB			30MG	A205634	002	Aug 25, 2016	Mar CAHN
AB			60MG	A205634	003	Aug 25, 2016	Mar CAHN
AB			100MG	A205634	004	Aug 25, 2016	Mar CAHN
AB			200MG	A205634	005	Aug 25, 2016	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP	+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr CFTG
AP		MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
AP		MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr NEWA
AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA

MUPIROCIN

OINTMENT;TOPICAL
BACTROBAN

>D>	AB	+	GLAXOSMITHKLINE	2%	N050591	001	Dec 31, 1987	May DISC
>A>		+	@	2%	N050591	001	Dec 31, 1987	May DISC
>D>	AB		MUPIROCIN					
>D>	AB		PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003	May CHRS
>A>	AB	!		2%	A065123	001	Nov 07, 2003	May CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL
MUPIROCIN

>D>	AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	May CAHN
>A>	AB		GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	May CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb NEWA
AP		MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar NEWA

NABILONE

CAPSULE;ORAL
CESAMET

+	!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar CAHN
---	---	---------------------	-----	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL
NADOLOL

>A>	AB		AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
>A>	AB			40MG	A208832	002	Jun 02, 2017	May NEWA
>A>	AB			80MG	A208832	003	Jun 02, 2017	May NEWA

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL
NAFTIFINE HYDROCHLORIDE

AB		TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
----	--	--------	----	---------	-----	--------------	----------

NALDEMEDINE TOSYLATETABLET;ORAL
SYMPROIC

+! SHIONOGI INC

EQ 0.2MG BASE

N208854 001 Mar 23, 2017 Mar NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@ WEST-WARD PHARMS INT

0.4MG/ML

A070298 001 Sep 24, 1986 Jan CAHN

@

0.4MG/ML

A070496 001 Sep 24, 1986 Jan CAHN

NALOXONE HYDROCHLORIDE

AP AKORN

0.4MG/ML

A208871 001 Feb 28, 2017 Feb NEWA

AP

0.4MG/ML

A208872 001 Mar 14, 2017 Feb NEWA

SPRAY, METERED;NASAL

NARCAN

+ ADAPT

2MG/SPRAY

N208411 002 Jan 24, 2017 Jan NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

AB AUROBINDO PHARMA LTD

250MG

A200429 001 Nov 08, 2011 Jan CAHN

AB

375MG

A200429 002 Nov 08, 2011 Jan CAHN

AB

500MG

A200429 003 Nov 08, 2011 Jan CAHN

>A> @ CHARTWELL MOLECULES

250MG

A074410 001 Apr 28, 1995 May CAHN

>A> @

375MG

A074410 002 Apr 28, 1995 May CAHN

>A> @

500MG

A074410 003 Apr 28, 1995 May CAHN

>D> @ DAVA PHARMS INC

250MG

A074410 001 Apr 28, 1995 May CAHN

>D> @

375MG

A074410 002 Apr 28, 1995 May CAHN

>D> @

500MG

A074410 003 Apr 28, 1995 May CAHN

>D> AB HIKMA INTL PHARMS

250MG

A076494 001 Jan 14, 2004 May DISC

>A> @

250MG

A076494 001 Jan 14, 2004 May DISC

>D> AB

375MG

A076494 002 Jan 14, 2004 May DISC

>A> @

375MG

A076494 002 Jan 14, 2004 May DISC

>D> AB

500MG

A076494 003 Jan 14, 2004 May DISC

>A> @

500MG

A076494 003 Jan 14, 2004 May DISC

>D> @ WATSON LABS

250MG

A074163 001 Feb 10, 1995 May CAHN

>D> @

375MG

A074163 002 Feb 10, 1995 May CAHN

>D> @

500MG

A074163 003 Feb 10, 1995 May CAHN

>A> @ WATSON LABS TEVA

250MG

A074163 001 Feb 10, 1995 May CAHN

>A> @

375MG

A074163 002 Feb 10, 1995 May CAHN

>A> @

500MG

A074163 003 Feb 10, 1995 May CAHN

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

>D> AB GLENMARK GENERICS

EQ 250MG BASE

A078314 001 Apr 27, 2007 May CAHN

>D> AB

EQ 500MG BASE

A078314 002 Apr 27, 2007 May CAHN

>A> AB GLENMARK PHARMS LTD

EQ 250MG BASE

A078314 001 Apr 27, 2007 May CAHN

>A> AB

EQ 500MG BASE

A078314 002 Apr 27, 2007 May CAHN

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+! NOVARTIS PHARMS CORP 5%

N050514 001 Jan CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

>A> @ GLENMARK PHARMS LTD

EQ 2.5MG BASE

A203821 001 May 25, 2017 May DISC

>A> AB

EQ 2.5MG BASE

A203821 001 May 25, 2017 May NEWA

>A> @

EQ 5MG BASE

A203821 002 May 25, 2017 May DISC

>A> AB

EQ 5MG BASE

A203821 002 May 25, 2017 May NEWA

>A> @

EQ 10MG BASE

A203821 003 May 25, 2017 May DISC

>A> AB

EQ 10MG BASE

A203821 003 May 25, 2017 May NEWA

>A> @

EQ 20MG BASE

A203821 004 May 25, 2017 May DISC

>A> AB

EQ 20MG BASE

A203821 004 May 25, 2017 May NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTANTABLET; ORAL
BYVALSON

>D>	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	May CRLD
>A>	+	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	May CRLD

NELFINAVIR MESYLATEPOWDER; ORAL
VIRACEPT

@ AGOURON PHARMS

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jan CAHN

TABLET; ORAL
VIRACEPT

+! AGOURON PHARMS

EQ 250MG BASE

N020779 001 Mar 14, 1997 Jan CAHN

+!

EQ 625MG BASE

N021503 001 Apr 30, 2003 Jan CAHN

NEOMYCIN SULFATESOLUTION; ORAL
NEO-FRADIN

@ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002 Feb DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN G.U. IRRIGANT

AT ! MONARCH PHARMS

EQ 40MG BASE/ML;200,000 UNITS/ML

A060707 001

Apr CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP PAR STERILE PRODUCTS

5MG/10ML (0.5MG/ML)

A208405 001 Apr 26, 2017 Apr NEWA

AP

10MG/10ML (1MG/ML)

A208405 002 Apr 26, 2017 Apr NEWA

NEVIRAPINETABLET, EXTENDED RELEASE; ORAL
NEVIRAPINE

AB AUROBINDO PHARMA LTD

400MG

A207698 001 Feb 28, 2017 Mar CAHN

AB AUROBINDO PHARMA USA

400MG

A207698 001 Feb 28, 2017 Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT

25MG/10ML (2.5MG/ML)

A078714 001 Dec 28, 2009 Jan CAHN

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE

20MG/200ML (0.1MG/ML)

N022276 002 Apr 07, 2016 Feb NEWA

40MG/200ML (0.2MG/ML)

N022276 003 Apr 07, 2016 Feb NEWA

NIFEDIPINETABLET, EXTENDED RELEASE; ORAL
AFEDITAB CR

>D> AB1 WATSON LABS

30MG

A075128 001 Mar 10, 2000 May CAHN

>A> AB1 WATSON LABS TEVA

30MG

A075128 001 Mar 10, 2000 May CAHN

NIFEDIPINE

>D> AB2 MYLAN LABS LTD

30MG

A090602 001 Sep 13, 2010 May DISC

>A> @

30MG

A090602 001 Sep 13, 2010 May DISC

AB2

30MG

A090602 001 Sep 13, 2010 Mar CAHN

>D> AB2

60MG

A090602 002 Sep 13, 2010 May DISC

>A> @

60MG

A090602 002 Sep 13, 2010 May DISC

AB2

60MG

A090602 002 Sep 13, 2010 Mar CAHN

>D> AB2

90MG

A090602 003 Sep 13, 2010 May DISC

>A> @

90MG

A090602 003 Sep 13, 2010 May DISC

AB2

90MG

A090602 003 Sep 13, 2010 Mar CAHN

NIRAPARIB TOSYLATECAPSULE; ORAL
ZEJULA

+! TESARO INC

EQ 100MG BASE

N208447 001 Mar 27, 2017 Mar NEWA

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
SULAR

>A>	AB	+	!	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May CAHN
>A>		+	@		10MG	N020356	001	Feb 02, 1995	May CAHN
>A>	AB	+	!		17MG	N020356	007	Jan 02, 2008	May CAHN
>A>		+	@		20MG	N020356	002	Feb 02, 1995	May CAHN
>A>		+	@		25.5MG	N020356	006	Jan 02, 2008	May CAHN
>A>		+	@		30MG	N020356	003	Feb 02, 1995	May CAHN
>A>	AB	+	!		34MG	N020356	005	Jan 02, 2008	May CAHN
>A>		+	@		40MG	N020356	004	Feb 02, 1995	May CAHN
>D>	AB	+	!	COVIS PHARMA SARL	8.5MG	N020356	008	Jan 02, 2008	May CAHN
>D>		+	@		10MG	N020356	001	Feb 02, 1995	May CAHN
>D>	AB	+	!		17MG	N020356	007	Jan 02, 2008	May CAHN
>D>		+	@		20MG	N020356	002	Feb 02, 1995	May CAHN
>D>		+	@		25.5MG	N020356	006	Jan 02, 2008	May CAHN
>D>		+	@		30MG	N020356	003	Feb 02, 1995	May CAHN
>D>	AB	+	!		34MG	N020356	005	Jan 02, 2008	May CAHN
>D>		+	@		40MG	N020356	004	Feb 02, 1995	May CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A>	AB			AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	May NEWA
-----	----	--	--	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

! FOUGERA PHARMS INC 2%

A087355	001	Jul 08, 1988	Jan CAHN
---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP				WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan CAHN
----	--	--	--	----------------------	----------------	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB				TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar CAHN
AB					EQ 25MG BASE	A075520	003	May 08, 2000	Mar CAHN
AB					EQ 50MG BASE	A075520	001	May 08, 2000	Mar CAHN
AB					EQ 75MG BASE	A075520	002	May 08, 2000	Mar CAHN

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>D>	AA	!		PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May CAHN
>A>	AA	!			EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May CAHN

NYSTATIN

POWDER;TOPICAL

NYSTATIN

>A>	AT			LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May NEWA
>A>	AT			NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May NEWA

SUSPENSION;ORAL

NYSTATIN

AA				FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan CAHN
>D>	AA			PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May CAHN
>A>	AA				100,000 UNITS/ML	A203621	001	Jan 07, 2016	May CAHN
AA				TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCOLOG-II

@ MYLAN PHARMS INC 100,000 UNITS/GM;0.1%

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT				FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan CAHN
----	--	--	--	--------------------	-----------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

MYCOLOG-II

@ MYLAN PHARMS INC 100,000 UNITS/GM;0.1%

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT				DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan NEWA
AT				FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan CAHN

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb CAHN
----	------------	------	---------	-----	--------------	----------

SOLUTION/DROPS;OTIC
OFLOXACIN

AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb CAHN
----	------------	------	---------	-----	--------------	----------

OLANZAPINETABLET;ORAL
OLANZAPINE

AB	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Mar CAHN
AB		5MG	A076866	002	Apr 23, 2012	Mar CAHN
AB		7.5MG	A076866	003	Apr 23, 2012	Mar CAHN
AB		10MG	A076866	004	Apr 23, 2012	Mar CAHN
AB		15MG	A076866	005	Apr 23, 2012	Mar CAHN
AB		20MG	A076866	006	Apr 23, 2012	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A> AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May NEWA
>A> AB		10MG	A204320	002	May 30, 2017	May NEWA
>A> AB		15MG	A204320	003	May 30, 2017	May NEWA
>A> AB		20MG	A204320	004	May 30, 2017	May NEWA

OLAPARIBCAPSULE;ORAL
LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar CRLD
----	--------------------	------	---------	-----	--------------	----------

OLMESARTAN MEDOXOMILTABLET;ORAL
OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr NEWA
>A> AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May NEWA
>A> AB		20MG	A203281	002	May 25, 2017	May NEWA
>A> AB		40MG	A203281	003	May 25, 2017	May NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr NEWA

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

OLSALAZINE SODIUM

CAPSULE;ORAL
DIPENTUM

+	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar CAHN
---	---------------------	-------	---------	-----	--------------	----------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS
SYNRIBO

+	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr CAHN
---	------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

>D>	AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May CAHN
-----	----	---------------	--	---------	-----	--------------	----------

>A>	AB		1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May CAHN
-----	----	--	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN	
AB		20MG	A203270	002	Aug 19, 2015	Jan CAHN	
AB		40MG	A203270	003	Aug 19, 2015	Jan CAHN	
>A>	AB	TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May NEWA
>A>	AB		40MG	A204661	002	Jun 13, 2017	May NEWA

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC

>D>	+	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
>D>	+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN
>A>	+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
>A>	+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC	
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC	
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD	
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD	
	ZEGERID						
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

@	CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar CAHN
@		8MG	A076506	002	Dec 26, 2006	Mar CAHN
@		16MG	A077406	001	Dec 26, 2006	Mar CAHN
@		24MG	A077406	002	Dec 26, 2006	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan CAHN
AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan CAHN

INJECTABLE; INJECTION

ZOFTRAN

+ @ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CRLD
ZOFTRAN PRESERVATIVE FREE					
+ @ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CRLD

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

@ TELIGENT	30MG/ML	N013055	001		Apr CAHN
------------	---------	---------	-----	--	----------

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

>A> AB	AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May NEWA
>A> AB		EQ 45MG BASE	A209093	002	May 17, 2017	May NEWA
>A> AB		EQ 75MG BASE	A209093	003	May 17, 2017	May NEWA
AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb NEWA
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb NEWA
AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb NEWA

OSPEMIFENE

TABLET; ORAL

OSPHERA

+! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Mar CAHN
--------------	------	---------	-----	--------------	----------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

+ @ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan CRLD	
OXALIPLATIN						
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar NEWA
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar NEWA
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar NEWA
AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan NEWA
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan NEWA
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan NEWA
>A> AP		50MG/VIAL	A207385	001	May 23, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan NEWA
>A> AP		100MG/VIAL	A207385	002	May 23, 2017	May NEWA
>A> AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May NEWA
>A> AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

>A> AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May CMS1
>A> AB		15MG	A072253	003	Apr 14, 1988	May CMS1
>D>	@ WATSON LABS	10MG	A072952	001	Sep 28, 1990	May CAHN
>A>	@ WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990	May CAHN

TABLET; ORAL

OXAZEPAM

@ SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jan CAHN
------------------	------	---------	-----	--------------	----------

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>D> AB	GLENMARK GENERICS	150MG	A077802	001	Oct 09, 2007	May CAHN
>D> AB		300MG	A077802	002	Oct 09, 2007	May CAHN
>D> AB		600MG	A077802	003	Oct 09, 2007	May CAHN
>A> AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May CAHN
>A> AB		300MG	A077802	002	Oct 09, 2007	May CAHN
>A> AB		600MG	A077802	003	Oct 09, 2007	May CAHN

TABLET;ORAL

OXCARBAZEPINE

AB	JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Apr CAHN
AB		300MG	A090239	002	Jan 25, 2010	Apr CAHN
AB		600MG	A090239	003	Jan 25, 2010	Apr CAHN

OXYBUTYNIN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

	+ @ ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Feb DISC
--	------------------------	----	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

DITROPAN

	+ @ ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan CRLD
--	--------------------------	---------	---------	-----	--	----------

OXYBUTYNIN CHLORIDE

>D>	AA	PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	May CAHN
>A>	AA		5MG/5ML	A075137	001	Dec 18, 1998	May CAHN

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

>D>	AB	COREPHARMA	5MG	A090895	001	Aug 24, 2009	May CAHN
>D>	AB		15MG	A090895	002	Aug 24, 2009	May CAHN
>D>	AB		30MG	A090895	003	Aug 24, 2009	May CAHN
>A>	AB	EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009	May CAHN
>A>	AB		15MG	A090895	002	Aug 24, 2009	May CAHN
>A>	AB		30MG	A090895	003	Aug 24, 2009	May CAHN
>A>	AB	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	May NEWA
>A>	AB		10MG	A204021	002	Jun 12, 2017	May NEWA
>A>	AB		15MG	A204021	003	Jun 12, 2017	May NEWA
>A>	AB		20MG	A204021	004	Jun 12, 2017	May NEWA
>A>	AB		30MG	A204021	005	Jun 12, 2017	May NEWA
		ROXYBOND					
		INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Apr NEWA
			15MG	N209777	002	Apr 20, 2017	Apr NEWA
			30MG	N209777	003	Apr 20, 2017	Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADÉ

	+! ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan NEWA
--	-----------------	----	---------	-----	--------------	----------

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

	+! MYLAN SPECIALITY LP	50MG	N016848	001		Mar CAHN
--	------------------------	------	---------	-----	--	----------

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

>D>	AB	COREPHARMA	5MG	A201187	001	Dec 15, 2014	May CAHN
>D>	AB		10MG	A201187	002	Dec 15, 2014	May CAHN
>A>	AB	EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014	May CAHN
>A>	AB		10MG	A201187	002	Dec 15, 2014	May CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

	AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr CAHN
	AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
	AB		10MG	A079046	004	Jul 11, 2013	Apr CAHN
	AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN
	AB		20MG	A079046	005	Jul 11, 2013	Apr CAHN
	AB		30MG	A079046	006	Jul 11, 2013	Apr CAHN
	AB		40MG	A079046	007	Jul 11, 2013	Apr CAHN
>D>	AB	PAR PHARM	5MG	A200792	001	Oct 24, 2014	May DISC
>A>		@	5MG	A200792	001	Oct 24, 2014	May DISC
>D>	AB		7.5MG	A200792	002	Oct 24, 2014	May DISC
>A>		@	7.5MG	A200792	002	Oct 24, 2014	May DISC
>D>	AB		10MG	A200792	003	Oct 24, 2014	May DISC
>A>		@	10MG	A200792	003	Oct 24, 2014	May DISC
>D>	AB		15MG	A200792	004	Oct 24, 2014	May DISC
>A>		@	15MG	A200792	004	Oct 24, 2014	May DISC

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

>D>	AB		20MG	A200792	005	Oct 24, 2014	May DISC
>A>		@	20MG	A200792	005	Oct 24, 2014	May DISC
>D>	AB		30MG	A200792	006	Oct 24, 2014	May DISC
>A>		@	30MG	A200792	006	Oct 24, 2014	May DISC
>D>	AB		40MG	A200792	007	Oct 24, 2014	May DISC
>A>		@	40MG	A200792	007	Oct 24, 2014	May DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar CAHN
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

>D>	AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May CAHN
>A>	AB		1MCG	A204327	001	Jan 13, 2016	May CAHN
>D>	AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
>A>	AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
>D>	AB		4MCG	A204327	003	Jan 13, 2016	May CAHN
>A>	AB		4MCG	A204327	003	Jan 13, 2016	May CAHN

SOLUTION;INTRAVENOUS
PARICALCITOL

AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb NEWA
AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr CAHN
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr CAHN
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr CAHN

PAROXETINE HYDROCHLORIDE

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr DISC
@		EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr DISC
@		EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr DISC
@		EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr DISC

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan NEWA

PENCICLOVIR

CREAM;TOPICAL
DENA VIR

+	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan CAHN
---	------------------	----	---------	-----	--------------	----------

PENICILLAMINE

TABLET;ORAL
DEPEN

+	MYLAN SPECIALITY LP	250MG	N019854	001		Mar CAHN
---	---------------------	-------	---------	-----	--	----------

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION
BICILLIN L-A

>D>	+	KING PHARMS	300,000 UNITS/ML	N050141	003		May CAHN
>D>	BC	+	600,000 UNITS/ML	N050141	001		May CAHN
>A>	+	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		May CAHN
>A>	BC	+	600,000 UNITS/ML	N050141	001		May CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION
BICILLIN C-R

+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr CAHN
+		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr CAHN
+	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003		Apr CAHN

PENTOBARBITAL SODIUMINJECTABLE; INJECTION
PENTOBARBITAL SODIUM

AP	SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr CAHN
----	---------------	---------	---------	-----	--------------	----------

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
TRENTAL

	+ @ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CRLD
--	-----------------------	-------	---------	-----	--------------	----------

PERINDOPRIL ERBUMINE

TABLET; ORAL

>D>	ACEON					
>D> AB	+ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	May DISC
>A>	+ @	2MG	N020184	001	Dec 30, 1993	May DISC
>D> AB	+	4MG	N020184	002	Dec 30, 1993	May DISC
>A>	+ @	4MG	N020184	002	Dec 30, 1993	May DISC
>D> AB	+!	8MG	N020184	003	Dec 30, 1993	May DISC
>A>	+ @	8MG	N020184	003	Dec 30, 1993	May DISC
	PERINDOPRIL ERBUMINE					
>D> AB	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	May CHRS
>A> AB	!	2MG	A079070	001	Nov 10, 2009	May CHRS
>D> AB		4MG	A079070	002	Nov 10, 2009	May CHRS
>A> AB	!	4MG	A079070	002	Nov 10, 2009	May CHRS
>D> AB		8MG	A079070	003	Nov 10, 2009	May CHRS
>A> AB	!	8MG	A079070	003	Nov 10, 2009	May CHRS

PERMETHRINCREAM; TOPICAL
ELIMITE

AB	+! MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan CAHN
	PERMETHRIN					
>A> AB	ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	May CAHN
>D> AB	ACTAVIS MID ATLANTIC	5%	A074806	001	Jan 23, 1998	May CAHN

PERPHENAZINETABLET; ORAL
PERPHENAZINE

AB	MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017	Apr NEWA
AB		4MG	A206691	002	Apr 14, 2017	Apr NEWA
AB		8MG	A206691	003	Apr 14, 2017	Apr NEWA
AB		16MG	A206691	004	Apr 14, 2017	Apr NEWA

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

AB	PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan NEWA
----	---------------	------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

>A>	@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997	May CAHN
>A>	@	30MG	A040448	001	Jan 22, 2003	May CAHN
>A> AA		37.5MG	A040228	001	Jun 19, 1997	May CAHN
>D>	@ MIKAH PHARMA	30MG	A040227	001	Jun 18, 1997	May CAHN
>D>	@	30MG	A040448	001	Jan 22, 2003	May CAHN
>D> AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	May CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>A> AA	ELITE LABS INC	37.5MG	A040190	001	May 30, 1997	May CAHN
AA	KVK TECH INC	8MG	A203436	001	Mar 17, 2017	Mar NEWA
>D> AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May CAHN
AA	PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002	Feb CAHN

PHENTOLAMINE MESYLATEINJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

>D> AP	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	May CHRS
>A>	!	5MG/VIAL	A040235	001	Mar 11, 1998	May CHRS
>D>	REGITINE					
>D> AP	+! NOVARTIS	5MG/VIAL	N008278	003		May DISC

		INJECTABLE; INJECTION							
		REGITINE							
>A>	+	@	5MG/VIAL			N008278	003		May DISC
<u>PHENYLEPHRINE HYDROCHLORIDE</u>									
		SOLUTION; IV (INFUSION)							
		VAZCULEP							
	+	AVADEL LEGACY	10MG/ML (10MG/ML)			N204300	001	Jun 27, 2014	Jan CAHN
	+		50MG/5ML (10MG/ML)			N204300	002	Jun 27, 2014	Jan CAHN
	+	!	100MG/10ML (10MG/ML)			N204300	003	Jun 27, 2014	Jan CAHN
<u>PHENYTOIN</u>									
		TABLET, CHEWABLE; ORAL							
		DILANTIN							
AB	!	PFIZER	50MG			A084427	001		Feb CAHN
		PHENYTOIN							
>D>	AB	COREPHARMA	50MG			A040884	001	Nov 28, 2014	May CAHN
>A>	AB	EPIC PHARMA LLC	50MG			A040884	001	Nov 28, 2014	May CAHN
<u>PHENYTOIN SODIUM</u>									
		CAPSULE; ORAL							
		DILANTIN							
AB	!	PARKE-DAVIS	30MG EXTENDED			A084349	001		Feb CAHN
AB	!		100MG EXTENDED			A084349	002		Feb CAHN
		INJECTABLE; INJECTION							
		PHENYTOIN SODIUM							
>A>	AP	ACELLA PHARMS LLC	50MG/ML			A040573	001	Sep 13, 2006	May CAHN
		@ HOSPIRA	50MG/ML			A089521	001	Mar 17, 1987	Mar DISC
>D>	AP	X-GEN PHARMS	50MG/ML			A040573	001	Sep 13, 2006	May CAHN
<u>PHYTONADIONE</u>									
		INJECTABLE; INJECTION							
		AQUAMEPHYTON							
	+	@ TELIGENT	1MG/0.5ML			N012223	002		Apr CAHN
	+	@	10MG/ML			N012223	001		Apr CAHN
<u>PILOCARPINE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		PILOCARPINE HYDROCHLORIDE							
AB		ALLIED PHARMA INC	5MG			A076963	001	Dec 22, 2004	Mar CAHN
AB			7.5MG			A076963	002	Feb 27, 2007	Mar CAHN
AB		PERRIGO PHARMA INTL	5MG			A076746	001	Nov 16, 2004	Apr CAHN
<u>PINDOLOL</u>									
		TABLET; ORAL							
		PINDOLOL							
>D>		@ IDT AUSTRALIA LTD	5MG			A073608	001	Mar 29, 1993	May CMFD
>A>	AB		5MG			A073608	001	Mar 29, 1993	May CMFD
>D>		@	10MG			A073609	001	Mar 29, 1993	May CMFD
>A>	AB		10MG			A073609	001	Mar 29, 1993	May CMFD
<u>PIOGLITAZONE HYDROCHLORIDE</u>									
		TABLET; ORAL							
		PIOGLITAZONE HYDROCHLORIDE							
>D>	AB	WATSON LABS	EQ 15MG BASE			A076798	001	Oct 26, 2012	May CAHN
>D>	AB		EQ 30MG BASE			A076798	002	Oct 26, 2012	May CAHN
>D>	AB		EQ 45MG BASE			A076798	003	Oct 26, 2012	May CAHN
>A>	AB	WATSON LABS TEVA	EQ 15MG BASE			A076798	001	Oct 26, 2012	May CAHN
>A>	AB		EQ 30MG BASE			A076798	002	Oct 26, 2012	May CAHN
>A>	AB		EQ 45MG BASE			A076798	003	Oct 26, 2012	May CAHN
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>									
		INJECTABLE; INJECTION							
		PIPERACILLIN AND TAZOBACTAM							
AP		APOLLO PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL			A207847	001	Jan 13, 2017	Jan NEWA
AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL			A207847	002	Jan 13, 2017	Jan NEWA
AP			EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL			A207848	002	Jan 13, 2017	Jan NEWA
AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL			A207847	003	Jan 13, 2017	Jan NEWA
AP		WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG			A206996	001	Mar 22, 2017	Mar NEWA

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG	A206996	002	Mar 22, 2017	Mar NEWA
AP		BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	A206996	003	Mar 22, 2017	Mar NEWA
AP		BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	A207146	001	Mar 17, 2017	Mar NEWA
		BASE/VIAL				

PIRFENIDONE

TABLET; ORAL
ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr NEWA
AB		20MG	A208340	002	Apr 13, 2017	Apr NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL
PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

PLECANATIDE

TABLET; ORAL
TRULANCE

+	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA
---	----------------	-----	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010	Apr DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A204559	001	Apr 13, 2015	Apr CAHN
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Mar CAHN
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Feb NEWA
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004	Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL
COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
		COLYTE WITH FLAVOR PACKS				
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN

FOR SOLUTION;ORAL
COLYTE-FLAVORED

@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. 84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
PEG 3350 AND ELECTROLYTES					
@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5. 86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb CAHN
----	------------	--------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER					
AP + ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN
AP +	745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
AP +! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN
AP +	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
AP +! ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER					
AP +! ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ	IN SODIUM CHLORIDE 0.9%	IN PLASTIC	CONTAINER		
AP	ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ	IN SODIUM CHLORIDE 0.9%	IN PLASTIC	CONTAINER		
AP	ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@		0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@		0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@		0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@		1MG	A091254	005	Nov 30, 2010	Jan DISC
	@		1.5MG	A091254	006	Nov 30, 2010	Jan DISC
>D>	AB	ALEMBIC LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
>D>	AB		0.25MG	A078894	002	Oct 08, 2010	May CAHN
>D>	AB		0.5MG	A078894	003	Oct 08, 2010	May CAHN
>D>	AB		1MG	A078894	004	Oct 08, 2010	May CAHN
>D>	AB		1.5MG	A078894	005	Oct 08, 2010	May CAHN
>A>	AB	ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
>A>	AB		0.25MG	A078894	002	Oct 08, 2010	May CAHN
>A>	AB		0.5MG	A078894	003	Oct 08, 2010	May CAHN
>A>	AB		1MG	A078894	004	Oct 08, 2010	May CAHN
>A>	AB		1.5MG	A078894	005	Oct 08, 2010	May CAHN
	@	SANDOZ	0.125MG	A090190	001	Jul 06, 2010	Feb DISC
	@		0.25MG	A090190	002	Jul 06, 2010	Feb DISC
	@		0.5MG	A090190	003	Jul 06, 2010	Feb DISC
	@		0.75MG	A090190	006	Oct 08, 2010	Feb DISC
	@		1MG	A090190	004	Jul 06, 2010	Feb DISC

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

@ 1.5MG

A090190 005 Jul 06, 2010 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB ACTAVIS ELIZABETH 2.25MG

A203615 001 Oct 14, 2016 Apr CAHN

AB 3.75MG

A203615 002 Jan 03, 2017 Apr CAHN

AB MACLEODS PHARMS LTD 3.75MG

A206156 007 Jan 23, 2017 Jan NEWA

PRASTERONE

INSERT;VAGINAL

INTRAROSA

>A> +! AMAG PHARMS INC 6.5MG

N208470 001 Nov 16, 2016 May CAHN

>D> +! ENDOCEUTICS INC 6.5MG

N208470 001 Nov 16, 2016 May CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB AUROBINDO PHARMA LTD 10MG

A203367 001 Feb 02, 2017 Jan NEWA

AB 20MG

A203367 002 Feb 02, 2017 Jan NEWA

AB 40MG

A203367 003 Feb 02, 2017 Jan NEWA

AB 80MG

A203367 004 Feb 02, 2017 Jan NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

>A> IDT AUSTRALIA LTD EQ 1MG BASE

A072577 002 May 16, 1989 May CMS1

>A> EQ 5MG BASE

A072577 003 May 16, 1989 May CMS1

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

>D> AA PHARM ASSOC 15MG/5ML

A040399 001 Mar 05, 2003 May CAHN

>A> AA 15MG/5ML

A040399 001 Mar 05, 2003 May CAHN

AA VISTAPHARM 15MG/5ML

A040323 001 May 13, 1999 Mar CAHN

TABLET;ORAL

PREDNISOLONE

@ CHARTWELL RX 5MG

A084542 001 Apr CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

>D> AA AMNEAL PHARMS EQ 15MG BASE/5ML

A078345 001 Mar 10, 2009 May DISC

>A> @ EQ 15MG BASE/5ML

A078345 001 Mar 10, 2009 May DISC

>D> @ PHARM ASSOC EQ 5MG BASE/5ML

A076123 001 Dec 23, 2002 May CAHN

>A> @ EQ 5MG BASE/5ML

A076123 001 Dec 23, 2002 May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT ! BAUSCH AND LOMB EQ 0.23% PHOSPHATE;10%

A074449 001 Dec 29, 1995 Feb CAHN

AT SANDOZ INC EQ 0.23% PHOSPHATE;10%

A073630 001 May 27, 1993 Feb CAHN

PREDNISONE

TABLET;ORAL

METICORTEN

+ @ SCHERING 1MG

N009766 002 Mar CMS1

+ @ 5MG

N009766 001 Mar CMS1

PREDNISONE

@ CHARTWELL RX 5MG

A083059 001 Apr CAHN

@ CONTRACT PHARMACAL 5MG

A080209 001 Mar DISC

>D> AB MUTUAL PHARM 10MG

A089246 001 Dec 04, 1985 May CAHN

AB MYLAN PHARMS INC 5MG

A080292 001 Jan CAHN

AB 10MG

A088832 001 Dec 04, 1985 Jan CAHN

AB 20MG

A083677 001 Jan CAHN

>A> AB SUN PHARM INDS 10MG

A089246 001 Dec 04, 1985 May CAHN

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

AB ACTAVIS LABS FL INC 1MG

A204867 001 Apr 25, 2017 Apr NEWA

AB 2MG

A204867 002 Apr 25, 2017 Apr NEWA

AB 5MG

A204867 003 Apr 25, 2017 Apr NEWA

TABLET, DELAYED RELEASE;ORAL
RAYOS

AB	+	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr CFTG
AB	+		2MG	N202020	002	Jul 26, 2012	Apr CFTG
AB	+	!	5MG	N202020	003	Jul 26, 2012	Apr CFTG

PROBENECID

TABLET;ORAL

BENEMID

	+	@ MERCK	500MG	N007898	004		Jan CRLD
--	---	---------	-------	---------	-----	--	----------

PROBENECID

>D>	AB		WATSON LABS	500MG	A084442	004	Mar 29, 1983	May CAHN
>A>	AB		WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	May CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

	@	WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986	Jan CAHN
	@		500MG/ML	A089030	001	Apr 17, 1986	Mar CAHN

PROCARBAZINE HYDROCHLORIDE

CAPSULE;ORAL

MATULANE

	+	!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	Feb CAHN
--	---	---	---------------------	--------------	---------	-----	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

	@	ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Mar CAHN
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL

KEMADRIN

	@	MONARCH PHARMS	2MG	N009818	005		Apr CAHN
	@		5MG	N009818	003		Apr CAHN

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		DR REDDYS LABS INC	100MG	A208801	001	Feb 28, 2017	Feb NEWA
AB			200MG	A208801	002	Feb 28, 2017	Feb NEWA

INJECTABLE;INJECTION

PROGESTERONE

AO	+	!	ACTAVIS LABS UT INC	50MG/ML	N017362	002	Feb CAHN
----	---	---	---------------------	---------	---------	-----	----------

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PHENERGAN

	+	@	MYLAN PHARMS INC	50MG	N011689	001	Jan CAHN
--	---	---	------------------	------	---------	-----	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		PRINSTON INC	12.5MG	A040622	001	Jul 18, 2006	Feb CAHN
AB			25MG	A040622	002	Jul 18, 2006	Feb CAHN
AB			50MG	A040622	003	Jul 18, 2006	Feb CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

LARGON

	@	WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN
--	---	----------------------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INNOPRAN XL

BX		ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Mar CAHN
BX			120MG	N021438	002	Mar 12, 2003	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

BX		UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Apr CMFD
	@		60MG	A078311	001	Mar 06, 2009	Feb DISC
BX			80MG	A078311	002	Mar 06, 2009	Apr CMFD

CAPSULE, EXTENDED RELEASE;ORAL									
PROPRANOLOL HYDROCHLORIDE									
	@	80MG	A078311	002	Mar 06, 2009	Feb	DISC		
BX		120MG	A078311	003	Mar 06, 2009	Apr	CMFD		
	@	120MG	A078311	003	Mar 06, 2009	Feb	DISC		
BX		160MG	A078311	004	Mar 06, 2009	Apr	CMFD		
	@	160MG	A078311	004	Mar 06, 2009	Feb	DISC		
INJECTABLE;INJECTION									
PROPRANOLOL HYDROCHLORIDE									
AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN		
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar	CAHN		
TABLET;ORAL									
INDERAL									
	+ @ WYETH PHARMS INC	40MG	N016418	002		Jan	CRLD		
PROPRANOLOL HYDROCHLORIDE									
>D>	@ WATSON LABS	10MG	A070548	001	Jul 10, 1986	May	CAHN		
>D>	@	20MG	A070549	001	Apr 11, 1986	May	CAHN		
>D>	@	40MG	A070550	001	Apr 11, 1986	May	CAHN		
>A>	@ WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May	CAHN		
>A>	@	20MG	A070549	001	Apr 11, 1986	May	CAHN		
>A>	@	40MG	A070550	001	Apr 11, 1986	May	CAHN		
<u>PROPYLTHIOURACIL</u>									
TABLET;ORAL									
PROPYLTHIOURACIL									
	@ CHARTWELL RX	50MG	A084543	001		Apr	CAHN		
<u>PROTAMINE SULFATE</u>									
INJECTABLE;INJECTION									
PROTAMINE SULFATE									
	@ WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN		
	@	10MG/ML	A089475	001	Nov 05, 1986	Jan	CAHN		
<u>PYRIDOSTIGMINE BROMIDE</u>									
INJECTABLE;INJECTION									
REGONOL									
>D>	AP	SANDOZ	5MG/ML	N017398	001		May	CAHN	
>A>	AP	SANDOZ INC	5MG/ML	N017398	001		May	CAHN	
TABLET;ORAL									
PYRIDOSTIGMINE BROMIDE									
	@ IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb	CAHN		
<u>PYRIMETHAMINE</u>									
TABLET;ORAL									
DARAPRIM									
>D>	+!	TURING PHARMS AG	25MG	N008578	001		May	CAHN	
>A>	+!	TURING PHARMS LLC	25MG	N008578	001		May	CAHN	
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL									
QUETIAPINE FUMARATE									
>D>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	May	DISC	
>A>		@	EQ 25MG BASE	A090323	001	Mar 27, 2012	May	DISC	
TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
AB		ACCORD HLTHCARE	EQ 150MG BASE	A090681	001	May 09, 2017	Apr	NEWA	
AB			EQ 200MG BASE	A090681	002	May 09, 2017	Apr	NEWA	
AB			EQ 300MG BASE	A090681	003	May 09, 2017	Apr	NEWA	
AB			EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN	
AB		INTELLIPHARMACEUTICS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	NEWA	
AB			EQ 150MG BASE	A202939	002	May 09, 2017	Apr	NEWA	
AB			EQ 200MG BASE	A202939	003	May 09, 2017	Apr	NEWA	
AB			EQ 300MG BASE	A202939	004	May 09, 2017	Apr	NEWA	
AB			EQ 400MG BASE	A202939	005	May 09, 2017	Apr	NEWA	
>A>	AB	LUPIN LTD	EQ 50MG BASE	A204203	001	May 17, 2017	May	NEWA	
>A>	AB		EQ 150MG BASE	A204203	002	May 17, 2017	May	NEWA	
>A>	AB		EQ 200MG BASE	A204203	003	May 17, 2017	May	NEWA	
>A>	AB		EQ 300MG BASE	A204203	004	May 17, 2017	May	NEWA	
>A>	AB		EQ 400MG BASE	A204203	005	May 17, 2017	May	NEWA	
AB		PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA	
AB			EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA	
AB			EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA	

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr NEWA
AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr NEWA
AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr NEWA
AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr NEWA
AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr NEWA
AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr NEWA
AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr NEWA

SEROQUEL XR

AB	+	ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Apr CTEC
AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr CTEC
AB	+	!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr CTEC
AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Apr CTEC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB		AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb NEWA
AB		KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

>A>	+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May NEWA
-----	---	-------------------	---------------	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB		ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar CAHN
AB			2.5MG	A202392	002	Apr 15, 2014	Mar CAHN
AB			5MG	A202392	003	Apr 15, 2014	Mar CAHN
AB			10MG	A202392	004	Apr 15, 2014	Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+	!	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr CAHN
AP	+	!	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN

ZANTAC IN PLASTIC CONTAINER

>D>	@	IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May CAHN
>D>	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May CAHN
>A>	@	TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May CAHN
>A>	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan CAHN
>D> AA		PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May CAHN
>A> AA			EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D> AB		GLENMARK GENERICS	EQ 150MG BASE	A078542	001	Nov 19, 2008	May CAHN
>D> AB			EQ 300MG BASE	A078542	002	Nov 19, 2008	May CAHN
>A> AB		GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May CAHN
>A> AB			EQ 300MG BASE	A078542	002	Nov 19, 2008	May CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
+	!	1GM	N021526	001	Feb 12, 2007	Feb CTEC
	RANOLAZINE					
@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb DISC
@		1GM	A201046	002	Jul 29, 2013	Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A> AB		MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	May NEWA
>A> AB			EQ 1MG BASE	A201971	002	May 15, 2017	May NEWA

REPAGLINIDETABLET; ORAL
PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb CAHN
AB	+	!	2MG	N020741	003	Dec 22, 1997	Feb CAHN

RESERPINETABLET; ORAL
RESERPINE

+	@	SANDOZ	0.1MG	N009838	001		Apr DISC
+	@		0.25MG	N009838	002		Apr DISC

RIBAVIRINCAPSULE; ORAL
RIBASPHERE

AB		KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan CAHN
----	--	-------------------	-------	---------	-----	--------------	----------

TABLET; ORAL
RIBAVIRIN

AB		KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan CAHN
AB			400MG	A077456	002	Dec 05, 2005	Jan CAHN
AB		!	600MG	A077456	003	Dec 05, 2005	Jan CAHN

RIBOCICLIB SUCCINATETABLET; ORAL
KISQALI

+	!	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar NEWA
---	---	----------------------	---------------	---------	-----	--------------	----------

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb CAHN
AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan CAHN

RILUZOLETABLET; ORAL
RILUZOLE

>D>	AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	May CAHN
>A>	AB	GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May CAHN

RIMANTADINE HYDROCHLORIDETABLET; ORAL
RIMANTADINE HYDROCHLORIDE

@	IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb CAHN
---	----------------	-------	---------	-----	--------------	----------

RISPERIDONETABLET; ORAL
RISPERIDONE

@	JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr CAHN
@		0.5MG	A078828	002	Mar 23, 2009	Apr CAHN
@		1MG	A078828	003	Mar 23, 2009	Apr CAHN
@		2MG	A078828	004	Mar 23, 2009	Apr CAHN
@		3MG	A078828	005	Mar 23, 2009	Apr CAHN
@		4MG	A078828	006	Mar 23, 2009	Apr CAHN
AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

RIVASTIGMINE TARTRATECAPSULE; ORAL
RIVASTIGMINE TARTRATE

AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan NEWA
AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar CAHN
AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar CAHN
AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar CAHN

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar CAHN
----	--	-------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

AB	ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar CAHN
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb NEWA
AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

>D>	AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	May CAHN
>D>	AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May CAHN
>A>	AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May CAHN
>A>	AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May CAHN
	AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA
	AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA
	AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb NEWA
	AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb NEWA

ROCURONIUM BROMIDEINJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar NEWA
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar NEWA
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar CAHN
AP	!	100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb NEWA
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb NEWA

ROPINIROLE HYDROCHLORIDETABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb NEWA
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA
>D>	@ COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
>D>	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN
>D>	@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
>D>	@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
>D>	@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
>D>	@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
>D>	@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN
>A>	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
>A>	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN
>A>	@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
>A>	@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
>A>	@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
>A>	@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
>A>	@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

>D>	AB	ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
>D>	AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
>D>	AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN
>D>	AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
>D>	AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
>A>	AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
>A>	AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
>A>	AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

>A>	AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
>A>	AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
		@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar CAHN
AB			10MG	A206434	002	Oct 31, 2016	Mar CAHN
AB			20MG	A206434	003	Oct 31, 2016	Mar CAHN
AB			40MG	A206434	004	Oct 31, 2016	Mar CAHN
AB		ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar NEWA
AB			10MG	A206465	002	Mar 21, 2017	Mar NEWA
AB			20MG	A206465	003	Mar 21, 2017	Mar NEWA
AB			40MG	A206465	004	Mar 21, 2017	Mar NEWA
AB		TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr CAHN
AB			10MG	A201619	002	Oct 31, 2016	Apr CAHN
AB			20MG	A201619	003	Oct 31, 2016	Apr CAHN
AB			40MG	A201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

TABLET;ORAL
RUBRACA

>A>	+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May NEWA
-----	---	---------------------	---------------	---------	-----	--------------	----------

SAFINAMIDE MESYLATE

TABLET;ORAL
XADAGO

+		NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar NEWA
+	!		100MG	N207145	002	Mar 21, 2017	Mar NEWA
+		US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr CAHN
+	!		100MG	N207145	002	Mar 21, 2017	Apr CAHN

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

>A>	AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May CAHN
		@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan CAHN	
		@	5MG	A074641	001	Aug 02, 1996	Jan CAHN	
>D>	AB		STASON	5MG	A074912	001	Apr 30, 1998	May CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

@		ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar CAHN
---	--	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

@		ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar CAHN
@			EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar CAHN
@			EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar CAHN
@		MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar DISC
@			EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar DISC
@			EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar DISC
>D>		WATSON LABS	EQ 25MG BASE	A077663	001	Feb 06, 2007	May CAHN
>D>		@	EQ 50MG BASE	A077663	002	Feb 06, 2007	May CAHN
>D>		@	EQ 100MG BASE	A077663	003	Feb 06, 2007	May CAHN
>A>		WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May CAHN
>A>		@	EQ 50MG BASE	A077663	002	Feb 06, 2007	May CAHN
>A>		@	EQ 100MG BASE	A077663	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
RENEVELA

>D>	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May CFTG
>A>	AB	+	800MG/PACKET	N022318	001	Aug 12, 2009	May CFTG
>D>		+	2.4GM/PACKET	N022318	002	Feb 18, 2009	May CFTG
>A>	AB	+	2.4GM/PACKET	N022318	002	Feb 18, 2009	May CFTG
>A>		SEVELAMER CARBONATE					
>A>	AB	AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May NEWA
>A>	AB		2.4GM/PACKET	A207624	002	Jun 13, 2017	May NEWA

SILDENAFIL CITRATETABLET;ORAL
VIAGRA

>A>	+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	May CAHN
>A>	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May CAHN
>A>	+		EQ 100MG BASE	N020895	003	Mar 27, 1998	May CAHN
>D>	+	PFIZER IRELAND	EQ 25MG BASE	N020895	001	Mar 27, 1998	May CAHN
>D>	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May CAHN
>D>	+		EQ 100MG BASE	N020895	003	Mar 27, 1998	May CAHN

SILODOSINCAPSULE;ORAL
RAPAFLO

AB	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar CFTG
AB	+		8MG	N022206	002	Oct 08, 2008	Mar CFTG
		SILODOSIN					
AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar NEWA
AB			8MG	A204726	002	Mar 31, 2017	Mar NEWA

SIMVASTATINSUSPENSION;ORAL
SIMVASTATIN

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Jan CAHN

TABLET;ORAL
SIMVASTATIN

>D>	AB	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May DISC
>A>	@		5MG	A090868	001	Jun 08, 2010	May DISC
>D>	AB		10MG	A090868	002	Jun 08, 2010	May DISC
>A>	@		10MG	A090868	002	Jun 08, 2010	May DISC
>D>	AB		20MG	A090868	003	Jun 08, 2010	May DISC
>A>	@		20MG	A090868	003	Jun 08, 2010	May DISC
>D>	AB		40MG	A090868	004	Jun 08, 2010	May DISC
>A>	@		40MG	A090868	004	Jun 08, 2010	May DISC
>D>	AB		80MG	A090868	005	Jun 08, 2010	May DISC
>A>	@		80MG	A090868	005	Jun 08, 2010	May DISC
>D>	AB	WATSON LABS	5MG	A076685	001	Dec 20, 2006	May CAHN
>D>	AB		10MG	A076685	002	Dec 20, 2006	May CAHN
>D>	AB		20MG	A076685	003	Dec 20, 2006	May CAHN
>D>	AB		40MG	A076685	004	Dec 20, 2006	May CAHN
>D>	AB		80MG	A076685	005	Dec 20, 2006	May CAHN
>A>	AB	WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May CAHN
>A>	AB		10MG	A076685	002	Dec 20, 2006	May CAHN
>A>	AB		20MG	A076685	003	Dec 20, 2006	May CAHN
>A>	AB		40MG	A076685	004	Dec 20, 2006	May CAHN
>A>	AB		80MG	A076685	005	Dec 20, 2006	May CAHN

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb NEWA

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb CAHN
		SODIUM CHLORIDE 0.9%					
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN
		SODIUM CHLORIDE 0.9%					
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb CAHN
>A>	AP	LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr CAHN
		SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD

INJECTABLE;INJECTION

	SODIUM CHLORIDE IN PLASTIC CONTAINER						
	+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD
	SOLUTION;IRRIGATION						
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AT	ICU MEDICAL INC	900MG/100ML	N017514	001		Feb	CAHN
AT		900MG/100ML	N018314	001		Feb	CAHN

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP	AKORN	25MG/ML	A208635	001	May 04, 2017	Apr	NEWA
>A> AP	NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May	NEWA
	SOLUTION;IV (INFUSION)						
	NIPRIIDE RTU IN SODIUM CHLORIDE 0.9%						
	+! EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar	NEWA

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA	WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan	NEWA
	XYREM						
AA	+! JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan	CFTG

SODIUM PHENYLBUTYRATE

TABLET;ORAL

SODIUM PHENYLBUTYRATE

AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr	CAHN
AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar	CAHN
	SUSPENSION;ORAL, RECTAL						
	SPS						
AA	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr	CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

>D>	+! SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	May	CAHN
	+!	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar	CAHN
>A>	+! SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May	CAHN

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

>A> AB1	+ COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May	CAHN
>A> AB1	+	120MG	N019865	005	Apr 20, 1994	May	CAHN
>A> AB1	+!	160MG	N019865	002	Oct 30, 1992	May	CAHN
>A> AB1	+	240MG	N019865	003	Oct 30, 1992	May	CAHN
>A>	@	320MG	N019865	004	Oct 30, 1992	May	CAHN
>D> AB1	+ COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	May	CAHN
>D> AB1	+	120MG	N019865	005	Apr 20, 1994	May	CAHN
>D> AB1	+!	160MG	N019865	002	Oct 30, 1992	May	CAHN
>D> AB1	+	240MG	N019865	003	Oct 30, 1992	May	CAHN
>D>	@	320MG	N019865	004	Oct 30, 1992	May	CAHN
	BETAPACE AF						
>A>	@ COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May	CAHN
>A>	@	60MG	N021151	007	Apr 02, 2003	May	CAHN
>A> AB2	+	80MG	N021151	001	Feb 22, 2000	May	CAHN
>A>	@	100MG	N021151	005	Mar 14, 2003	May	CAHN
>A> AB2	+	120MG	N021151	002	Feb 22, 2000	May	CAHN
>A> AB2	+!	160MG	N021151	003	Feb 22, 2000	May	CAHN
>D>	@ COVIS PHARMA SARL	40MG	N021151	006	Apr 02, 2003	May	CAHN
>D>	@	60MG	N021151	007	Apr 02, 2003	May	CAHN
>D> AB2	+	80MG	N021151	001	Feb 22, 2000	May	CAHN
>D>	@	100MG	N021151	005	Mar 14, 2003	May	CAHN
>D> AB2	+	120MG	N021151	002	Feb 22, 2000	May	CAHN
>D> AB2	+!	160MG	N021151	003	Feb 22, 2000	May	CAHN

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@ TEVA	80MG	A076883	001	Jul 26, 2004	Apr	DISC
@	120MG	A076883	002	Jul 26, 2004	Apr	DISC
@	160MG	A076883	003	Jul 26, 2004	Apr	DISC

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB	ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar	CAHN
AB		50MG	A203512	002	Sep 19, 2016	Mar	CAHN
AB		100MG	A203512	003	Sep 19, 2016	Mar	CAHN
>D> AB	AMNEAL PHARMS	25MG	A091426	001	Jun 08, 2010	May	CMS1
>A> AB		25MG	A091426	001	Jul 02, 2010	May	CAHN
>A> AB		25MG	A091426	001	Jul 02, 2010	May	CMS1
>D> AB		50MG	A091426	002	Jun 08, 2010	May	CMS1
>A> AB		50MG	A091426	002	Jul 02, 2010	May	CAHN
>A> AB		50MG	A091426	002	Jul 02, 2010	May	CMS1
>D> AB		100MG	A091426	003	Jun 08, 2010	May	CMS1
>A> AB		100MG	A091426	003	Jul 02, 2010	May	CAHN
>A> AB		100MG	A091426	003	Jul 02, 2010	May	CMS1

STAVUDINE

CAPSULE;ORAL

STAVUDINE

>D> AB	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May	DISC
>A>	@	30MG	A078775	001	Jan 05, 2009	May	DISC
AB		30MG	A078775	001	Jan 05, 2009	Mar	CAHN
>D> AB		40MG	A078775	002	Jan 05, 2009	May	DISC
>A>	@	40MG	A078775	002	Jan 05, 2009	May	DISC
AB		40MG	A078775	002	Jan 05, 2009	Mar	CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan	CAHN
	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	100%	N018233	001		Feb	CAHN
AP	+!	100%	N019869	001	Dec 26, 1989	Apr	CAHN
AP	TARO	100%	A077393	001	Aug 11, 2006	Apr	CAHN

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	100%	N017513	001		Feb	CAHN
AT		100%	N018313	001		Feb	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

>D> AP	+! SANDOZ	20MG/ML	N008453	002		May	CAHN
>D>	@	50MG/ML	N008453	003		May	CAHN
>D>	@	500MG/VIAL	N008453	001		May	CAHN
>D>	@	1GM/VIAL	N008453	004		May	CAHN
>A> AP	+! SANDOZ INC	20MG/ML	N008453	002		May	CAHN
>A>	@	50MG/ML	N008453	003		May	CAHN
>A>	@	500MG/VIAL	N008453	001		May	CAHN
>A>	@	1GM/VIAL	N008453	004		May	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT	SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb	CAHN
----	------------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SEPTRA

>D> AB	MONARCH PHARMS	400MG;80MG	N017376	001		May	CAHN
>A> AB		400MG;80MG	N017376	001		May	CAHN
	SEPTRA DS						
>D> AB	MONARCH PHARMS	800MG;160MG	N017376	002		May	CAHN
>A> AB		800MG;160MG	N017376	002		May	CAHN

TABLET;ORAL								
SULFAMETHOXAZOLE AND TRIMETHOPRIM								
AB	CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar	CAHN	
AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar	CAHN	
AB	CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan	CAHN	
AB		800MG;160MG	A078060	001	Jan 25, 2007	Jan	CAHN	
<u>SULFANILAMIDE</u>								
CREAM;VAGINAL								
AVC								
+	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987	Mar	CAHN	
SUPPOSITORY;VAGINAL								
AVC								
	@ MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN	
<u>SUMATRIPTAN SUCCINATE</u>								
INJECTABLE;SUBCUTANEOUS								
SUMATRIPTAN SUCCINATE								
	@ SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar	CAHN	
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar	CAHN	
AP	WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan	CAHN	
SYSTEM;IONTOPHORESIS								
ZECUITY								
+	@ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan	DISC	
<u>SUNITINIB MALATE</u>								
CAPSULE;ORAL								
SUTENT								
+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Mar	CTEC	
+		EQ 25MG BASE	N021938	002	Jan 26, 2006	Mar	CTEC	
+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Mar	CTEC	
+	!	EQ 50MG BASE	N021938	003	Jan 26, 2006	Mar	CTEC	
<u>TALC</u>								
POWDER;INTRAPLEURAL								
STERITALC								
+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017	Apr	NEWA	
+		3GM/VIAL	N205555	002	May 01, 2017	Apr	NEWA	
+	!	4GM/VIAL	N205555	003	May 01, 2017	Apr	NEWA	
<u>TAMSULOSIN HYDROCHLORIDE</u>								
CAPSULE;ORAL								
TAMSULOSIN HYDROCHLORIDE								
AB	MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan	NEWA	
<u>TAZAROTENE</u>								
AEROSOL, FOAM;TOPICAL								
FABIOR								
+	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan	CAHN	
CREAM;TOPICAL								
AVAGE								
AB	+	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar	CFTG
TAZAROTENE								
AB		TARO	0.1%	A208258	001	Apr 03, 2017	Mar	NEWA
TAZORAC								
AB	+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar	CFTG
<u>TECHNETIUM TC-99M MEDRONATE KIT</u>								
INJECTABLE;INJECTION								
MDP-BRACCO								
AP	CARDINAL HEALTH 414	N/A	N018107	001		Apr	CAHN	
<u>TECHNETIUM TC-99M TILMANOCEPT</u>								
INJECTABLE;INJECTION								
LYMPHOSEEK KIT								
+	CARDINAL HLTH 414	N/A	N202207	001	Mar 13, 2013	Mar	CAHN	

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)
VIBATIV

>D>	+	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May CAHN
>A>	+		EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May CAHN
>D>	+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May CAHN
>A>	+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May CAHN

TELMISARTAN

TABLET; ORAL
TELMISARTAN

>D>	AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	May CAHN
>D>	AB		40MG	A090032	002	Jul 07, 2014	May CAHN
>D>	AB		80MG	A090032	003	Jul 07, 2014	May CAHN
>A>	AB	GLENMARK PHARMS LTD	20MG	A090032	001	Jul 07, 2014	May CAHN
>A>	AB		40MG	A090032	002	Jul 07, 2014	May CAHN
>A>	AB		80MG	A090032	003	Jul 07, 2014	May CAHN
	AB	PRINSTON INC	20MG	A207882	001	May 03, 2017	Apr NEWA
	AB		40MG	A207882	002	May 03, 2017	Apr NEWA
	AB		80MG	A207882	003	May 03, 2017	Apr NEWA

TELOTRISTAT ETIPRATE

TABLET; ORAL
XERMELO

+! LEXICON PHARMS INC EO 250MG BASE N208794 001 Feb 28, 2017 Feb NEWA

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

>A>	AB	ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May CMS1
	AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
	AB		15MG	A201781	002	Jun 04, 2015	Feb CAHN
	AB		22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
	AB		30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb	NEWA
AB		20MG	A201528	002	Feb 27, 2017	Feb	NEWA
AB		100MG	A201528	003	Feb 27, 2017	Feb	NEWA
AB		140MG	A201528	004	Feb 27, 2017	Feb	NEWA
AB		180MG	A201528	005	Feb 27, 2017	Feb	NEWA
AB		250MG	A201528	006	Feb 27, 2017	Feb	NEWA
AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr	NEWA
AB		20MG	A207658	002	Apr 26, 2017	Apr	NEWA
AB		100MG	A207658	003	Apr 26, 2017	Apr	NEWA
AB		140MG	A207658	004	Apr 26, 2017	Apr	NEWA
AB		180MG	A207658	005	Apr 26, 2017	Apr	NEWA
AB		250MG	A207658	006	Apr 26, 2017	Apr	NEWA
AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr	NEWA
AB		20MG	A203959	002	Apr 18, 2017	Apr	NEWA
AB		100MG	A203959	003	Apr 18, 2017	Apr	NEWA
AB		140MG	A203959	004	Apr 18, 2017	Apr	NEWA
AB		250MG	A203959	005	Apr 18, 2017	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A 075140 002	Feb 11, 2000	Mar CAHN
AB		EQ 2MG BASE	A 075140 003	Feb 11, 2000	Mar CAHN
AB		EQ 5MG BASE	A 075140 001	Feb 11, 2000	Mar CAHN
AB		EQ 10MG BASE	A 075140 004	Feb 11, 2000	Mar CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE

AP ! ATHENEX INC 1MG/ML A076770 001 Apr 23, 2004 Mar CAHN

TABLET; ORAL
BRETHINE

+ @ ANI PHARMS INC	2.5MG	N017849 001	Feb CAHN
--------------------	-------	-------------	----------

TABLET;ORAL
BRETHINE

+ @	5MG	N017849	002		Feb CAHN
TERBUTALINE SULFATE					
! LANNETT	5MG	A077152	002	Mar 25, 2005	Jan CHRS

TESTOSTERONE

GEL;TRANSDERMAL
TESTIM

>D> AB2	+!	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May CAHN
>A> AB2	+!	AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May CAHN
GEL, METERED;TRANSDERMAL							
TESTOSTERONE							
AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar CAHN
SOLUTION, METERED;TRANSDERMAL							
AXIRON							
AT	+!	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb CFTG
TESTOSTERONE							
AT		PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb NEWA
TABLET, EXTENDED RELEASE;BUCCAL							
STRIANT							
>D>	+!	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	May CAHN
>A>	+!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

AO		SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
AO			200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
AO		WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
AO		WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION
TESTOSTERONE ENANTHATE

AO		WATSON PHARMS INC	200MG/ML	A085598	001		Feb CAHN
----	--	-------------------	----------	---------	-----	--	----------

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB		APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan NEWA
AB			25MG	A207682	002	Jan 31, 2017	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
ACHROMYCIN V

AB	+	HERITAGE PHARMA	250MG	N050278	003		Jan CAHN
AB	+!		500MG	N050278	001		Jan CAHN
TETRACYCLINE HYDROCHLORIDE							
AB		CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr CAHN
AB			500MG	A062752	002	Aug 12, 1988	Apr CAHN

THEOPHYLLINE

ELIXIR;ORAL
THEOPHYLLINE

>D>	@	CHARTWELL RX	80MG/15ML	A085952	001		Apr CAHN
>A>	@	PHARM ASSOC	80MG/15ML	A086720	001		May CAHN
>A>	@		80MG/15ML	A086720	001		May CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

>D> AB		NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	May CAHN
>D> AB			200MG	A088321	001	Feb 21, 1985	May CAHN
>D>	@		300MG	A087400	002	Jan 11, 1983	May CAHN
>A> AB		NOSTRUM PHARMS LLC	100MG	A088320	001	Feb 21, 1985	May CAHN
>A> AB			200MG	A088321	001	Feb 21, 1985	May CAHN
>A>	@		300MG	A087400	002	Jan 11, 1983	May CAHN
THEOPHYLLINE							
>D> AB		ALEMBIC LTD	300MG	A090430	001	Oct 27, 2010	May CAHN
>D>	!		450MG	A090430	002	Oct 27, 2010	May CAHN
	!		450MG	A090430	002	Oct 27, 2010	Apr CHRS

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

>A>	AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CAHN
>A>	!		450MG	A090430	002	Oct 27, 2010	May CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

@	WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan CAHN
---	----------------------	----------	---------	-----	--	----------

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

THIORIDAZINE HYDROCHLORIDE

	@	ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987	Jan CAHN
>D>	@	PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997	May CAHN
>A>	@		30MG/ML	A040187	001	Aug 28, 1997	May CAHN
>D>	@		100MG/ML	A040213	001	May 29, 1998	May CAHN
>A>	@		100MG/ML	A040213	001	May 29, 1998	May CAHN

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

>D>	@	WATSON LABS	15MG	A088477	001	Nov 08, 1983	May CAHN
>D>	@		25MG	A088567	001	May 11, 1984	May CAHN
>D>	@		200MG	A088872	001	Apr 26, 1985	May CAHN
>A>	@	WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983	May CAHN
>A>	@		25MG	A088567	001	May 11, 1984	May CAHN
>A>	@		200MG	A088872	001	Apr 26, 1985	May CAHN

THIOTEPA

POWDER;IV (INFUSION)

TEPADINA

+	!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan NEWA
+	!		100MG/VIAL	N208264	002	Jan 26, 2017	Jan NEWA

TICAGRELOR

TABLET;ORAL

BRILINTA

+		ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
+	!		90MG	N022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

POWDER;IV (INFUSION)

TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb CDFR
		TYGACIL					
AP	+	!	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005
							Feb CDFR

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB		SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb CAHN
AB			EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb CAHN

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT	!	ALCON RES LTD	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Jan CHRS
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Jan CHRS
AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN

TIMOPTIC

+	@	ATON	EQ 0.25% BASE	N018086	001		Jan DISC
+	@		EQ 0.5% BASE	N018086	002		Jan DISC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB			500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb NEWA
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb NEWA
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb NEWA
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

>D>	AB	COREPHARMA	EQ 2MG BASE	A076347	001	Oct 11, 2002	May CAHN
>D>	AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May CAHN
>A>	AB	EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May CAHN
>A>	AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May CAHN
	AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
	AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

>D>	AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May CAHN
>A>	AN		300MG/5ML	A205501	001	Jul 13, 2015	May CAHN
	AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBREX

AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb CAHN
----	------------	------	---------	-----	--------------	----------

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

@	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr DISC
---	----------------	---------------	---------	-----	--------------	----------

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

>D>	AB	MYLAN	25MG	A076314	001	Mar 27, 2009	May DISC
>A>	@		25MG	A076314	001	Mar 27, 2009	May DISC
>D>	AB		50MG	A076314	002	Mar 27, 2009	May DISC
>A>	@		50MG	A076314	002	Mar 27, 2009	May DISC
>D>	AB		100MG	A076314	003	Mar 27, 2009	May DISC
>A>	@		100MG	A076314	003	Mar 27, 2009	May DISC
>D>	AB		200MG	A076314	004	Mar 27, 2009	May DISC
>A>	@		200MG	A076314	004	Mar 27, 2009	May DISC

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

+	!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
---	---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+	!	20MG	N020136	003	Aug 23, 1993	Mar CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar CAHN	
>D>	AB	AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May CAHN
>A>	AB		50MG	A076003	001	Jun 20, 2002	May CAHN

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

+	@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CRLD
+	@		200MG	N021692	002	Sep 08, 2005	Mar CRLD
+	@		300MG	N021692	003	Sep 08, 2005	Mar CRLD

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

>D>	@	COREPHARMA	1MG	A077256	001	Jun 12, 2007	May CAHN
>D>	@		2MG	A077256	002	Jun 12, 2007	May CAHN
>D>	@		4MG	A077256	003	Jun 12, 2007	May CAHN
>A>	@	EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007	May CAHN
>A>	@		2MG	A077256	002	Jun 12, 2007	May CAHN
>A>	@		4MG	A077256	003	Jun 12, 2007	May CAHN
BX		INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007	Apr CTEC
BX			2MG	A078320	002	Jun 12, 2007	Apr CTEC
BX			4MG	A078320	003	Jun 12, 2007	Apr CTEC
>D> AB		MYLAN	1MG	A078346	001	Apr 28, 2008	May DISC
>A>	@		1MG	A078346	001	Apr 28, 2008	May DISC
>D> AB			2MG	A078346	002	Apr 28, 2008	May DISC
>A>	@		2MG	A078346	002	Apr 28, 2008	May DISC
>D> AB			4MG	A078346	003	Apr 28, 2008	May DISC
>A>	@		4MG	A078346	003	Apr 28, 2008	May DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP		AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb NEWA
AP		GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>D> AB		MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	May DISC
>A>	@		50MG	A090514	001	Jun 02, 2009	May DISC
>D> AB			100MG	A090514	002	Jun 02, 2009	May DISC
>A>	@		100MG	A090514	002	Jun 02, 2009	May DISC
>D> AB			150MG	A090514	003	Jun 02, 2009	May DISC
>A>	@		150MG	A090514	003	Jun 02, 2009	May DISC
>D> AB			300MG	A090514	004	Jun 02, 2009	May DISC
>A>	@		300MG	A090514	004	Jun 02, 2009	May DISC

TRETINOIN

CAPSULE; ORAL

VESANOID

>A>	+	@	CHEPLAPHARM	10MG	N020438	001	Nov 22, 1995	May CAHN
>D>	+	@	ROCHE	10MG	N020438	001	Nov 22, 1995	May CAHN

CREAM; TOPICAL

TRETINOIN

	@	ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Feb DISC
	@		0.075%	A202209	001	Oct 11, 2012	Feb DISC
AB2		ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan NEWA
AT			0.1%	A208763	002	Feb 01, 2017	Jan NEWA
AT			0.5%	A208763	003	Feb 01, 2017	Jan NEWA
AT	+	MYLAN PHARMS INC	0.025%	N011601	003		Jan CAHN
AT	+		0.1%	N011601	006		Jan CAHN
	@	TARO	0.025%	A040038	001	Oct 26, 1994	Apr CAHN
AT			0.1%	A040039	001	Nov 26, 1997	Apr CAHN
AT			0.1%	A040039	001	Nov 26, 1997	Mar CAHN

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

	@	SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr CAHN
	@		40MG/ML	A090164	001	Jun 01, 2009	Apr CAHN

OINTMENT; TOPICAL

KENALOG

AT		MYLAN PHARMS INC	0.025%	N011600	003		Jan CAHN
AT			0.1%	N011600	001		Jan CAHN
		TRIAMCINOLONE ACETONIDE					
	@	TARO	0.025%	A040040	001	Sep 30, 1994	Apr CAHN
AT			0.1%	A040037	001	Sep 30, 1994	Apr CAHN
AT		TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb NEWA

OINTMENT;TOPICAL

		TRIAMCINOLONE ACETONIDE IN ABSORBASE							
	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr	CAHN	
		PASTE;DENTAL							
		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA	
		SPRAY, METERED;NASAL							
		TRIAMCINOLONE ACETONIDE							
	@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN	

TRIFLURIDINE

		SOLUTION/DROPS;OPHTHALMIC							
		TRIFLURIDINE							
AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN	
		VIROPTIC							
AT	+	MONARCH PHARMS	1%	N018299	001		Feb	CAHN	

TRIHEXYPHENIDYL HYDROCHLORIDE

		ELIXIR;ORAL							
		TRIHEXYPHENIDYL HYDROCHLORIDE							
>D> AA	!	PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN	
>A> AA	!		2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN	
		TABLET;ORAL							
		TRIHEXYPHENIDYL HYDROCHLORIDE							
AA		VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN	
AA			5MG	A040254	002	Dec 24, 1998	Mar	CAHN	

TRIMETHOBENZAMIDE HYDROCHLORIDE

		CAPSULE;ORAL							
		TIGAN							
>D> AB	+	KING PHARMS	300MG	N017531	006	Dec 13, 2001	May	CAHN	
>A> AB	+	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN	

TRIMIPRAMINE MALEATE

		CAPSULE;ORAL							
		TRIMIPRAMINE MALEATE							
>A> AB		ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN	
>A> AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN	
>A> AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN	
>D> AB		MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN	
>D> AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN	
>D> AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN	

TROPICAMIDE

		SOLUTION/DROPS;OPHTHALMIC							
		MYDRIACYL							
AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN	

ULIPRISTAL ACETATE

		TABLET;ORAL							
		ELLA							
AB	+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG	
		LOGILIA							
AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA	

URSODIOL

		CAPSULE;ORAL							
		URSODIOL							
>D> BX		IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May	DISC	
>A>	@		300MG	A077895	001	Jul 27, 2006	May	DISC	
BX			300MG	A077895	001	Jul 27, 2006	Apr	CTEC	
AB			300MG	A077895	001	Jul 27, 2006	Feb	CAHN	

VALBENZAZINE TOSYLATE

		CAPSULE;ORAL							
		INGREZZA							
	+	NEUROCRINE	40MG	N209241	001	Apr 11, 2017	Apr	NEWA	

VALPROATE SODIUMINJECTABLE;INJECTION
VALPROATE SODIUM

AP	ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar CAHN
----	-------------	------------------	---------	-----	--------------	----------

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
>D> AA	PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	May CAHN
>A> AA		250MG/5ML	A075379	001	Dec 15, 2000	May CAHN
AA	VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb CAHN

VALSARTANTABLET;ORAL
VALSARTAN

>D> AB	AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	May CAHN
>A> AB		40MG	A204011	001	Jan 11, 2016	May CAHN
>D> AB		80MG	A204011	002	Jan 11, 2016	May CAHN
>A> AB		80MG	A204011	002	Jan 11, 2016	May CAHN
>D> AB		160MG	A204011	003	Jan 11, 2016	May CAHN
>A> AB		160MG	A204011	003	Jan 11, 2016	May CAHN
>D> AB		320MG	A204011	004	Jan 11, 2016	May CAHN
>A> AB		320MG	A204011	004	Jan 11, 2016	May CAHN
AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN

VARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
VARDENAFIL HYDROCHLORIDE

>D> AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	May CAHN
>A> AB	WATSON LABS TEVA	10MG	A203689	001	Apr 22, 2015	May CAHN

VASOPRESSINSOLUTION;IV (INFUSION)
VASOSTRICT

>D>	+ @ PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May CMFD
>A>	+!	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May CMFD
	+ @	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr DISC
	+!	20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr NEWA
>A>	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May NEWA

VECURONIUM BROMIDEINJECTABLE;INJECTION
VECURONIUM BROMIDE

	@ WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar CAHN
AP		10MG/VIAL	A075549	001	Jun 13, 2000	Jan CAHN
	@	20MG/VIAL	A075218	002	Aug 23, 1999	Mar CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Jan CAHN

VENLAFAXINE HYDROCHLORIDETABLET;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar NEWA
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar NEWA
AB	+ OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG

VERAPAMIL HYDROCHLORIDE

	INJECTABLE;INJECTION						
	ISOPTIN						
	+ @ MT ADAMS	2.5MG/ML	N018485	001			Apr CRLD
	TABLET, EXTENDED RELEASE;ORAL						
	CALAN SR						
	+ @ PFIZER	180MG	N019152	002	Dec 15, 1989		Jan CRLD
	COVERA-HS						
	@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996		Jan DISC
	@	240MG	N020552	002	Feb 26, 1996		Jan DISC
	VERAPAMIL HYDROCHLORIDE						
AB	CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017		Apr NEWA
AB		240MG	A206173	002	May 05, 2017		Apr NEWA

VIGABATRIN

	FOR SOLUTION;ORAL						
	SABRIL						
AA	+! LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009		Apr CFTG
	+!	500MG/PACKET	N022006	001	Aug 21, 2009		Jan CAHN
	VIGABATRIN						
AA	PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017		Apr NEWA
	TABLET;ORAL						
	SABRIL						
	+! LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009		Jan CAHN

VINORELBINE TARTRATE

	INJECTABLE;INJECTION						
	VINORELBINE TARTRATE						
AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003		Mar CAHN
AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003		Jan CAHN

VORICONAZOLE

	POWDER;IV (INFUSION)						
	VORICONAZOLE						
	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017		Mar NEWA

VORTIOXETINE HYDROBROMIDE

	TABLET;ORAL						
	TRINTELLIX						
	+ @ TAKEDA PHARMS USA	EQ 15MG BASE	N204447	003	Sep 30, 2013		Mar DISC

WARFARIN SODIUM

	TABLET;ORAL						
	WARFARIN SODIUM						
	@ MYLAN	1MG	A040415	001	Sep 27, 2004		Apr DISC
	@	2MG	A040415	002	Sep 27, 2004		Apr DISC
	@	2.5MG	A040415	003	Sep 29, 2004		Apr DISC
	@	3MG	A040415	004	Sep 27, 2004		Apr DISC
	@	4MG	A040415	005	Sep 27, 2004		Apr DISC
	@	5MG	A040415	006	Sep 27, 2004		Apr DISC
	@	6MG	A040415	007	Sep 27, 2004		Apr DISC
	@	7.5MG	A040415	008	Sep 27, 2004		Apr DISC
	@	10MG	A040415	009	Sep 27, 2004		Apr DISC
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999		Mar CAHN
AB		2MG	A040301	003	Jul 15, 1999		Mar CAHN
AB		2.5MG	A040301	004	Jul 15, 1999		Mar CAHN
AB		3MG	A040301	005	Jul 15, 1999		Mar CAHN
AB		4MG	A040301	006	Jul 15, 1999		Mar CAHN
AB		5MG	A040301	007	Jul 15, 1999		Mar CAHN
AB		6MG	A040301	008	Jul 15, 1999		Mar CAHN
AB		7.5MG	A040301	009	Jul 15, 1999		Mar CAHN
AB		10MG	A040301	001	Jul 15, 1999		Mar CAHN

ZIDOVUDINE

	TABLET;ORAL						
	ZIDOVUDINE						
>A>	@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011		May CAHN
>D>	@ SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011		May CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL
ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar CAHN
ZYFLO CR						
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan NEWA
>D>	PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May CAHN
>A>	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May CAHN

ZOLMITRIPTAN

TABLET;ORAL
ZOLMITRIPTAN

AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL
ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN

TABLET;SUBLINGUAL
EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan NEWA
	@ SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr DISC
	@	12.5MG	A078483	002	Jun 06, 2011	Apr DISC

ZONISAMIDE

CAPSULE;ORAL
ZONISAMIDE

>D>	@ COREPHARMA	25MG	A077876	001	Feb 21, 2007	May CAHN
>D>	@	50MG	A077876	002	Feb 21, 2007	May CAHN
>D>	@	100MG	A077876	003	Feb 21, 2007	May CAHN
>A>	@ EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May CAHN
>A>	@	50MG	A077876	002	Feb 21, 2007	May CAHN
>A>	@	100MG	A077876	003	Feb 21, 2007	May CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ALLIED PHARMA INC 5MG/5ML

A091327 001 Oct 17, 2011 Apr CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ALLIED PHARMA INC 5MG/5ML

A091327 002 Oct 17, 2011 Apr CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT CADISTA 5MG

A078933 001 Jun 15, 2010 Apr CAHN

10MG

A078933 002 Jun 15, 2010 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

JUBILANT CADISTA 5MG

A078933 003 Jun 15, 2010 Apr CAHN

10MG

A078933 004 Jun 15, 2010 Apr CAHN

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

PHARMASEAL SCRUB CARE

>D> @ CAREFUSION 4%

N019793 001 Dec 02, 1988 May CAHN

>A> @ CAREFUSION 2200 4%

N019793 001 Dec 02, 1988 May CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL MULTI-SYMPTOM COLD & FLU

+! PFIZER 4MG;200MG;10MG

N022113 002 Apr 28, 2017 Apr NEWA

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

>D> +! BAYER HEALTHCARE LLC 8MG;120MG

N018397 001 May DISC

>A> + @ 8MG;120MG

N018397 001 May DISC

CIMETIDINE

TABLET;ORAL

CIMETIDINE

L PERRIGO CO 200MG

A075285 001 Oct 29, 1998 Apr CAHN

@ SANDOZ INC 100MG

A075122 001 Jun 19, 1998 Mar CAHN

@ 200MG

A075122 002 Jun 19, 1998 Mar CAHN

>D> @ WATSON LABS 200MG

A075425 001 Jul 29, 1999 May CAHN

>A> @ WATSON LABS TEVA 200MG

A075425 001 Jul 29, 1999 May CAHN

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

L PERRIGO CO 1.34MG

A074512 001 Nov 22, 1995 Apr CAHN

TAVIST-1

+! GLAXOSMITHKLINE CONS 1.34MG

N020925 001 Aug 21, 1992 Apr CAHN

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

TARO 1%

A072641 001 Dec 04, 1995 Apr CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL 30MG;600MG

A091070 001 Aug 31, 2015 Mar CAHN

60MG;1.2GM

A091070 002 Aug 31, 2015 Mar CAHN

AUROBINDO PHARMA LTD 30MG;600MG

A206941 001 Mar 17, 2017 Mar NEWA

60MG;1.2GM

A206941 002 Mar 17, 2017 Mar NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

PERRIGO R AND D 20MG

A077351 001 Sep 25, 2006 Apr CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

ACTAVIS LABS FL 1.2GM

A091009 002 Sep 03, 2015 Mar CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG
1.2GM;120MG

A091071 001 May 27, 2015 Mar CAHN
A091071 002 May 27, 2015 Mar CAHN

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>D> AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM
SALT

A202300 001 Dec 23, 2011 May CAHN

>A> EQ 200MG FREE ACID AND POTASSIUM
SALT

A202300 001 Dec 23, 2011 May CAHN

SUSPENSION/DROPS;ORAL

IBUPROFEN

L PERRIGO CO 40MG/ML

A075217 001 Dec 16, 1998 Apr CAHN

TABLET;ORAL

IBUPROFEN

AIPING PHARM INC 200MG

A207095 001 May 05, 2017 Apr NEWA

AMNEAL PHARMS 200MG

A079233 001 Mar 18, 2014 Apr CAHN

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO 100MG

A075367 001 Apr 22, 1999 Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML)

N209090 001 Jan 31, 2017 Feb CAHN

+ UCB INC 2.5MG/5ML (0.5MG/ML)

N209090 001 Jan 31, 2017 Jan NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG

N209089 001 Jan 31, 2017 Feb CAHN

+ UCB INC 5MG

N209089 001 Jan 31, 2017 Jan NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

RECKITT BENCKISER 1.5MG

A202246 001 Jun 05, 2015 Apr CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC 1MG/5ML

A073079 001 Apr 30, 1992 Mar CAHN

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

L PERRIGO CO 2MG

A075232 001 Jan 06, 2000 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ @ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997 Jan DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ @ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996 Jan DISC

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO 2MG;125MG

A076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL

LORATADINE

TARO PHARM 1MG/ML

A201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

	CREAM;VAGINAL						
	MICONAZOLE NITRATE						
	TARO	2%	A074444	001	Jan 13, 1997	Apr	CAHN
	SUPPOSITORY;VAGINAL						
	MICONAZOLE NITRATE						
>D>	ACTAVIS MID ATLANTIC	100MG	A073507	001	Nov 19, 1993	May	CAHN
>A>	ACTAVIS PHARMA	100MG	A073507	001	Nov 19, 1993	May	CAHN

MINOXIDIL

	AEROSOL, FOAM;TOPICAL						
	MINOXIDIL (FOR MEN)						
	WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Feb	NEWA
	SOLUTION;TOPICAL						
	MINOXIDIL (FOR MEN)						
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999	Apr	CAHN
	MINOXIDIL (FOR WOMEN)						
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999	Apr	CAHN

NAPROXEN SODIUM

	TABLET;ORAL						
	NAPROXEN SODIUM						
	LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017	Jan	NEWA

NICOTINE POLACRILEX

	GUM, CHEWING;BUCCAL						
	NICOTINE POLACRILEX						
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr	CAHN

OXYMETAZOLINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	OCUCLEAR						
>D>							
>D>	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May	DISC
>A>	@	0.025%	N018471	001	May 30, 1986	May	DISC

PERMETHRIN

	LOTION;TOPICAL						
	PERMETHRIN						
>D>	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May	CAHN
>A>		1%	A075014	001	Mar 28, 2000	May	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	PSEUDOEPHEDRINE HYDROCHLORIDE						
>A>	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May	NEWA
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr	CAHN

RANITIDINE HYDROCHLORIDE

	TABLET;ORAL						
	RANITIDINE HYDROCHLORIDE						
	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
	ZANTAC 150						
+!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN
	ZANTAC 75						
	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN
	TABLET, EFFERVESCENT;ORAL						
	ZANTAC 75						
+	@ SANOFI US	EQ 75MG BASE	N020745	001	Feb 26, 1998	Mar	CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2017

NO MAY 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	>A> 8148333	Nov 08, 2027	DP			
	>A> 8748382	Oct 03, 2027	U-2009			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	>A> 9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	>A> 8445543	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Sep 17, 2022	DS DP U-1167			
	>A> 6967208	Sep 17, 2022	DS DP U-1200			
	>A> 6967208	Sep 17, 2022	DS DP U-1301			
	>A> 6967208	Sep 17, 2022	DS DP U-1302			
	>A> 6967208	Sep 17, 2022	DS DP U-1323			
	>A> 6967208	Sep 17, 2022	DS DP U-1501			
	>A> 6967208	Sep 17, 2022	DS DP U-1502			
	>A> 6967208	Sep 17, 2022	DS DP U-1729			
	>A> 6967208	Sep 17, 2022	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	>A> 6967208	Sep 17, 2022	DS DP U-1200			
	>A> 6967208	Sep 17, 2022	DS DP U-1301			
	>A> 6967208	Sep 17, 2022	DS DP U-1302			
	>A> 6967208	Sep 17, 2022	DS DP U-1323			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					>A> NCE	Aug 27, 2017
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	>A> 5998402	Apr 04, 2018	DS DP U-594		>A> NCE	Oct 13, 2018
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	>A> 9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	>A> 9273077	May 21, 2029	U-1927			
	>A> 9611283	Apr 10, 2034	U-1927			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	>A> 9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	>A> 9273077	May 21, 2029	U-1927			
	>A> 9611283	Apr 10, 2034	U-1927			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	7367333	Nov 11, 2018	DP		PED	Jul 27, 2020
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	>A> 6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	>A> 9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	>A> 9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	>A> 9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	>A> 9655843	Jul 23, 2027	DP U-2017			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	>A> 5847170	Mar 26, 2021	DS DP		>A> M-201	May 17, 2020
	>A> 5847170*PED	Sep 26, 2021			>A> PED	Nov 17, 2020
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	>A> 8927592	Oct 27, 2030	U-1630			
	>A> 8927592*PED	Apr 27, 2031				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
	>A> 9629797	Nov 10, 2028	U-2004			
	>A> 9629797	Nov 10, 2028	U-2005			
	>A> 9629797	Nov 10, 2028	U-2006			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	>A> 9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	>A> 9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	>A> 9636407	Dec 21, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	>A> 9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	>A> 9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001					>A> M-199	May 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					>A> M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					>A> M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					>A> M-200	May 23, 2020
<u>COBICISTAT - TYBOST</u>						
N 203094 001					>A> NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					>A> NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		>A> NCE	Aug 27, 2017
					>A> NCE	Nov 05, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		>A> NCE NPP	Aug 27, 2017 Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572	002				NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572	003				NPP	Mar 29, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001 >A> 6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002 >A> 6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003 >A> 6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	003				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	004				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001 9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	002 9579359	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001 9522155	Feb 21, 2028	DP U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	001 7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	002 7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	001				PC	Aug 28, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	NCE	Apr 03, 2022
		9233959	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9296739	Sep 18, 2033	DP		
		9550780	Sep 18, 2033	DS DP U-1846		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	NCE	Apr 03, 2022
		9233959	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9296739	Sep 18, 2033	DP		
		9550780	Sep 18, 2033	DS DP U-1846		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	NCE	Apr 03, 2022
		9233959	Sep 18, 2033	DP	ODE	Apr 03, 2024
		9296739	Sep 18, 2033	DP		
		9550780	Sep 18, 2033	DS DP U-1846		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	9592242	Oct 20, 2020	U-1989		
		9592242	Oct 20, 2020	U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	>A> 9616049	Jan 04, 2032	DP		
		>A> 9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	>A> 9616049	Jan 04, 2032	DP		
		>A> 9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	>A> 9616049	Jan 04, 2032	DP		
		>A> 9616049*PED	Jul 04, 2032			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	>A> 9089489	Feb 18, 2033	DP U-1382			
	>A> 9375404	Feb 18, 2033	DP U-1382			
	>A> 9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	>A> 6933310	Nov 13, 2020	U-2013		>A> NCE	May 05, 2022
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9562722	Jan 03, 2028	U-1969			
	>A> 9662394	Oct 02, 2034	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		>A> NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		>A> NCE	Aug 27, 2017
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	>A> 9669008	Mar 25, 2036	DP			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	>A> 9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	>A> 9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 003	>A> 7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALICK</u>						
N 020800 004	>A> 7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	>A> 9295657	Mar 13, 2035	U-1829			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	9566244	Oct 23, 2028	DP			
	>A> 9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	9566244	Oct 23, 2028	DP			
	>A> 9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	9566244	Oct 23, 2028	DP			
	>A> 9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	9566244	Oct 23, 2028	DP			
	>A> 9643929	Apr 21, 2026	DP			
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001				>A> PC		Apr 15, 2017
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	>A> 8999932	Jul 29, 2030	DS DP U-2014		NCE	Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	>A> 8999932	Jul 29, 2030	DS DP U-2014		NCE	Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	>A> 8999932	Jul 29, 2030	DS DP U-2014		NCE	Feb 07, 2022
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287	001				PC	Sep 11, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001				>A> ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002				>A> ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003				>A> ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004				>A> ODE	Feb 26, 2023
<u>FENTANYL - SUBSYS</u>						
N 202788	001	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	002	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	003	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	004	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	005	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	006	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL - SUBSYS</u>						
N 202788	007	>A> 9289387	Jan 25, 2027	DP U-55		
		>A> 9642797	Jan 25, 2027	DP U-55		
		>A> 9642844	Jan 25, 2027	DP		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	001	>A> 9597288	Jul 23, 2027	DP U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	002	>A> 9597288	Jul 23, 2027	DP U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	003	>A> 9597288	Jul 23, 2027	DP U-767		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004 >A>	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005 >A>	9597288	Jul 23, 2027	DP U-767			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001					>A> M-202	May 15, 2020
					>A> NCE	May 10, 2018
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002					>A> M-202	May 15, 2020
					>A> NCE	May 10, 2018
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001					>A> NPP	Apr 28, 2020
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
>A>	9669024	Oct 30, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1491		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002					>A> NCE	Jul 26, 2017
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	>A> RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9597374	Oct 08, 2031	U-1987			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9597374	Oct 08, 2031	U-1987			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9597374	Oct 08, 2031	U-1987			
<u>IVACAFTOR; LUMACFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
<u>IVACAFTOR; LUMACFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP >A> ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	>A> 8324225	Jun 17, 2028	DS DP		>A> NCE	Mar 13, 2022
	>A> 8415355	Feb 19, 2031	DS DP			
	>A> 8685980	May 25, 2030	DS DP			
	>A> 8962630	Dec 09, 2029	U-1981			
	>A> 9193732	Nov 09, 2031	DS DP			
	>A> 9416136	Aug 20, 2029	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISINOPRIL - OBRELS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	>A> 9649318	Mar 31, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002 >A>	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002 >A>	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003 >A>	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
>A>	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	>A> 9259427	Jan 02, 2033	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	>A> 9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	>A> 9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	>A> 9669096	Apr 08, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	>A> 7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	>A> 8222244	Oct 29, 2022	U-2007		>A> ODE	Apr 28, 2024
	>A> 8575146	Dec 02, 2030	U-2008		>A> ODE	Apr 28, 2024
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001 >A>	9662398	Dec 01, 2030	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018	U-1942			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001 >A>	6149054	Dec 19, 2016	DP			
	>A> 6149054*PED	Jun 19, 2017				
	>A> 6846413	Aug 28, 2018	DP			
	>A> 6846413*PED	Feb 28, 2019				
	>A> 6977042	Aug 28, 2018	DP			
	>A> 6977042*PED	Feb 28, 2019				
	>A> 6988496	Feb 23, 2020	DP			
	>A> 6988496*PED	Aug 23, 2020				
	>A> 7284474	Aug 26, 2024	DP			
	>A> 7284474*PED	Feb 26, 2025				
	>A> 7396341	Oct 10, 2026	DP			
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7802568	Feb 26, 2019	DP			
	>A> 7802568*PED	Aug 26, 2019				
	>A> 7837235	Mar 13, 2028	DP			
	>A> 7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNTRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	>A> 5792795	May 13, 2018	DP			
	>A> 5948818	May 13, 2018	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	>A> 9649352	Jul 16, 2035	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9592200	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	>A> 7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	>A> 7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	>A> 7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	002				PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001				M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001	7351834	Jun 28, 2022	DS	>A> I-744 >A> ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001	8324225	Jun 17, 2028	DS DP	NCE	Mar 13, 2022
		8415355	Feb 19, 2031	DS DP		
		8685980	May 25, 2030	DS DP		
		8962630	Dec 09, 2029	U-1981		
		9193732	Nov 09, 2031	DS DP		
		9416136	Aug 20, 2029	U-1981		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	9629828	Jul 24, 2029	U-1994		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	8404702	Apr 04, 2027	U-1741		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	001				>A> M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	002				>A> M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	003				>A> M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	004				>A> M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	005				>A> M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	006				>A> M-203	Mar 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	>A> 7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	>A> 7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	>A> 6495541	Jan 10, 2020	DS DP			
	>A> 7351701	Jul 23, 2024	U-2012			
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8754072	Feb 10, 2031	DS DP			
	>A> 8859562	Aug 04, 2031	U-2012			
	>A> 9045487	Feb 10, 2031	DS DP			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	>A> 9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	>A> 9345724	Mar 29, 2031	DS DP U-2015			
	>A> 9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	>A> 9345724	Mar 29, 2031	DS DP U-2015			
	>A> 9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 008	>A> RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 009	>A> RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 010	>A> RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 011	>A> RE46363	Aug 03, 2026	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	9561251	Jan 23, 2030	DP U-1468			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	>A> 9649456	Oct 21, 2030	DP U-1719			
	>A> 9649456	Oct 21, 2030	DP U-2010			
	>A> 9649456	Oct 21, 2030	DP U-2011			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001 >A>	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027	U-1979			
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028	U-1979			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					ODE	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					ODE	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002 >A>	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
>A>	6453795	Dec 05, 2016	DP			
>A>	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
>A>	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026	U-1751			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026	U-1751			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001 >A>	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001 >A>	8298576	Apr 04, 2028	DP U-106			
	>A> 8298576	Apr 04, 2028	DP U-1992			
	>A> 8298580	Nov 16, 2027	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-1992			
	>A> 8663683	Nov 16, 2027	DP U-106			
	>A> 8663683	Nov 16, 2027	DP U-1992			
	>A> 8877248	Nov 16, 2027	DP U-106			
	>A> 8877248	Nov 16, 2027	DP U-1992			
	>A> 8889191	Nov 16, 2027	U-106			
	>A> 8889191	Nov 16, 2027	U-1992			
	>A> 8992989	Nov 16, 2027	DP U-1675			
	>A> 8992989	Nov 16, 2027	DP U-1992			
	>A> 9549940	Nov 16, 2027	DP U-1675			
	>A> 9549940	Nov 16, 2027	DP U-1992			
	>A> 9555004	Nov 16, 2027	DP U-1675			
	>A> 9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002 >A>	8298576	Apr 04, 2028	DP U-106			
	>A> 8298576	Apr 04, 2028	DP U-1992			
	>A> 8298580	Nov 16, 2027	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-1992			
	>A> 8663683	Nov 16, 2027	DP U-106			
	>A> 8663683	Nov 16, 2027	DP U-1992			
	>A> 8877248	Nov 16, 2027	DP U-106			
	>A> 8877248	Nov 16, 2027	DP U-1992			
	>A> 8889191	Nov 16, 2027	U-106			
	>A> 8889191	Nov 16, 2027	U-1992			
	>A> 8992989	Nov 16, 2027	DP U-1675			
	>A> 8992989	Nov 16, 2027	DP U-1992			
	>A> 9549940	Nov 16, 2027	DP U-1675			
	>A> 9549940	Nov 16, 2027	DP U-1992			
	>A> 9555004	Nov 16, 2027	DP U-1675			
	>A> 9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003 >A>	8298576	Apr 04, 2028	DP U-106			
	>A> 8298576	Apr 04, 2028	DP U-1992			
	>A> 8298580	Nov 16, 2027	DP U-106			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	>A> 8298580	Nov 16, 2027	DP U-1992			
	>A> 8663683	Nov 16, 2027	DP U-106			
	>A> 8663683	Nov 16, 2027	DP U-1992			
	>A> 8877248	Nov 16, 2027	DP U-106			
	>A> 8877248	Nov 16, 2027	DP U-1992			
	>A> 8889191	Nov 16, 2027	U-106			
	>A> 8889191	Nov 16, 2027	U-1992			
	>A> 8992989	Nov 16, 2027	DP U-1675			
	>A> 8992989	Nov 16, 2027	DP U-1992			
	>A> 9549940	Nov 16, 2027	DP U-1675			
	>A> 9549940	Nov 16, 2027	DP U-1992			
	>A> 9555004	Nov 16, 2027	DP U-1675			
	>A> 9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	>A> 8298576	Apr 04, 2028	DP U-106			
	>A> 8298576	Apr 04, 2028	DP U-1992			
	>A> 8298580	Nov 16, 2027	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-1992			
	>A> 8663683	Nov 16, 2027	DP U-106			
	>A> 8663683	Nov 16, 2027	DP U-1992			
	>A> 8877248	Nov 16, 2027	DP U-106			
	>A> 8877248	Nov 16, 2027	DP U-1992			
	>A> 8889191	Nov 16, 2027	U-106			
	>A> 8889191	Nov 16, 2027	U-1992			
	>A> 8992989	Nov 16, 2027	DP U-1675			
	>A> 8992989	Nov 16, 2027	DP U-1992			
	>A> 9549940	Nov 16, 2027	DP U-1675			
	>A> 9549940	Nov 16, 2027	DP U-1992			
	>A> 9555004	Nov 16, 2027	DP U-1675			
	>A> 9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					>A> NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					>A> NCE	May 10, 2018
					>A> NCE	Dec 18, 2018
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		>A> NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	>A> 9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	>A> 9375478	Jan 30, 2035		U-1857		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031		U-674		
	9597281	Apr 06, 2027		U-674		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm